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 ABSTRACT 
 
Although only a small proportion of the human genome encodes proteins, most of our DNA is 
transcribed into a myriad of different RNA species, collectively termed the transcriptome. 
Investigation of this pervasive transcription has unveiled unanticipated context-specific regulation 
and biological significance for some of these RNA transcripts. Therefore, the common perception 
of the transcriptome has evolved, from RNA being a simple mediator between the genetic code and 
proteins, to RNA being a multifaceted complex genetic element. The human genome is now 
regarded as a sophisticated combination of intertwined protein-coding and non-coding sequences, 
generating a transcriptome much more versatile and heterogeneous than previously envisioned.  
 
The transcriptome exhibits a wide dynamic range, with a few genes generating the majority of 
transcripts within a cell, whilst the majority of genes are expressed at low levels, and have context-
restricted expression. Investigating these rare transcripts has been hampered by inconsistent and 
limited coverage using standard next-generation sequencing. This thesis investigates the potential of 
using RNA CaptureSeq to expand the breadth of transcriptomic studies by reaching saturating 
coverage of an enriched selected fraction of the transcriptome.  
 
The RNA CaptureSeq protocol was optimised and is comprehensively described. In addition to the 
detailed laboratory procedure and the suggested method for analysing generated datasets, 
experimental design considerations, anticipated results and troubleshooting approaches are 
presented. Co-sequencing ERCC RNA Spike-In transcripts added to samples during processing acts 
as an internal control to validate coverage of transcripts of multiple lengths and concentrations.  
 
The power of RNA CaptureSeq was exploited to focus sequencing coverage towards transcripts 
originating from human chromosome 21 (Hsa 21) in the human myelogenous leukemia cell line 
K562, and in 3 primary tissues. The ERCC Spike-In RNAs of the lowest concentrations (10-22 
mole/L) were sequenced with a sufficient number of reads to enable accurate assembly. RNA 
CaptureSeq revealed extensive transcription of Hsa 21, with the vast majority of sequenced reads 
mapping to entirely novel introns and exons. The dataset includes a large fraction of novel isoforms 
and entirely novel transcripts. These RNAs derive from regions previously considered intergenic, or 
spanning multiple annotated genes, and the complete dataset overall surpasses the existing 
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GENCODE annotations. Analysis of transcription in brain, kidney and testis revealed a great 
prevalence of tissue-restricted transcription, especially for non-coding transcripts.  
 
RNA CaptureSeq was also applied to matching mouse tissues for syntenic regions to Hsa 21. This 
study expanded the catalogue of transcription in the mouse by at least 2.5-fold. While the number 
and density of genes was similar to human, the number of introns and lncRNAs were lower, which 
is in agreement with current theories for speciation. Furthermore, the newly annotated coding and 
non-coding genes showed a similar degree of evolutionary conservation to currently annotated 
sequences. In addition, the impact of cis-encoded regulation was questioned by probing Hsa 21 
transcription in the mouse nuclear environment. RNA CaptureSeq was applied using Hsa 21-
specific probes, to organs from the aneuploid mouse Tc1, which contains an additional copy of 
human chromome 21 in its nuclei. The resulting dataset demonstrated the majority of human 
transcripts were present in Tc1 brain, kidney and testis nuclei. Therefore, the regulation of the 
expanded transcriptome revealed by CaptureSeq is mediated by local cis-encoded regulatory 
elements. This precise regulation of novel noncoding RNAs is inconsistent with previous 
assumptions of noncoding transcripts being spurious transcriptional noise. 
 
Altogether these studies suggest that the transcriptome is vastly greater even than inferred from 
ENCODE. RNA CaptureSeq exposes the currently unappreciated chromosome 21 transcriptome, as 
the large majority of sequenced reads map to entirely novel introns and exons.  
 
In addition to increasing the breadth of sequencing, RNA CaptureSeq also has the potential to 
resolve rare splice variants. This capacity was explored in human hematopoietic cancer tissues, 
using probes targeting intron-exon boundaries and branchpoint sites of cancer-related genes. This 
experiment was initially designed to investigate aberrant splicing events in tumours exhibiting a 
mutation in the SF3B1 splicing factor, but is proposed to have a larger range of applications, such 
as evidencing breakpoint translocations in fusion genes. 
 
Collectively, this work demonstrates the huge potential and versatility of the RNA CaptureSeq 
method to expand the breadth of the analysed transcriptome to saturation. Exposing the full 
catalogue of transcripts originating from a defined genomic area provides the opportunity for more 
accurate and precise hypothesis-testing, and for developing conceptual advances in various fields of 
research including regulation of gene expression and oncogenesis. 
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“The transition from a paradigm in crisis to a new one from which a new tradition of normal science 
can emerge is far from a cumulative process, one achieved by an articulation or extension of the old 
paradigm. Rather, it is a reconstruction of the field from new fundamentals, a reconstruction that 
changes some of the field’s most elementary theoretical generalizations as well as many of its 
paradigm methods and applications. During the transition period, there will be a large but never 
complete overlap between the problems that can be solved by the old and by the new paradigm. But 
there will also be a decisive difference in the modes of solutions. When the transition is complete, 
the profession will have changed its view of the field, its methods, and its goals.” 
 
Thomas Kuhn, The Structure of Scientific Revolution (1962), 84-5. 
Chapter 1
General Introduction
1
  
 
 
 
 
 
 
 
 
 
 
 
 
 GENERAL INTRODUCTION 
1.1 The majority of the Human genome does not encode proteins 
 
The Human Genome Project revealed that only a small fraction of our DNA encodes 
proteins, with the majority comprises noncoding DNA (ncDNA) and intergenic regions 
(Lander et al., 2001). The number of protein-coding genes is very similar amongst 
metazoans despite a huge range of complexity (Taft et al., 2007). Currently GENCODE 
reports 20,345 protein-coding genes in humans, a number surprisingly similar to the 
14,692 and 20,470 protein-coding genes comprised in the fruit fly Drosophila 
melanogaster (Brown et al., 2014), and the worm Caenorhabditis elegans (WormBase, 
release WS227) genomes, respectively. Therefore, it has been proposed that the 
complexity of an organism is driven by evolutionary innovations in the noncoding areas 
of its genome rather than in protein-coding genes. Indeed, ncDNA broadly correlates 
with measures of complexity between organisms (Taft et al., 2007). This includes 
noncoding RNAs (ncRNA), involved in regulatory and epigenetic processes that 
delineate differential transcriptional programmes (Taft et al., 2007). However, a recent 
and notable exception to this trend was the aquatic bladderwort Utricularia gibba, a 
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carnivorous plant which exhibits almost no noncoding regions (Ibarra-Laclette et al., 
2013). The U. gibba genome is only 83 Mb but contains 28,500 protein-coding genes 
and only 3% repetitive elements.  
 
A major portion of ncDNA in the human genome is derived from repeat elements (Lander 
et al., 2001). Transposons are DNA sequences that can duplicate and relocate, 
“transpose” themselves within the genome (Luning Prak & Kazazian Jr, 2000; 
McClintock, 1950). Beyond reproducing themselves, transposons and their derivative 
sequences were considered functionless “junk DNA” (Ono, 1972). Doolittle and 
Sapienza concluded that “when a given DNA […] of unproven phenotypic function can 
be shown to have evolved a strategy (such as transposition) which ensures its genomic 
survival, then no other explanation for its existence is necessary” (Doolittle & Sapienza, 
1980).  
 
Less than 0.05% of transposons retain the ability to relocate within the genome (Mills et 
al., 2007), a process linked to diseases (Hancks & Kazazian, 2012; Kazazia Jr et al., 
1988; Mills et al., 2007). Although deleterious transposons are rapidly purged by 
selection (Nellaker et al., 2012), there is also evidence that transposable elements have 
undergone purifying selection during mammalian evolution as significant regulators of 
transcription (Lowe et al., 2007). Accumulating evidence shows that a small proportion 
of active transposable elements disrupt or alter gene expression, and therefore impact 
their host genomes (Kim et al., 2012), and shape selection (Feschotte & Pritham, 2007). 
To test whether ncDNA is dispensable to the normal function of the genome, a mouse 
strain was engineered that lacks 1% of its ncDNA including transposons and other 
noncoding regions. These mice are viable and exhibit similar functions (reproduction, 
behaviour) to wild-type (WT) littermates but show minor expression differences 
(Nóbrega et al., 2004).  
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1.2 Pervasive transcription of noncoding DNA 
 
Over the following decade, additional studies have shown that this ncDNA can be 
transcribed into RNAs that, while not encoding proteins, function intrinsically as RNA 
molecules. The abundance and function of these noncoding RNAs (ncRNAs) has been 
the subject of intense debate. 
 
The first functional ncRNAs, identified in the late 1950’s, represented core basal 
components of the cell (Hoagland et al., 1958). Transfer RNAs (tRNAs) recruit amino 
acids during protein translation (Crick, 1968; Hoagland et al., 1958). Ribosomal RNAs 
(rRNAs) comprise sites of translation that catalyse the formation of peptide bonds 
between amino acids in newly synthesized proteins (Siekevitz & Zamecnik, 1981).  
Small nucleolar RNAs (snoRNAs) guide and target major RNA modifications such as 
pseudouridylation and methylation (Bachellerie et al., 2002). Small nuclear RNAs 
(snRNAs), also called spliceosomal RNAs, are ~150 nucleotide (nt) long transcripts 
found in the nucleus associated with specific sets of proteins to form small nuclear 
ribonucleoproteins (snRNPs). snRNPs assemble into the spliceosome, which mediates 
splicing of pre-mRNA. (Padgett et al., 1986; Yang et al., 1981). The basal functions and 
ancient origin of these functional RNAs is often cited as supporting evidence for the RNA 
world hypothesis that postulates proto-life was originally comprised of RNA, before 
devolving catalytic and information functions to proteins and DNA, respectively (Gilbert, 
1986). 
 
Apart for these “generic” ncRNAs, the transcription of ncRNAs in eukaryotes was not 
observed until 1997, when in situ hybridization revealed nascent transcription from 
intergenic areas along the entire human -globin gene cluster (Ashe et al., 1997). These 
initial observations have been supported by a range of additional assays, revealing an 
increasing proportion of the human genome being transcribed (Kapranov et al., 2007b) 
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Microarrays provided some of the first indications that the human genome was 
pervasively transcribed. Microarray studies are based on detection of the hybridization 
of a transcript, or part thereof, to a complementary probe. Tiling probes across genomic 
regions are then able to detect novel transcription including noncoding transcripts and 
novel coding isoforms. Tiling arrays spanning chromosomes 21 and 22, the two smallest 
chromosomes in the human genome, revealed pervasive transcription, with almost half 
of the identified transcripts representing novel RNAs (Johnson et al., 2005; Kampa et 
al., 2004; Rinn et al., 2003). The existence of novel ncRNAs was validated using RT-
PCR.  
 
Large-scale cDNA libraries also suggested the abundance of novel ncRNAs. SAGE 
(Serial Analysis of Gene Expression) tags were generated from treatment of mRNA with 
restriction enzymes, before sequencing (Velculescu et al., 1995). Pioneering studies 
using SAGE reported as much as 23% tags from unannotated regions (Lal et al., 1999; 
Velculescu et al., 1995). Analysis of SAGE tags produced from 101 human tissue 
libraries later confirmed that ~70% of unmatched tags originated from novel intergenic 
transcription (Chen et al., 2002). 
 
Capped analysis of gene expression (CAGE) sequences fragments from the 5’ end of 
capped mRNA (Carninci et al., 2005b; Okazaki et al., 2002). The FANTOM consortium 
used this method to investigate transcription initiation in many tissues and 
developmental stages in the mouse (Carninci et al., 2005b), finding a huge number of 
ncRNAs transcribed from intronic, intergenic and antisense sequences in a dynamically 
regulated manner (Katayama et al., 2005).  
 
Early large-scale, full-length cDNA sequencing provided a broad profile of long 
noncoding transcripts > 200 nt in length, termed long ncRNAs (lncRNAs). Theses 
studies indicated that, like messenger RNA (mRNAs), lncRNAs were spliced, 
polyadenylated (PolyA+), and dynamically expressed (Numata et al., 2003). These early 
studies represented major efforts at the time, but advances in high-throughput 
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sequencing mean that RNA sequencing (RNAseq) is now within the reach of most 
laboratories. 
 
RNAseq is now a common and global approach to profile the transcriptome, and this 
technique routinely identifies noncoding transcription. RNA transcripts are reverse 
transcribed, fragmented and then sequenced on high throughput instruments, such as 
the Illumina HiSeq (Mortazavi et al., 2008; Wang et al., 2009). The ENCODE study 
performed RNAseq on a wide range of samples (147 cells types) as part of a larger 
effort (comprising 1640 datasets) to identify functional elements within the human 
genome. Results from RNAseq led authors to conclude that “the majority of [the 
genome’s] bases is associated with at least one primary transcript” (Birney et al., 2007). 
Collective analysis of RNAseq libraries evidences the transcription of at least 93% of the 
genome (Dunham et al., 2012).  
 
The veracity and significance of pervasive transcription has been debated. van Bakel 
and colleagues compared tilling arrays and RNAseq datasets obtained from replicate 
samples, finding that tiling arrays produced much more signal in intergenic regions than 
RNAseq (van Bakel et al., 2010b). van Bakel et al concluded that microarrays were 
prone to false positive signal, likely due to the cross hybridization of low abundance 
transcripts, and that the genome was not as pervasively transcribed as claimed by the 
ENCODE paper (Phillips, 2010a; Phillips, 2010b; Robinson, 2010; van Bakel et al., 
2010b). However, Clark and colleagues highlighted clear issues in the experimental and 
analytical processes used by van Bakel et al. such as an inconsistent and low coverage 
depth, poor genome reconstruction, and the absence of validation from unbiased, 
independent techniques (Clark et al., 2011b).  
 
In addition to the pervasiveness of transcription, van Bakel et al. also disputed the 
functional relevance of low abundance noncoding transcription, arguing that most 
ncRNAs are too rare to be functionally significant, as demonstrated by the large number 
of cycles required for their validation by RT-PCR. Therefore van Bakel et al concluded 
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that such noncoding transcription was likely the insignificant result of spurious, leaky 
transcription of the genome (van Bakel et al., 2011a). 
 
1.3 Splicing generates transcriptional diversity 
 
RNAseq has revealed that splicing often generates a complex range of isoforms, both 
coding and noncoding, from a single gene locus (Figure 1). These multiple transcripts 
often form embedded, overlapping, multidirectional transcript networks termed “complex 
loci” (Engström et al., 2006).  
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Figure 1: A sequence of genomic DNA can generate a variety of transcripts 
Pervasive transcription has revealed the modular and complex architecture of the genome, where a single 
canonical coding sequence (green) can yield various transcripts including coding splice-variants but also 
small and long non coding RNAs and antisense RNA, discussed later in this chapter. The sections 
highlighted in yellow exemplify the complexity of transcriptome research where targeting a single 
canonical gene sequence experimentally may enrich for a variety of additional transcript. Abbreviations: 
PASRs, promoter-associated small RNAs; TALRs, terminal-associated long RNAs; tiRNAs, tiny RNAs. 
Reproduced with permission from Oxford University Press (Dinger et al., 2009). 
 
This modular architecture of the genome is achieved through the process of splicing, 
predominant in eukaryotic genomes to convert pre-mRNA into a mature mRNA 
transcript ready for protein translation. During conventional splicing, introns, seemingly 
random genomic DNA (gDNA) sequences generally devoid of open reading frames 
(ORFs), are removed from pre-mRNA sequences, connecting the remaining exons 
(Figure 2). The splicing reaction is catalysed by the spliceosome, defined earlier as a 
complex assembly of snRNPs (Will & Lührmann, 2011). The spliceosome recognises at 
least three genetic elements within every intron: the 5’ splice site, the 3’ splice site and 
the branchpoint ((Reed & Maniatis, 1985), Appendix B). 
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Figure 2: The canonical splicing reaction 
During the first step of the splicing reaction, the spliceosome catalyses a transesterification reaction 
between the 5’ splice site and the branhpoint, which creates a closed loop structure called an intron lariat, 
first observed by electron microscopy during analysis of adenovirus mRNA synthesis (Berget et al., 1977). 
The 3’ splice site subsequently undergoes transesterification with the free 5’ splice site to ligate the two 
exons together causing the release of the intron lariat (Will & Lührmann, 2011). 
 
The multiple isoforms transcribed from a same locus originate from alternative splicing 
patterns of a single pre-mRNA sequence. The vast majority (~95%) of human protein-
coding genes exhibit alternative splicing (Wang et al., 2008), where exons can be 
rearranged into numerous different combinations (Figure 3) to form alternative mRNA 
isoforms that are then translated into distinct protein sequences (Keren et al., 2010; Pan 
et al., 2008). By contrast, extensive investigations of transcription and associated 
splicing of the ~15,000 protein-coding gene in D. melanogaster found that ~50% 
transcripts were constitutively spliced to produce a single isoform only (Brown et al., 
2014).  
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Figure 3: Examples of alternative splicing outcomes 
Different types of known alternative splicing are illustrated here with constitutive exons in blue boxes and 
alternatively-spliced exons in purple boxes, and include: (a) exons skipping, where an exon is spliced out 
together with its flanking intron (b-c) alternative 3’ and 5’ splice site selection, (d) retention of intronic 
sequence, (e) mutually exclusive exons, and (f-g) alternative promoters or polyA+. Modified and 
reproduced with authorization from Nature Publishing Group (Keren et al., 2010). 
 
1.4 Long noncoding RNAs 
 
LncRNAs exhibit similar features to mRNAs, they are spliced, polyA+ and 3’ capped 
(Carninci et al., 2005b). However, instead of encoding a protein, lncRNAs function 
directly as RNA molecules. These transcripts can be produced from intergenic areas 
previously termed “gene deserts” (Hangauer et al., 2013), from intronic sequences 
(Louro et al., 2009), and from regions antisense to coding transcripts (Kampa et al., 
2004), and can be predicted by the absence of significant ORFs with codon-specific 
evolutionary conservation (Clamp et al., 2007; Derrien et al., 2012). However, short 
ORFs or distal exon usage can confound efforts to distinguish mRNAs and lncRNAs. 
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Indeed, enrichment of RNA-bound ribosomes in the yeast Saccharomyces cerevisiae 
followed by RNAseq revealed short ORFs are contained within long RNAs previously 
thought as noncoding, and translated (Smith et al., 2014). Furthermore, multiple lines of 
evidence suggest lncRNAs in yeast and in mammals are sensitive to nonsense-
mediated decay (Smith et al., 2014; Tani et al., 2013). 
 
Although lncRNAs are a feature of most eukaryotic genomes, these transcripts are 
generally poorly conserved between species (Calin et al., 2007). This is cited as 
evidence that the majority lncRNA transcription may be spurious and biologically 
irrelevant (van Bakel et al., 2011a). However, despite this general trend, several highly 
conserved lncRNAs have been identified, and functional roles are being increasingly 
ascribed to lncRNAs (Morris & Mattick, 2014). 
 
A major function of lncRNAs is their ability to regulate the epigenome (Lee, 2012). 
LncRNAs bind chromatin-modifying complexes such as the Polycomb Repressive 
Complex 2 (PRC2) (Khalil et al., 2009). PRC2 can act as a gene silencer through tri-
methylation of H3K27, causing chromatin condensation and inaccessibility for the 
transcription machinery (Cao et al., 2002), and is a core regulatory component of many 
developmental programs. The lncRNA HOTAIR is a ~2.2kb spliced RNA transcribed 
antisense from the HOXC locus, and is required to silence the HOXD locus at a distant 
genomic region from its own origin (Rinn et al., 2007). HOTAIR binds to the EZH2-
component of PRC2 and acts in the nucleus to recruit EZH2 in close physical proximity 
to the HOXD locus that is subsequently silenced (Figure 4a, (Tsai et al., 2010)). 
HOTAIR can act as a molecular scaffold with binding domains for both the 
methyltransferase EZH2 on the 5’ site, and the demethylase LSD1 on the 3’ site (Spitale 
et al., 2011; Tsai et al., 2010). 
 
LncRNAs are also involved in the epigenetic silencing of gene expression during gene 
dosage and compensation whereby male and female gene expression is equalised in 
mammalian cells (Reik & Walter, 2001). The lncRNA X-inactive specific transcript (Xist) 
11
  
coats the second X chromosome in female cells, recruiting PRC2 to silence gene 
expression in a process called X inactivation (Figure 4b, (Brown et al., 1991)). 
 
 
Figure 4: Example of regulation of gene expression by lncRNA. 
(a) Regulation in trans is accomplished by the antisense lncRNA HOTAIR, which acts as a scaffold to 
recruit 2 complexes PRC2 and CoREST. (b) Xist acts in cis to recruit methyltransferases and repressive 
complexes (DNMT3 and PRC2) that cause repressive chromatin. Modified and reproduced with 
permission from Nature Publishing Group (Fatica & Bozzoni, 2014). 
 
LncRNAs can also impact gene expression locally. A subclass of lncRNAs exhibits 
enhancer-like functions (elncRNA), and acts in cis to activate the transcription of 
neighbouring genes (Andersson et al., 2014; Ørom et al., 2010). An example of such 
enhancer lncRNAs binds through a chromatin loop to the co-activator complex Mediator, 
resulting in activation of promoters of cis-encoded genes (Lai et al., 2013). Similarly, 
17-oestradiol-induced elncRNAs expression correlates with transcription of nearby 
coding genes, and the elncRNA-induced looping required for initiating gene expression 
may be stabilised by binding cohesin complexes (Li et al., 2013). 
 
LncRNAs regulate post-transcriptional processes, such as splicing and translation. 
LncRNAs control the translation of E-cadherin mRNA in conjunction with snRNP 
complexes containing several RNA-binding proteins, like FXR1. The initial protein-
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lncRNA complex binds to E-cadherin mRNA to prevent it being efficiently translated in 
cancer cells (Gumireddy et al., 2013). The lncRNA Gomafu acts as a scaffold binding 
several splicing factors such as SRSF1, and thereby indirectly regulates alternative 
splicing (Barry et al., 2014). Decreased expression of Gomafu leads to higher splicing 
factor concentration and is correlated with aberrant splicing of genes involved in 
schizophrenia.  
 
Given roles in development and differentiation, deregulation of lncRNA expression and 
function can contribute to disease (Esteller, 2011; Huang et al., 2013; Taft et al., 2010). 
LncRNAs are implicated in cancers, neurodegenerative and metabolic diseases, for 
instance schizophrenia (Barry et al., 2014) and diabetes (Guay et al., 2012), and 
cardiovascular diseases (Fichtlscherer et al., 2010). LncRNAs like HOTAIR can promote 
oncogenesis through over-expression, as observed in breast cancer (Gupta et al., 
2010), or may prevent malignant transformation, such as lincRNAp21, that promotes 
apoptosis from DNA damage by interactions with the tumour suppressor p53 (Huarte et 
al., 2010). Genome wide association studies (GWAS) implicate lncRNA expression 
more broadly in disease. Many haplotype blocks, regions of linkage disequilibrium 
around disease-associated single nucleotide polymorphisms (SNPs), occur in intergenic 
space lacking annotated transcripts. Some intergenic SNPs correlate with transcription 
levels of long intergenic noncoding RNAs (lincRNAs) but not neighbouring coding genes 
(Kumar et al., 2013).  
 
1.5 Analysing the transcriptome 
 
These advances in our understanding of the transcriptome, including the discovery and 
analysis of lncRNAs, are the result of continuing technical developments in gene 
profiling and expression quantification methods, including sequencing. However, the full 
transcriptome is both too large and too complex to be sequenced in its entirety, even 
with modern sequencing technologies. Therefore, various methods have been devised 
to partition the transcriptome into smaller fractions for targeted analysis. 
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Quantitative real-time PCR can amplify and quantify any transcript region between two 
selected primers, and is an ideal method to detect known ncRNAs and other low 
abundance transcripts (Freeman et al., 1999). However, qRT-PCR is relatively low 
throughput, with usually a single target amplified per reaction, unless protocol 
optimizations allow amplification of several targets without primer dimerization or 
unspecific product amplification. In addition, the design of primers requires previous 
gene annotations and is ill suited to discover novel transcripts. Finally, gene abundance 
is determined from the amplification of small region of cDNA that encompasses several 
annotated exons that may be alternatively spliced to generate additional products of 
different sizes, confounding analysis (Figure 5). This limits the use of qRT-PCR to 
resolve the complexity of the transcriptome. 
 
 
Figure 5: Quantitative RT-PCR measures the amplification rate of a gene amplicon to estimate 
abundance but provides no information on gene structure. 
qRT-PCR requires the design of two primers (blue) using previous gene annotations (a). However, the 
existence of unannotated exons that generate additional amplicons will invalidate abundance 
measurement (b) and qRT-PCR is unable to detect or distinguish additional gene isoforms (c)  
 
RNAseq is able to simultaneously identify and quantify gene expression (Garber et al., 
2011). However, RNAseq performance is limited when profiling low abundance genes. 
The transcriptome is extremely unequal with a 106 fold difference between the most 
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abundant and the least abundant transcript in a cell. Within the K562 cell line, the top 
1.5% genes constitute about 43% mRNA transcripts while the least abundant 44% 
genes constitute less than 1% of the total RNA content within a cell (Jiang et al., 2011). 
This limits the use of RNAseq to profile transcriptome diversity, as most abundant genes 
are oversampled, while rare transcripts have poor coverage that prevents their accurate 
assembly (Figure 6). For example, a 2kb transcript present in average abundance in 
0.1% brain cells (10 copies per cell) would be sampled once every 40 million reads when 
sequencing RNA from brain cells (~170 million cells, (Azevedo et al., 2009; Clark et al., 
2011b)). Furthermore, to cover this transcript in its entirety with 100 bp paired-end reads 
would require 400 million reads (Clark et al., 2011b). It is estimated that at least 8-10 
fold coverage is required to confidently identify a transcript (Lander et al., 2001). 
Therefore, a minimum 4 billion reads are required to assemble this transcript de novo. 
Despite advances in sequencing technologies, this is beyond the scope and feasibility 
of most laboratories, as the highest sample coverage reported to date is one billion reads 
per run using the Illumina HiSeq 2000 (Sims et al., 2014). It is not realistic to simply 
increase sequencing depth to improve sensitivity because coverage of highly abundant 
transcripts increases proportionally, resulting in further decreasing sequencing 
efficiency. This imposes an inherent limit to which RNAseq can actually sequence the 
transcriptome, and technical improvements are needed. 
 
Figure 6: Dynamic range of a cell's RNA population prevents RNAseq from achieving 
sequencing coverage of lowly expressed genes. 
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Gene expression has a wide dynamic range, over 106 fold difference between the highest and lowest 
abundance genes, with the top 1.5% most abundant genes comprise 43% of the mRNA population (red), 
while the lowest 44% comprise less than 1% of the population (blue) (Mercer et al., 2012b).(Right panel) 
Due to this wide dynamic range, RNAseq inefficiently re-samples abundant housekeeping genes, but only 
rarely sampling lowly expressed genes that often include regulatory genes and disease-associated genes. 
 
To address this problem, partitioning strategies can be employed whereby parts of the 
genome or transcriptome are targeted for sequencing. Examples of partitioning 
strategies are targeting selected mRNAs (exons) in a tissue (Levin et al., 2009), 
discovering the full transcriptional content originating from a small genomic area (Rinn 
et al., 2003), or profiling the expression of disease-associated low abundance transcripts 
(Ziats & Rennert, 2013).  
 
Multiplex polymerase chain reaction (PCR) co-amplifies multiple targets from a single 
template during a single reaction. However, as for qRT-PCR, the method has a low 
throughput because of the formation of secondary structures and primer-dimers. In 
addition, bias in target amplification can lead to heterogeneous sequencing coverage 
and inaccurate quantification. The chance of non-specific priming and false-positive 
amplification increases with the addition of each additional primer pair, which 
complicates the design process and complicates optimizations (Edwards & Gibbs, 
1994). An alternative strategy is to perform individual PCRs and pool amplicons in equal 
concentrations before sequencing. This method was employed to identify SNPs in 
genomic regions involved in prostate and colon cancer by GWAS (Yeager et al., 2008). 
This pooling strategy was also successfully applied to the transcriptome to validate 
>70% predicted splice junctions from eight polyA+ cDNA libraries (Howald et al., 2012).  
 
Sequences of interest can be first captured for enrichment through selective 
amplification. A molecular inversion probe (also called “padlock probe”) is a single 
stranded oligonucleotide sequence that binds target single-stranded DNA (ssDNA) 
(Landegren et al., 2004; Nilsson et al., 1994). The binding is mediated by two 
complementary binding motifs present in the probe, which surround the target sequence 
on the ssDNA in a single step, ssDNA and the padlock probe are ligated together by 
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DNA ligase, and a polymerase is used to close the remaining gap. Synthesizing the 
complement to the target sequence creates a circular DNA template ready for 
amplification. To the best of my knowledge, this method has not yet been used for 
transcriptome analysis, but was employed to genotype 12,000 SNPs in a single reaction 
(Hardenbol et al., 2005), and later employed to capture 50,000 exons with high 
sensitivity (Turner et al., 2009). This capture technique is performed without the 
requirement of prior amplification, and can be used with low starting template and 
without the need for library preparation.  
 
Regions of the transcriptome can be enriched by hybridisation to complementary 
oligonucleotide probes (Figure 7). Oligonucleotide probes may tile along, and entirely 
blanket, a selected genomic region to identify any transcription originating from this DNA 
sequence, or alternatively can target sequences of known annotations.  Hybridization of 
the probes to target cDNAs is followed by the elution of non-hybridized, off-target cDNA. 
The ‘captured’ cDNA is can then be amplified and sequenced (Levin et al., 2009) 
Targeting a subset of exons is often sufficient to capture the full-length mRNA and 
therefore, in contrast to amplification of molecular inversion probes, this technique is 
ideal to identify novel exons and isoforms and to explore populations of complexly 
spliced RNAs.  
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Figure 7: Overview of the in-solution capture-by-hybridization protocol. 
RNA samples are reverse transcribed into cDNA and fragmented during the library preparation step. The 
cDNA library is then hybridized to oligonucleotide probes custom-designed to be complementary to 
relevant genomic/spliced regions. After hybridization, the cDNA/oligo probe complexes are immobilized 
to allow removal of off-target library fragments. Enriched libraries are usually amplified before sequencing. 
 
Hybridization capture methods can be customized to investigate in greater details the 
complexity of the transcriptome. Mercer et al. illustrated the huge complexity present 
ubiquitously, albeit at low levels, by enriching transcripts originating from selected tiling 
regions comprising a total ~0.77 Mb. The resulting ~380-fold enrichment unveiled 
hundreds of novel isoforms to both protein-coding transcripts and lncRNAs, while 
retaining accurate quantification of gene expression (Mercer et al., 2012b). As a proof-
of-concept to the utility of transcriptome enrichment by hybridization capture in 
biomedical research, Levin et al. enriched the transcriptome of the leukaemia cell line 
K562 for 467 cancer-related genes. The great increase in coverage allowed to almost 
double the amount of identified exon junctions, distinguished novel alternative splicing, 
and described cancer-specific fusion genes resulting from the BCR-ABL1 1 and NUP214-
XKR3 translocations (Levin et al., 2009).  
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1.6 Conclusions 
 
The decade following the completion of the human genome has seen two major findings 
that challenged our understanding of genome biology: the genome is pervasively 
transcribed, and the majority of transcripts do not encode proteins. Collectively, these 
conclusions expand our conception of the transcriptome to a much larger and complex 
catalogue than initially anticipated. Furthermore, current sequencing protocols do not 
allow the full characterization of a transcriptional output, and require optimizations. 
 
A wide range of functions has been evidenced for lowly abundant ncRNAs, and their 
individual implication in many cancers and other metabolic diseases is now established. 
Therefore considering the full transcriptome, including rare events, promises advances 
in many areas of biological sciences, from fundamental principles of cellular 
mechanisms to disease etiology, and therapeutics research.  
1.7 Thesis outline 
 
In this thesis, I sought to standardize the successful genome-partitioning approach of 
transcriptome enrichment using capture-by-hybridization and demonstrate its potential 
and versatility in two independent research settings.  
 
First, I participated in the development and optimization of a robust method termed RNA 
CaptureSeq, which incorporates RNA library preparation and custom targeted capture 
using hybridization oligonucleotides (Chapter 2).  
 
Then, I used the RNA CaptureSeq protocol to target all transcription originating from a 
small portion of the genome, tiling along the human chromosome 21 (Hsa 21) and its 
syntenic regions in the mouse, using human (Chapter 3) and mouse tissues (Chapter 
4). This experiment aimed to reach the deepest coverage to date at a chromosomal 
level to illustrate the complexity of the transcriptome with the greatest definition available 
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at the time of writing. Examination of both mouse and human transcripts evidenced 
conservation of rare RNAs, suggesting a functional role for scarce transcripts such as 
lncRNAs. Using this method, I further enriched transcripts from Tc1 mouse tissues, 
which contain an extra human chromosome 21, in order to question the expression of 
human Ch21 in the mouse environment and obtain an insight into gene expression 
regulation at the greatest definition (Chapter 4).  
 
Finally, I explored a different setting for CaptureSeq, by applying a different 
oligonucleotide array of probes, to enriching a human hematopoietic cancer cell line and 
primary leukemia tissues for cancer-related genes (Chapter 5). This design targeted 
intron-exon boundaries and splicing-specific sequences, such as branchpoints. Initially 
designed to observe the impact of a mutation in the spliceosomal protein SF3B1 on the 
splicing of oncogenes, this protocol can be used more broadly to evidence non-
canonical splicing events, and evidence differential gene expression in cancer samples. 
 
Overall this thesis describes RNA CaptureSeq as a novel tool to mine the transcriptome. 
It illustrates its potential for transcripts discovery by examining the extent of the 
transcriptional repertoire of the smallest human chromosome, and is applied in a 
hypothesis-driven context to inspect rare non-canonical transcriptional events in cancer 
samples. 
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 TARGETED SEQUENCING FOR GENE 
DISCOVERY AND QUANTIFICATION USING 
RNA CAPTURESEQ 
 
Determining the spliced structure of lowly expressed genes is difficult. PCR-
based amplification methods are able to detect rare transcripts, but are ill suited 
for identifying new genes, or resolving complex alternative splicing events. 
RNAseq is able to reconstruct complex spliced gene structure. However, this 
requires sufficient sequence coverage, which can be difficult to achieve for 
transcripts with rare abundance. 
 
In an effort to analyse lowly-expressed transcripts, such as lncRNAs, Mercer and 
colleagues developed a technique, termed RNA CaptureSeq, based on the 
Nimblegen SeqCap EZ aqueous-phase capture array, where custom 
oligonucleotide probes tiled along a few small genomic area totalling ~0.77 Mb 
(Mercer et al., 2012b). Sequencing of the captured transcripts derived from a 
human foot fibroblast cell line validated this enrichment strategy, with ~81% reads 
aligning to the probed region, yielding an overall ~380-fold enrichment compared 
to a matched, non-enriched RNAseq coverage. Furthermore, RNA CaptureSeq 
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allowed the identification of novel, unannotated protein-coding and noncoding 
isoforms, lncRNAs and alternative splicing herein, which suggests that RNA 
CaptureSeq is a platform of choice to investigate the context-specific, full 
transcriptional profile of a selected genomic region. 
 
In order to standardize the method and facilitate access to the research 
community, we performed experiments to optimize and validate the protocol as a 
robust and reliable platform, and made it available online through the Nature 
Publishing Group. This chapter introduces the RNA CaptureSeq protocol, informs 
users on sensitive and customizable steps, delineates the method step-by-step 
and offers a troubleshooting section.  
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IntroDuctIon
RNAseq is a global technique for simultaneously measuring gene 
abundance, detecting unannotated genes and reconstructing the 
complex gene isoforms (both known and novel) that result from 
splicing1–5. However, owing to the wide dynamic range of the 
transcriptome, in which a minority of highly expressed genes 
constitute the majority of RNA molecules within a cell6, RNAseq 
achieves only sparse coverage of weakly expressed transcripts, 
impairing accurate transcript assembly and quantification.
Targeted RNAseq can overcome the challenge posed by the 
wide dynamic range of the cellular RNA population by focusing 
sequencing on targeted genes of interest, thereby providing a huge 
enrichment of sequencing read coverage7,8 (Fig. 1). This enables 
more sensitive gene discovery, quantification and assembly of 
even weakly expressed transcripts. Furthermore, in combination 
with multiplex library preparation, the increased efficiency of 
targeted RNAseq can also reduce reagent costs.
Here we describe a protocol for RNA CaptureSeq that facilitates 
the targeted and focused sequencing of RNAs of interest7. 
This protocol uses labeled in-solution DNA oligonucleotides 
to capture RNA targets of interest that are then purified and 
subjected to sequencing.
Applying CaptureSeq to investigations of RNA biology
The increased sequencing coverage afforded by CaptureSeq can be 
applied to a wide range of transcriptional analyses. CaptureSeq is 
a highly sensitive tool for novel gene discovery, with the contigu-
ous probing of genomic regions often revealing the existence of 
novel and weakly expressed transcripts7. CaptureSeq can also be 
used to selectively target exons to achieve improved coverage of 
known genes, identify novel splicing events and exons7 and even 
distinguish allele-specific gene expression9.
We recently demonstrated the use of CaptureSeq for quantita-
tive gene profiling (M.B.C. et al., unpublished data), finding that 
CaptureSeq accurately retained the quantitative abundance of the 
original RNA samples for all but the most abundant genes. Each 
gene of interest is targeted by a diversity of probes that are present 
with excessive abundance relative to the targeted gene; hence, 
probe availability does not impose a limit on gene sampling (with 
the potential exception of the most abundant genes). Therefore, 
although nontargeted genes are omitted, those genes that are 
targeted are sampled representatively. Indeed, for weakly expressed 
genes, the sequence coverage and high sampling rate provided a 
more accurate measurement of abundance than matched RNAseq, 
which achieved only a low coverage and variable sampling rate. 
This quantitative capacity permits the use of CaptureSeq to 
profile specific gene pathways, marker genes, classes of genes (such 
as long noncoding RNAs) and genes associated with disease8.
CaptureSeq can also be applied as an analytical tool to investigate 
aspects of RNA biology, such as dissecting the pathways involved 
in RNA synthesis, processing and degradation. CaptureSeq can 
sufficiently enrich transient or intermediate RNA species for 
analysis, or it can resolve specific transcriptional features with 
high coverage and resolution. For example, padlock capture has 
been used to achieve sufficient coverage for the high-confidence 
detection and analysis of RNA-editing events10.
Alternative platforms for CaptureSeq
This protocol has been developed by modifying and combining 
RNAseq platforms with the target enrichment platforms that are 
commonly used for targeted DNA sequencing (often referred to as 
exome sequencing)11. These platforms have been well developed 
for the analysis of genetic variation, and they involve a range of 
alternative enrichment strategies. Direct comparisons between 
the technical features of these alternative strategies (including 
coverage, enrichment, uniformity, specificity and so on) have 
been previously reported11,12, and here we discuss the application 
of the three major strategies for targeting RNA transcripts13,14.
Mutliplex PCR amplification uses a pool of primer pairs to 
simultaneously amplify regions of interest for sequencing15, and 
it has been successfully applied for the large-scale validation of 
splice isoforms16. Despite relying on previous gene annotations, 
this approach can also identify novel exons that are amplified 
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rna sequencing (rnaseq) samples the majority of expressed genes infrequently, owing to the large size, complex splicing  
and wide dynamic range of eukaryotic transcriptomes. this results in sparse sequencing coverage that can hinder robust  
isoform assembly and quantification. rna capture sequencing (captureseq) addresses this challenge by using oligonucleotide 
probes to capture selected genes or regions of interest for targeted sequencing. targeted rnaseq provides enhanced coverage 
for sensitive gene discovery, robust transcript assembly and accurate gene quantification. Here we describe a detailed protocol 
for all stages of rna captureseq, from initial probe design considerations and capture of targeted genes to final assembly 
and quantification of captured transcripts. Initial probe design and final analysis can take less than 1 d, whereas the central 
experimental capture stage requires ~7 d. 
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between primer pairs. Although primer design must be performed 
carefully, as differences between individual primers may result in 
heterogeneous coverage, this is a relatively fast protocol, and it can 
be potentially used for quantitative gene profiling. Commercially 
available kits, such as the Life Technologies Ion Ampliseq gene 
panels, have recently become available for multiplex PCR-targeted 
RNAseq.
Capture by circularization targets two paired regions with 
a chimeric probe that forms a circle of the targeted region for 
amplification17,18. This strategy enjoys high specificity, owing to 
the requirement for two complementary sequences in the correct 
orientation, but it relies on previous gene annotations, and it has 
similar disadvantages to multiplex PCR.
In-solution capture uses labeled RNA or DNA oligonucleotides 
that can be hybridized to cRNA or cDNA of interest. Only part 
of a gene needs to be targeted for successful capture, and this 
approach can resolve alternative splicing, transcription initiation 
and termination events. Multiple overlapping probes that target a 
single sequence help average the differential performance of indi-
vidual probes, thereby resulting in a relatively uniform coverage 
and accurate measurement of quantitative abundance. However, 
because of hybridization and washing steps, the protocol is longer 
and more involved than the other approaches.
The protocol described here is based on the use of TruSeq 
stranded mRNA sample preparation (Illumina) in combination 
with SeqCap EZ library (Roche/NimbleGen). This platform uses 
in-solution DNA oligonucleotides for targeted enrichment, is 
fully customizable and can target a large area with high coverage 
(2.1 million in-solution oligonucleotide probes that cover up to 
200 Mb of sequence). Alternative targeted in-solution oligonu-
cleotide capture platforms are available, and they include Agilent 
SureSelect or Illumina TruSeq custom/exome enrichment, both 
of which have recently released commercially available dedicated 
kits for targeted RNAseq.
Protocol overview
This protocol provides detail on the application of CaptureSeq 
for gene discovery and quantification, as previously described7. 
CaptureSeq consists of three major phases (Fig. 2). The first phase 
involves the design of DNA oligonucleotide probes (Box 1). This 
design phase determines which portion of the transcriptome will 
be enriched, and careful design and forethought at this phase are 
critical for the subsequent success of the CaptureSeq method. 
The second phase constitutes the preparation of cDNA librar-
ies, hybridization of libraries to probes, washing and removal of 
nontargeted cDNA and elution of targeted cDNA for sequenc-
ing. This phase encompasses the majority of experimental work 
Gene
Probes designed against target sequences (i.e., gene exons)
Wash away other transcriptsProbes ‘capture’ targeted transcripts
Sequencing
High sequence coverage for transcript assembly
Library of expressed transcripts
Novel exons
Sequence
coverage
a
b
c
Figure 1 | Schematic overview of targeted RNAseq. (a) Oligonucleotide 
probes that are designed to target the exons of a gene are added to a library 
of expressed transcripts. (b) Probes hybridize and capture targeted RNAs of 
interest, whereas other nontargeted RNAs are washed away. The purified RNA 
of interest is then subjected to deep sequencing. (c) The resulting highly 
enriched sequencing coverage enables robust transcript assembly, abundance 
quantification and sensitive detection of novel exons and isoforms. 
Figure 2 | Schematic overview of targeted  
RNAseq in three stages: design (red), capture 
(purple) and analysis (blue). Controls to assess 
and inform experimental performance are 
indicated (shaded gray). During the initial  
design phase (red), complementary 
oligonucleotide probes are targeted to RNA 
transcripts or genomic regions of interest.  
Box 1 provides additional detail for probe  
design. A suite of control probes are also 
included within the design and, before 
manufacture, we recommend iterative design 
validation and estimation of expected fold 
enrichment by comparison with RNAseq libraries. 
The capture phase (purple) encompasses the 
experimental steps of the protocol, including 
sample preparation and central capture steps (shaded purple). PCR amplification cycles are minimized during capture, and qPCR is used to evaluate 
enrichment before sequencing. The final analysis phase (blue) involves the alignment, transcript assembly and quantification of sequenced reads. The 
parallel evaluation of control reads (Box 2 provides further detail on how assessment is performed) permits an assessment of targeted RNAseq performance 
and informs the computational parameters used for experimental sequence read analysis.
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that is conducted within the laboratory, and it is described in 
detail within this protocol. The final stage is the computational 
analysis of the resultant sequenced libraries for which there are 
a range of RNAseq analysis packages available according to the 
user’s requirements3,19. Here we have focused on data analysis 
features specific to CaptureSeq.
Experimental design
Probe design. Users may use fixed probe designs or may wish to 
customize probe design according to their specific requirements. 
Fixed designs target commonly used content, do not require the 
user to undertake probe design and often have the advantages of 
previous validation and optimization. However, if fixed designs 
do not overlap the genes of interest, users may be required to 
customize designs.
Probes can be designed to tile contiguous genomic regions, 
with no reference to prior gene annotations, permitting the dis-
covery of entirely novel genes transcribed from these regions. 
Current oligonucleotide probe platforms can target up to ~6% of 
the human genome when contiguously tiled. Alternatively, exons 
Box 1 | Probe design 
This initial design phase is only necessary for users requiring custom probe manufacture; users using fixed designs can proceed  
directly from Step 1 of the PROCEDURE. Design consideration may vary among platforms, and this protocol is designed for use with 
SeqCap EZ probe library (Roche/NimbleGen).
retrieving a custom gene list
Users designing custom probes are required to generate a tab-delimited file (0-based) containing chromosome start and stop  
coordinates of regions to be targeted by probes. As an example of how to generate a custom target gene list, we describe the  
retrieval of exon coordinates for GENCODE long intergenic noncoding RNAs (lincRNAs) by using the UCSC Genome Browser  
(http://genome.ucsc.edu).
1. Go to the ‘Table Browser’ tool (click ‘Tables’ in top blue header menu) and select the latest GENCODE annotation (select the  
following from drop-down fields; clade: mammal / genome: human / assembly Feb 2009 (GRCh37/hg19)/group: Genes and Gene  
Prediction Tracks / track: GENCODE Genes V17/table: Basic (wgEncodeGencodeBasicV17). Select ‘create’ in the filter field, scroll  
down and select to activate the ‘Linked Tables’ (hg19 wgEncodeGencodeAttrsV17 Basic set of attributes associated with all  
GENCODE transcripts) and select ‘allow filtering using fields in checked tables’ and type into the field ‘geneType does match:  
lincRNA’ and select ‘submit’.
(Optional) Gene identifiers (including names or accession IDs) can be pasted in the identifier (names/accession) field to return a 
selected gene list.
2. Select ‘output format: BED’ and select ‘get output’. On the following screen, ‘Output wgEncodeGencodeBasicV17 as BED’,  
select ‘create one BED record per: Exons’ and select ‘get Bed’. The first three columns of the retrieved tab-delimited file provide the 
chromosome, start and stop coordinates of exons required for probe design. The GENCODE (v17) lincRNAs output file should comprise 
16,525 exons (that represent 6,020 full-length transcripts).
Visualizing targeted sequences
3. Upload coordinate files for review and visualization in the UCSC Genome Browser by using the ‘Add custom Tracks’ tool.  
We recommend thorough review of coordinates to confirm that they correspond to user requirements. Although we do not screen  
for repetitive regions (screening of nonunique sequences is performed during Roche/NimbleGen probe sequence manufacture),  
we recommend omitting any regions that overlap structural ncRNA genes (such as tRNAs, snRNAs and rRNAs) that can be visualized 
with the RepeatMasker track in the UCSC Genome Browser.
estimating expected fold enrichment
4. First, build an index from the probed region sequences. The sequences of GENCODE (v17) lincRNAs can be retrieved as a .fasta file 
by using the Table Browser settings listed for ‘Retrieving a custom gene list’ and selecting output format: ‘sequence’.
(Optional) The fasta sequence file for an uploaded custom track can be selected from the table browser by selecting group:  
‘Custom Tracks’ and selecting output format: ‘sequence’.
$ bowtie2-build probe_sequence.fa probe_index
and then align reads from a matched RNAseq library to this probe sequence index:
$ bowtie2 –-no-head -x probe_index -U RNAseq_library.fastq \
 -S alignments.sam
The output file (‘alignments.sam’) contains the alignment of reads to the probe sequence. For further details on the SAM file format, 
see Li et al.40.
5. To count all alignments to probe sequences, type the following command:
$ awk ‘$2 != 4’ alignments.sam | wc –l
Dividing the number of reads that align to the genome divided by the number of reads that align to probe sequences provides an  
estimate of fold enrichment.
6. Provide the tab-delimited coordinate file of probe regions to a commercial vendor to manufacture the probe sequences.  
Supplied probe libraries should be prepared as described in Reagent Setup.
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can be selectively targeted, with interven-
ing introns ignored. Targeting only part of 
a transcript is often sufficient to capture 
the full-length transcript, including addi-
tional spliced exons within the same tran-
script. Indeed, this is a major advantage of 
CaptureSeq that allows the identification 
of novel exons and splice isoforms for the 
expansion of known annotations. Specific 
isoforms can be also targeted by spanning 
probes across an exon-exon junction (Fig. 3); however, this biases 
against the identification of intervening novel exons.
Strategies for optimizing probe sequences that were originally 
developed for microarray technologies can be similarly applied to 
CaptureSeq20. Efficient probe design aims to minimize differences 
between individual probe melting temperature and nucleotide 
content and to avoid stable secondary structures. High probe 
coverage, with multiple probes overlapping a single region, also 
provides redundancy, averaging the differential performance 
between probes. Probe features vary substantially between 
different enrichment platforms, but they are typically longer than 
100 nt, which affords high specificity11.
Estimating fold enrichment. The scale of enrichment and 
sequencing coverage realized by CaptureSeq is inversely pro-
portional to the collective expression of targeted transcripts. 
Therefore, to maintain a high enrichment, a large number of 
weakly expressed genes or a smaller number of moderately 
expressed genes can be targeted. Targeting all known exons to 
1,000 randomly selected ‘average’ human genes corresponds 
to an expected ~55-fold target enrichment (Fig. 4), and we 
recommend aiming to achieve at least ~20-fold enrichment, 
which corresponds to targeting ~2,700 genes21.
Before manufacture, we recommend estimating the expected 
maximal fold enrichment of probe designs by using RNAseq 
libraries from matched or closely similar tissue sources (Box 1). 
These can often be retrieved from a public sequence data archive 
(such as Gene Expression Omnibus (GEO)) or consortium (such 
as Encyclopedia of DNA Elements (ENCODE))22. The fractional 
overlap of read alignments to targeted regions (including control 
probes) allows an estimate of fold enrichment, and fractional 
overlap with individual targeted genes can inform iterative 
design amendments that omit highly expressed genes or identify 
off-target hybridization from homologous transcribed sequences. 
In practice, we generally return a lower enrichment than 
the estimated fold enrichment because of the additional capture 
of novel exons and isoforms and contamination by off-target 
transcripts.
The estimated fold enrichment can also inform the sequencing 
depth required to achieve the user’s aim. Gene discovery 
applications generally require high sequence coverage for 
robust de novo assembly of spliced transcripts, with an esti-
mated minimum eightfold coverage required for the assem-
bly of spliced genes6. Sequence coverage is also a function of 
read length, and sequencing with paired-end reads of maximum 
length is highly advantageous for efficient transcript assembly3. 
For gene profiling applications, the sequencing depth may be 
lower, as coverage only needs to be sufficient for robust 
abundance measurements. Accordingly, users may prefer to 
profile larger numbers of multiplexed samples, with a commen-
surately lower coverage.
Targeting repeats. Repetitive sequences require special considera-
tion during probe design. Repetitive sequences span a range of 
uniqueness, from repeats with a unique sequence (albeit highly 
similar to others) to identical sequences found in high numbers 
throughout the genome. Targeting a transcript that harbors a 
repetitive or similar sequence can result in off-target hybridiza-
tion and, if probes become saturated, incomplete coverage of the 
original targeted RNA. Although some designs may specifically 
target and exploit a repeat element to target a class of RNA23, we 
generally recommend masking out highly transcribed repetitive 
genes (such as rRNAs, tRNAs and small nuclear RNAs (snRNAs)) 
whose off-target capture will substantially reduce enrichment.
Probes crossing splice junction–bias against detection of novel exons
Gene
Probes not crossing splice junction–can detect novel exons
Novel exon
ProbesFigure 3 | Designing probes at splice junctions. 
Designing probes that traverse exon-exon 
junctions (blue) excludes novel cassette exons. 
Designing probes that target exons but do 
not traverse exon-exon junctions permits the 
identification of novel exons (purple).
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Figure 4 | Estimated fold enrichment achieved relative to the number of 
genes targeted. The estimated fold enrichment was calculated according 
to the number of genes targeted by the probe design. Estimated fold 
enrichment was calculated based on mean expression of a random selection 
of genes in three replicates of the K562 human cell type45.
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Control probe design. We recommend the inclusion of control 
probes to appraise capture performance. For example, control 
probes targeting nontranscribed genomic regions can indicate DNA 
contamination and measure false-positive alignment and transcript 
assembly. The inclusion of probes to housekeeping genes provides 
positive controls that also help evaluate correct transcript assembly 
Box 2 | Control probe design and analysis 
We recommend the inclusion of the following control probes that permit the assessment of CaptureSeq performance:
• Probes targeting a nontranscribed intergenic region (<100 kb) to identify gDNA contamination.
• Control probes targeting a subset (>5) of endogenous genes that cover a range of expression levels (avoiding highly expressed 
genes). These genes can be used to determine library enrichment by qPCR before sequencing and evaluate read alignment and  
transcript assembly parameters.
• Sequences from E. coli or other common laboratory species to detect library contamination.
• If investigating the expression of single exon transcripts or sites of transcriptional initiation or termination, users can include nearby 
intergenic regions (of at least a random subset), to help distinguish signal from noise.
• Control probes targeting a subset of ERCC RNA spike-in standards24 to assess performance, sensitivity, dynamic linear range,  
enrichment and off-target capture. The RNA spike-ins standards consist of 92 in vitro–transcribed polyadenylated transcripts,  
combined at varying abundance spanning an ~106-fold range in concentration, that are included during initial RNA sample preparation 
according to the manufacturer’s instructions. To minimize the reduction in global enrichment caused by sequencing of highly expressed 
control probes instead of captured gene targets, we suggest not targeting the ERCC spike-in probes present at the highest three or  
four concentrations (unless the user aims to analyze and profile highly expressed genes). Capturing a subset of the controls also  
allows the measurement of off-target capture. Details of probes are available in the ERCC RNA spike-in control mixes user guide.
linear dynamic range
CaptureSeq can perform quantitative measurement of targeted genes. However, targeting abundant genes can saturate probes, imposing 
an upper limit where the CaptureSeq dynamic range flattens. To determine this upper limit, we plot the FPKM (fragments per kilobase 
per million mapped reads) measurement for each RNA standard against its known molar concentration, and use linear regression to 
determine the best-fit line and then perform segmented regression to determine the upper limit to the CaptureSeq dynamic range. 
Detection of ERCC probes also indicates the limit of sensitivity with which weakly expressed transcripts can be detected. CaptureSeq is 
sensitive enough to routinely detect the lowest molar amount of ERCC probes present in the sample.
To illustrate this, we have plotted the measured abundance of ERCC RNA spike-ins (in FPKM) against their known concentrations  
within the example data (Fig. 6a), observing a linear relationship across the full dynamic range. This reveals that probes targeting 
even the most abundant ERCC RNA spike-ins have not become saturated. Similarly, we do not detect the least abundant ERCC  
spike-ins, indicating the lower limit of sensitivity. This indicates that the enriched sequence coverage of the example library has  
not achieved saturation, probably owing to both the large number of transcripts targeted for captured within this design and also  
the relatively shallow sequenced library depth. By comparison, we have included a plot of ERCC concentration and measured  
abundance derived from a CaptureSeq experiment with sufficient sequencing depth and enrichment to approach saturated sequencing 
coverage of ERCC RNA spike-ins (Fig. 6b). Robust sequencing coverage is achieved for all concentrations of ERCC spike-ins, indicating 
high sensitivity and low variability.  
An inflection point determined by  
segmental linear regression identifies an 
upper limit to the CaptureSeq quantitative 
range owing to probe saturation.
endogenous gene quantification
Comparison of the measured FPKM of 
endogenous transcripts with the  
FPKM of ERCC spike-ins at known  
concentrations provides an estimate of 
endogenous transcript concentration 
within the initial RNA sample.
off-target capture
The capture of novel exons that are 
spliced to captured exons can prevent 
a clear measure of off-target capture. 
Given that highly abundant ERCC  
spike-ins may not be targeted because 
they may reduce global enrichments, 
these abundant ERCC spike-ins provide 
an ideal measure of off-target capture, 
and they indicate the stringency of the 
CaptureSeq enrichment.
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Figure 6 | Analysis of ERCC RNA spike-ins to assess the performance of CaptureSeq experiments.  
(a,b) Scatter plot indicating the measured abundance of ERCC RNA spike-ins relative to known 
concentration within a sample, for CaptureSeq example data with low sequencing coverage (a) and 
high sequence coverage (b). (a) The absence of detection of low-abundance ERCC spike-ins and high 
variability of measured abundance indicates low sequencing coverage due to shallow library sequencing 
depth and/or targeting a large portion of transcriptome. (b) Low variability and representative 
sampling and the presence of an inflection point followed by increasing underestimation of measured 
abundance owing to probe saturation indicate high sequencing coverage achieved by CaptureSeq.
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parameters. Probes targeting RNA Spike-In controls added dur-
ing sample preparation can also indicate the quantitative accuracy, 
dynamic range and sensitivity of each capture and aid comparative 
analysis between different CaptureSeq experiments. This protocol 
includes the use of External RNA Control Consortium (ERCC) 
ExFold RNA spike-in mixes, which are added to the RNA sample 
before capture (see Box 2 for further details)24.
RNA input. Although many RNAseq library preparation protocols 
require as little as 100 ng of total RNA or 10 ng of rRNA-depleted 
RNA, the resultant cDNA library yield may be insufficient for 
subsequent capture steps (encompassing hybridization, wash 
and elution steps). We find that 5 µg of total RNA will give a 
final yield of at least 250 ng (and more commonly ~500 ng) of 
amplified cDNA library that is ready for capture. However, we 
recommend preparing at least 1.15 µg of cDNA library per cap-
ture (1 µg for capture steps, 150 ng for later quantitative PCR 
(qPCR)). Although additional library amplification can increase 
the library yield, this increases the effect of PCR amplification 
biases and there is an added risk of transcript ‘drop-out’ when 
targeting weakly expressed transcripts from a small RNA sam-
ple input. Therefore, one effective strategy to generate sufficient 
library input is to combine multiple multiplex-prepared samples 
in a single capture hybridization (see ‘Multiplexing’ below).
Minimizing PCR amplification cycles. PCR amplification 
is required for both cDNA library preparation before capture 
and for the amplification of the postcapture library before 
sequencing. These two stages of PCR amplification can risk 
unwanted PCR amplification artifacts or biases. To minimize the 
effect of PCR amplification artifacts, we reduce the number of 
amplification cycles as much as possible during the procedure. 
For example, before precapture ligation-mediated PCR (LMPCR; 
using Phusion polymerase) we create test libraries to estimate 
the minimum number of cycles required. In our experience, low 
test library concentrations of 2.5–4 ng/µl require 12 precapture 
LMPCR cycles to generate >450–500 ng of cDNA library yield 
(Fig. 5). Concentrations between 5 and 9 ng/µl require 11 cycles 
to generate >500 ng of cDNA library, and a test library concen-
tration of >10 ng/µl requires 10 cycles of pre-capture LMPCR to 
provide more than 500 ng of library yield. Contrary to expecta-
tions, higher test library concentrations often do not result in pro-
portionally higher yield (for example, 20 ng/µl doesn’t generally 
provide >500 ng after nine cycles). Note that differing conditions 
and polymerases will affect the number of cycles required.
Evaluating the postcapture library. We recommend using 
qPCR to evaluate the fold enrichment and capture performance 
before commencing sequencing. Endogenous control genes, 
capture targets and/or ERCC RNA spike-ins can be compared 
between pre- and postcapture libraries to estimate the fold 
enrichment achieved. Similarly, measuring the fold depletion of 
transcripts not targeted by the capture probes provides a measure 
of capture stringency.
Multiplexing. CaptureSeq is compatible with multiplexed library 
preparation, permitting multiple libraries to be processed in a sin-
gle capture (hybridization/wash/elution) reaction. This permits 
CaptureSeq to be used to efficiently profile a gene set of interest 
in large numbers of samples at reduced sequencing costs, which 
is a major advantage for gene expression profiling applications. 
A further benefit is that multiple uniquely bar-coded libraries 
can be combined to provide sufficient library yield input for 
capture. However, it is important that blocking or hybridization-
enhancing (HE) oligonucleotides are coordinated with multi-
plex bar-code sequences (Supplementary Data). Despite these 
advantages of multiplexing, users should be aware that precapture 
pooling could potentially result in PCR recombination artifacts. 
These artifacts can be mitigated by the use of double index 
primers, if required25.
Performing a control DNA capture experiment. Although it is 
not strictly required, a control capture using matched genomic 
DNA (gDNA) can be used to identify anomalous probe hybridiza-
tion artifacts and normalize RNA expression by the efficiency with 
which each oligonucleotide probe captures DNA. This control is a 
standard gDNA capture, and it should not be performed by using 
K-562 test library–low yield
3.5 ng/µl
Postcapture–ready for sequencing
Unincoporated
primers
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d
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K-562 postcapture LMPCR
~250 ng
Figure 5 | Example Agilent Bioanalyzer results for pre- and postcapture 
libraries. (a,b) Examples of K-562 test libraries with high and low yields 
owing to different RNA inputs into the Illumina TruSeq library preparation 
and the generation of sufficient library yield with different numbers of cycles 
during pre-capture LMPCR. Libraries show typical fragment size ranges.  
(c) Agilent high-sensitivity chip showing K-562 postcapture LMPCR library. 
The library shows typical size range, with blue arrow indicating small nucleic 
acid species, probably unincorporated primers, which, if present, should 
be removed by a second round of purification. (d) Example of a purified 
postcapture LMPCR library ready for sequencing.
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the protocol described below. Instead, we recommend following 
the standard gDNA capture protocol, described in the Roche/
NimbleGen SeqCap EZ library SR User’s Guide (see Equipment), 
with the minor amendments of fragmenting gDNA to a similar 
size range to RNAseq libraries and making corresponding adjust-
ments to AMPure DNA cleanup steps. Similarly to cDNA capture, 
extra precapture LMPCR cycles may also be required to generate 
sufficient DNA for capture.
CaptureSeq data analysis. The computational analysis of 
CaptureSeq data is similar to that of other RNAseq applications. 
The wide range of tools for sequence read quality control, 
aligning reads to the genome or transcriptome and across 
splice junctions, assembling aligned reads into full-length 
transcripts and quantifying genes are applicable and well 
documented12,26–28. We recommend that users familiarize 
themselves with RNAseq analysis protocols that provide detailed 
information for downloading, installing and running the required 
software3,19. Within this protocol, we have only focused on 
computational considerations specific to the analysis of 
CaptureSeq data.
We have assumed that users operate software through the 
UNIX shell command line. Users unfamiliar with the UNIX shell, 
or without access to sufficient computational resources, can 
perform data analysis within GenePattern29 or the Galaxy 
Project30, which provides web-interface access to cloud- 
computing bioinformatic resources, including TopHat2 (ref. 31) 
and Cufflinks26, in an intuitive graphical format.
MaterIals
REAGENTS
 crItIcal Although we generally recommend that most reagents be  
purchased from the listed companies, generic reagents (such as Cot-1,  
nuclease-free water and so on) can be purchased from alternative vendors. 
Most equipment can also be purchased from manufacturers other than those 
listed, and some procedures (such as nucleic acid quantification or qPCR) 
can be equivalently performed with alternative protocols. For software  
packages listed below, we recommend using the most recent release version, 
as well as reading corresponding documentation.
Sodium acetate, 3 M, pH 5.0
Agarose (for DNA electrophoresis)
Agencourt AMPure XP, 60-ml kit (Beckman Coulter Genomics,  
cat. no. A63881)
Agilent DNA 1000 kit (Agilent Technologies, cat. no. 5067-1504)
Agilent high-sensitivity DNA kit (Agilent Technologies, cat. no. 5067-4626)
Agilent RNA 6000 nano kit (Agilent Technologies, cat. no. 5067-1511)
Agilent RNA 6000 pico kit (Agilent Technologies, cat. no. 5067-1513)
Cot-1 human DNA, fluorometric grade, 1 mg/ml; 1 ml (Life Technologies, 
cat. no. 15279-011)
DNA electrophoresis buffer (1× sodium boric acid buffer (35 mM boric 
acid, pH to 8.5 with sodium hydroxide))
DNA electrophoresis loading dye and ladder
dNTP set (Life Technologies, cat. no. 10297-018)
Dynabeads M-270 (Life Technologies, cat. no. 65305)
EPH buffer (2× FPF buffer; Illumina—supplied as special request item)
ERCC ExFold RNA spike-in mixes (Life Technologies, cat. no. 4456739)
Ethanol (absolute)
NimbleGen SeqCap EZ choice/choice XL libraries (solution-based captures)
NimbleGen SeqCap EZ hybridization and wash kit (Roche Diagnostics,  
cat. no. 05634261001 24rxns)
Oligonucleotides (for sequences and concentrations, see Supplementary Data)
Phusion high-fidelity (HF) DNA polymerase with 5× HF buffer,  
100 reactions (NEB Finnzymes, cat. no. M0530S)
QIAquick PCR purification kit, 50 (Qiagen, cat. no. 28104)
Ribo-Zero rRNA magnetic kit (Epicentre, cat. no. MRZH116)
RNA sample(s) for analysis (sample(s) should be of sufficient quality  
(RNA integrity number (RIN) >6–7))
RNase-/DNase-free water (Life Technologies, cat. no. 10977-023)
RNeasy MinElute cleanup kit (Qiagen, cat. no. 74204)
Species-specific gDNA (or similar)
SuperScript II reverse transcriptase (Life Technologies, cat. no. 18064-014)
SYBR Green PCR master mix, 5ml (Applied Biosystems, cat. no. 4309155) 
(alternative quantitative PCR methods can be similarly used for accurate 
quantification32)
SYBR Safe DNA gel stain (Applied Biosystems, cat. no. S33102)
Taq DNA polymerase (Fisher Biotec, cat. no. TAQ-1) (Taq polymerase from 
alternative vendors can be similarly used for DNA contamination testing)
TruSeq stranded mRNA sample prep kit (Illumina, cat. no. RS-122-2101 kit A)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
TURBO DNase (Life Technologies, cat. no. AM2238)
EQUIPMENT
Nuclease-free PCR tubes, 0.2 ml (Eppendorf, cat. no. 951010006)
DNA LoBind tubes, 1.5 ml (Eppendorf, cat. no. 022431021)
RNase/DNase-free Falcon tubes, 15 ml (Corning, cat. no. 352095)
RNase/DNase-free Falcon tubes, 50 ml (Corning, cat. no. 352070)
PCR plates, 96 wells, 0.3 ml (Bio-Rad, cat. no. Hss-9601)
Agarose gel electrophoresis equipment
BD PrecisionGlide needle (18-G × 1 1/2 in) (Becton Dickinson,  
cat. no. 302032)
Benchtop centrifuges or microcentrifuges for 1.5-ml and 0.2-ml tubes
Benchtop centrifuge (that can centrifuge 96-well plates)
Bioanalyzer (Agilent Technologies)
DynaMag-2 magnet, to hold 1.5-ml tubes (Invitrogen, cat. no. 123-21D)
Freezers (−20 °C, −80 °C)
Magnetic stand 96 (Ambion, cat. no. AM10027)
Microseal ‘B’ adhesive seals (Bio-Rad, cat. no. MSB-1001)
NanoDrop (Thermo Scientific) (Alternative nucleotide acid quantification 
methods, such as the QuBit fluorometer, can be equivalently used)
PCR thermocycler(s) suitable for 0.2-ml tubes, 0.3-ml 96-well plates
Pipettors, l–10 µl, 20 µl, 200 µl, 1,000 µl
qPCR machine
Refrigerator, 4 °C
Vacuum concentrator
Vortex mixer
Water bath and/or heating blocks
Software
Bowtie2 (ref. 33) (http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml) 
is used to align reads by TopHat2 and also used to estimate the fold enrichment
TopHat2 (ref. 31) (http://tophat.cbcb.umd.edu/) is used within this protocol 
to align sequenced reads to the genome and across known and novel splice 
junctions. Alternative software, such as STAR34, SpliceMap35 and GSNAP36, 
can be similarly used
Cufflinks37 (http://cufflinks.cbcb.umd.edu/) is used within this protocol 
to assemble full-length transcripts from short-read alignments. Alternative 
software, such as iReckon38 and SLIDE39, can be similarly used
SAMtools40 (http://samtools.sourceforge.net/) permits manipulation of 
SAM- or BAM-formatted files
BEDTools41 (https://github.com/arq5x/bedtools2/) permits the  
manipulation BAM-, GTF- and BED-formatted files
Index for human reference genome and gene annotations (available for 
download at http://tophat.cbcb.umd.edu/igenomes.shtml)
(Optional) A gene annotation file (.gtf format) to aid Cufflinks-mediated 
transcript assembly: we recommend using the most recent and comprehensive 
GENCODE annotation available at http://www.gencodegenes.org/releases/
(Optional) Genome browser for visualization of read alignments  
and assembled transcripts: e.g., the Integrated Genome Viewer  
(http://www.broadinstitute.org/software/igv/) or the University of  
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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California, Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu).  
The UCSC Genome Browser also comprises a useful repository for gene  
annotations and permits simple bioinformatics queries. We recommend 
that users become familiar with using the UCSC Genome Browser42  
by completing the tutorial and training modules (http://genome.ucsc.
edu/training.html)
Additional documentation referred to within the protocol
Agilent DNA 1000 kit quick start guide, part no. G2938-90015 (revision B)
Agilent high-sensitivity DNA kit guide, part no. G2938-90322 (revision C)
Agilent RNA 6000 nano kit quick start guide, part no. G2938-90037 (revision C)
Agilent RNA 6000 pico kit quick start guide, part no. G2938-90049 (revision C)
ERCC RNA spike-in control mixes user guide, part no. 4455352 (revision D)
Illumina TruSeq stranded mRNA sample preparation guide, part no. 
15031047 (revision D; September 2012)
QIAquick spin handbook (May 2012)
Ribo-Zero magnetic kit protocol. lit. no. 335 (April 2013)
Roche/NimbleGen SeqCap EZ library SR user’s guide, v 4.0 (January 2013)
TURBO DNase, part no. 1907M (revision G)
REAGENT SETUP
Minimizing PCR contamination Because of the sensitivity of CaptureSeq,  
it is recommended that reagents required for PCR amplification be divided 
into separate stocks for pre- and postcapture LMPCR amplification steps. 
Ideally, all pre-PCR amplification steps should be performed in a  
separate location and with separate equipment for post-PCR steps.
Probe library preparation Upon receipt of SeqCap EZ probe library, thaw 
the tube(s) on ice. Once they have thawed, vortex the tube(s) for 3 s and  
centrifuge each tube at 10,000g for 30 s at room temperature (20–25 °C) to 
accumulate the solution at the bottom of the tube. Transfer 4.5-µl aliquots of 
SeqCap EZ probe library into 0.2-ml PCR tubes to create single-use aliquots 
and store them at −20 °C until use. The sequence capture libraries are  
potentially sensitive to multiple freeze-thaw cycles, and they can be stored  
at −20 °C for at least 6 months.
HE oligo preparation If you are starting from lyophilized oligos, make up 
1,000 µM stocks of HE oligos in nuclease-free water. Divide the stocks into 
•
•
•
•
•
•
•
•
•
•
smaller volumes to minimize future freezing and thawing. For all HE oligos 
corresponding to indexes, also prepare several aliquots at 100 µM. Freeze 
those aliquots that are not required for immediate capture hybridization at 
−20 °C.
EQUIPMENT SETUP
Maintaining hybridization and wash temperatures Several steps during 
capture, including hybridization and washing, are highly sensitive to time 
delays and temperature changes. To prevent delays and to prevent samples 
from cooling when being transferred between equipment, we recommend 
that these steps be performed with localized equipment. If this is not possible, 
the samples should be stored in a heated block to maintain temperature when 
being transferred between equipment. Thermocyclers should be programmed 
with the required reaction programs before use.
Example data Data from M.B.C. et al. (unpublished data) are used here to 
demonstrate probe design and data analysis. The library comprises a  
single replicate of ~20 million reads from human K562 cells with a long  
noncoding RNA (lncRNA)–specific probe design. This library is chosen  
for its small memory requirements and fast processing time; however, the  
effective sequencing depth is less than the depth we recommend for novel 
gene discovery.
Raw sequencing reads and probe design coordinates, as well as anticipated 
results (coverage and assembled transcripts), are available through the Gene 
Expression Omnibus (accession no. GSE52503). Probe design coordinates 
targeting long noncoding RNAs are based on publicly available annotations 
from GENCODE (v12), lncRNAdb43, Cabili et al.44 and proprietary  
annotations. This includes GENCODE long intergenic noncoding RNA  
(lincRNA) annotations whose retrieval is described within the protocol  
(Box 1), but it also targets additional annotated lncRNAs.
An RNAseq library of the human K562 cell line is used to estimate fold 
enrichment before probe manufacture; it can be downloaded from UCSC/
ENCODE45 (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/
wgEncodeCaltechRnaSeq/wgEncodeCaltechRnaSeqK562R1x75dFastqRep1.
fastq.gz).
proceDure
preparation of Dna-free, rrna-depleted sample rna ● tIMInG ~1 d
 crItIcal For all steps involving RNA, perform experiments under RNase-free conditions with RNase-free reagents and 
labware. RNA samples should be kept on ice when thawed.
1| CaptureSeq is an extremely sensitive technique, and DNA contamination can confound interpretation of RNAseq  
results. Validate that the sample RNA is free from gDNA contamination by conducting PCR amplification for a short region  
of gDNA (~100 nt) by using 200 ng of RNA as a template. Include a positive gDNA and a negative H2O control.  
Primer sequences to amplify a 95-nt gDNA product within the human nuclear paraspeckle assembly transcript 1 (NEAT1)  
loci are provided within the supplementary Data. A variety of Taq polymerases and buffer conditions will be suitable;  
an example PCR assembly is as follows:
component amount (l) Final concentration
RNA, 200 ng/µl 1 10 ng/µl
dNTP, 10 mM (2.5 mM each) 0.8 0.4 mM
Fisher Biotec 10× reaction buffer 2 1×
Primer (forward, 10 µM) 0.5 250 nM
Primer (reverse, 10 µM) 0.5 250 nM
MgCl2, 25 mM 1.2 1.5 mM
Fisher Biotec Taq DNA polymerase, 5 U/µl 0.25 1.25 U
Distilled water 13.75
Total 20
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2| Perform a 35-cycle PCR by using the following cycling conditions:
cycle number Denature anneal extend
1 94 °C, 3 min
2–36 94 °C, 30 s 55 °C, 30 s 72 °C, 25 s
37 72 °C, 5 min
Final 4 °C, hold
3| Confirm that the RNA samples are free of DNA by agarose gel electrophoresis of the PCR product(s). Cast a 2.5% (wt/vol)  
agarose gel in DNA electrophoresis buffer (1× sodium boric acid buffer) with either 1× SYBR Safe dye or ethidium bromide. Run the 
gel at 170 V for 20 min to verify that amplification occurred for the positive control sample alone, and not for the RNA samples.  
If no DNA contamination is present in the RNA sample, proceed directly to Step 4. However, if DNA contamination is present, treat 
the RNA with TURBO DNase (as per the manufacturer’s instructions), purify it by using either standard phenol/chloroform extraction 
or an RNeasy column (as per the manufacturer’s instructions) and then repeat Steps 1–3 to recheck for DNA contamination.
4| Check the RNA sample integrity with an Agilent Bioanalyzer RNA Nanochip. Follow the Agilent RNA 6000 nano kit guide 
and select a Total RNA assay in the Bioanalyzer software. High RIN scores (>8) are ideal. Partially degraded RNA samples 
(RIN scores between 6 and 8) can be used but may benefit from a shorter fragmentation time (reduction from 8 to 6 min) 
(Step 10) before Illumina RNA TruSeq library construction. We have not validated this protocol on RNA with RINs <6; other 
library construction methods may perform better for degraded RNA46.
 pause poInt DNA-free RNA samples can be stored at −80 °C indefinitely.
5| rRNA-deplete the sample RNA by using Ribo-Zero purification as per the Ribo-Zero magnetic core kit protocol.  
Purify the rRNA-depleted sample RNA by using RNeasy MinElute columns according to the protocol in Appendix A of the 
Ribo-Zero magnetic kit. The ERCC RNA spike-in control mix can be added at this step before Ribo-Zero purification (instead  
of at Step 8 below); see the ERCC RNA spike-in control mixes user guide to calculate the correct amount to be added. 
 crItIcal step Given the abundance of rRNA compared with capture targets (often 1% or less of the ‘mRNA’ fraction), 
rRNA depletion is important to ensure that off-target rRNA does not erode enrichment levels. An additional concern is that 
highly abundant rRNA may preclude amplification of the less-abundant species during the initial PCR amplification step that 
precedes capture, probably resulting in a less-informative capture outcome.
 crItIcal step If required, the samples can be divided into smaller volumes for more efficient parallel rRNA depletion.
 pause poInt rRNA-depleted RNA samples can be stored at −80 °C for at least 1 week.
6| Determine the concentration of rRNA-depleted RNA samples. Analyze 1 µl from each sample on a NanoDrop according  
to the manufacturer’s instructions to provide a concentration estimate for correct Bioanalyzer loading. Dilute 1 µl of  
each rRNA-depleted RNA sample for analysis and quantification with an Agilent Bioanalyzer according to the Agilent RNA 
6000 pico kit guide and by selecting mRNA assay in the Bioanalyzer software. Confirm successful rRNA depletion of RNA.  
The expected yield is ~2–10% of the original input RNA.
 crItIcal step If multiple ribo-depletions were performed from the same total RNA sample (at Step 5), pool rRNA-depleted 
samples before preparing sequencing libraries.
? trouBlesHootInG
preparation of sequencing libraries with the Illumina truseq stranded mrna kit ● tIMInG ~2 d
7| A maximum of 400 ng of rRNA-depleted sample can be used as input for each sequencing library preparation.  
If the rRNA-depleted RNA yield is greater than 400 ng, add 400 ng of RNA into a new tube and adjust the volume to 8 µl 
by adding nuclease-free water. If the rRNA-depleted RNA yield is less than 400 ng, reduce the RNA volume to 8 µl with a 
vacuum concentrator (do not apply heat).
8| Add 1 µl of ERCC RNA spike-in control at an appropriate dilution, as indicated in the user guide for the ERCC RNA  
spike-in control mixes.
 crItIcal step ERCC RNA spike-in mixes provide important information for sequencing analysis (Box 2 and Fig. 6), and 
they are added in this step (if not previously added before rRNA depletion).
9| Add 9 µl of each rRNA-depleted RNA sample (now including ERCC RNA spike-in) to a well in a 96-well plate.  
Add 9 µl of EPH buffer and mix it thoroughly by pipetting. Return the EPH buffer to −20 °C and seal the 96-well plate with  
Microseal ‘B’ adhesive seal.
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10| Fragment the RNAs in a thermocycler (heat the plate to 94 °C for 8 min and then cool it to 4 °C). Centrifuge the plate 
at 280g for 10 s, if required. Proceed immediately to the next step.
11| Prepare RNA-sequencing libraries according to the Illumina TruSeq stranded mRNA sample preparation guide. Start at 
chapter ‘Synthesize first strand cDNA’. Proceed through the Illumina TruSeq stranded mRNA sample preparation guide protocol 
(including ‘Synthesize first strand cDNA’, ‘Synthesize second strand cDNA’, ‘Adenylate 3′ ends’ and ‘Ligate adaptors’ chapters) 
to a final step of ‘Ligate adaptors’ where unamplified libraries are ready to be transferred from the Clean-up ALP (CAP) plate.
 crItIcal step If libraries are being prepared for multiplex capture or sequencing, it is important to ensure that each 
library has a different index. Correct multiplex index combinations (provided in the Illumina TruSeq stranded mRNA sample 
preparation guide) are important, and they must be coordinated with corresponding blocking oligonucleotides used in Step 29.
12| Transfer 20 µl of the supernatant from each well of the CAP plate to a new 96-well plate and store the unamplified cDNA 
library for future precapture LMPCR (Step 19 below).
 crItIcal step A volume of 20 µl of unamplified cDNA library is saved for precapture LMPCR (Step 19), whereas 1 µl of the 
library remaining in the CAP plate is used to create an amplified test library for assessing library quality.
 pause poInt The unamplified 20-µl sample can be stored for at least 2 weeks at −20 °C.
13| The CAP plate should now have ~2.5 µl of supernatant and beads remaining. Carefully remove 1 µl of supernatant  
(without beads), and transfer it to a new 96-well plate labeled with an Illumina PCR bar code.
14| Dispense 19 µl of Illumina resuspension buffer into each well containing 1 µl of supernatant and mix it well by  
pipetting. This plate is used to amplify a test library.
 pause poInt The 96-well plate of unamplified test libraries can be stored for at least 1 week at −20 °C.
15| Create the test library (to assess the quality of the sequencing library before performing precapture LMPCR) by following 
the protocol in the Illumina TruSeq stranded mRNA sample preparation guide/‘Enrich DNA fragments’ chapter.
 pause poInt Purified amplified test library PCR plate can be stored for at least 1 week at −20 °C.
16| Measure the purified test library yield by loading 1 µl of the test library on an Agilent DNA 1000 Chip according to  
the Agilent DNA 1000 kit guide. The library size should range from 180 to 500 nt, with a peak at ~260–280 nt (Fig. 5a,b). 
Performing a ‘Smear analysis’ on this size range by using the 2100 Expert software provides a ng/µl value for the test  
library. Although concentrations above 10 ng/µl are desirable, libraries that provide much lower yields can still be  
successfully used; see ‘Minimizing PCR amplification cycles’ in Experimental design for further guidance.
? trouBlesHootInG
precapture lMpcr ● tIMInG ~3 h
17| Use the yield from the amplified test library to calculate the number of cycles required for precapture LMPCR of the 20-µl 
unamplified library from Step 12. See ‘Minimizing PCR amplification cycles’ in Experimental design for guidance.
 crItIcal step Performing as few PCR amplification cycles as possible to generate precapture LMPCR libraries will reduce 
the effect of PCR amplification artifacts. The number of cycles required will depend on the polymerase used and the amount 
of library required for capture.
18| Thaw the reagents and prepare LMPCR reactions on ice. A water control is required for each precapture LMPCR, and thus 
even a single library will need a minimum 2× LMPCR master mix. The volumes necessary for a 1× master mix are given below; 
however, creating 5–10% additional PCR master mix is recommended.
component amount (l) Final concentration
Phusion HF buffer, 5× 20 1×
dNTPs, 10 mM  2 200 µM
TS-PCR oligo1, 100 µM  2 2 µM
TS-PCR oligo2, 100 µM  2 2 µM
Nuclease-free water 53
Phusion DNA polymerase, 2 U/µl  1 2 U
Total 80
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19| Add the 20 µl of unamplified cDNA library (from Step 12), or nuclease-free water (for the negative control), into a  
PCR tube or well. Add 80 µl of the LMPCR master mix into each tube or well. Mix the sample and PCR master mix by gentle 
pipetting (about five times). Perform precapture LMPCR with the following cycling conditions:
cycle number Denature anneal extend
1 98 °C, 30 s
2–user defined 98 °C, 30 s 60 °C, 30 s 72 °C, 30 s
Final 72 °C, 5 min
4 °C, hold
 pause poInt Amplified precapture LMPCR cDNA library can be stored for 3 d at 4 °C, or at least for 1 week at −20 °C.
20| Transfer PCR reactions to separate 1.5-ml tubes, and clean up each amplified precapture LMPCR cDNA library and  
negative control by using either QIAquick PCR purification (option A) or AMPure XP beads (option B)
(a) QIaquick pcr purification kit
 (i)  Follow the QIAquick PCR purification kit user guide, ensuring that the library is eluted in 50 µl of nuclease-free water  
(pH 7.0–8.5).
(B) aMpure Xp beads
 (i)  Place AMPure XP beads at room temperature. Allow them to warm for 30 min before use.
 (ii)  While the beads are warming in Step 20B(i), prepare fresh 80% (vol/vol) ethanol sufficient for Step 20B(vi–viii) below.
 (iii)  Resuspend room temperature beads by vortexing to ensure a homogeneous mixture.
 (iv)  Add a 1.8× volume of beads to each PCR (i.e., add 180 µl to a 100-µl PCR), mix by brief vortexing and then incubate 
the beads for 15 min at room temperature.
 (v)  Place each tube on a magnetic plate or stand. Once the solution has cleared, without disturbing the beads, remove the 
supernatant and discard it.
 (vi) Keep the tubes on the magnetic stand and add 200 µl of 80% (vol/vol) ethanol (from Step 20B(ii)) to each tube.
 (vii) Incubate the tubes for 30 s, and then, without disturbing the beads, remove all of the ethanol.
 (viii) Repeat Step 20B(vi, vii) for a total of two ethanol washes.
 (ix)  Leave the tubes in the magnetic plate/stand with lids open for up to 15 min to remove all ethanol traces and to dry 
the beads. Once the beads or the tube is dry, continue with the next step. Do not overdry (the bead cluster appears 
cracked) the beads, as this inhibits elution of DNA from the beads.
 (x)  Take the tubes off the magnetic stand and resuspend the beads in 52 µl of nuclease-free water by pipette-mixing ten 
times. If the beads were overdried, perform extra pipette mixes.
 (xi)  Incubate the tubes for 2 min at room temperature, and then place them on a magnetic stand. Once the solution has 
cleared, collect 50 µl of supernatant (contains cleaned-up LMPCR library) and transfer it to a new 1.5-ml tube.
 pause poInt Purified precapture LMPCR library can be stored for at least 3 months at −20 °C.
21| Validate successful precapture LMPCR library construction by analyzing 1 µl of purified DNA with an Agilent DNA  
1000 chip according to the Agilent DNA 1000 kit guide. The library size should range from 180 to 500 nt, with a peak at 
~260–280 nt (Fig. 5a,b). Performing a smear analysis on this size range by using the 2100 Expert software provides a  
ng/µl value for the precapture LMPCR library. Negative-control PCR reactions should contain no amplicon peaks between  
180 and 500 nt; however, a small peak corresponding to unincorporated primers is not a concern.
? trouBlesHootInG
Hybridization of precapture lMpcr libraries to seqcap eZ probe library ● tIMInG ~2 h plus 3 d of incubation
 crItIcal Evaporation during the 3-d incubation can result in the failed enrichment of target genes. Before performing  
an experimental hybridization, confirm that tubes or plates to be used experience little or no sample evaporation during  
a 72-h incubation at 47 °C (a maximum 3 µl of evaporation from 15 µl is acceptable). Although we find that the plates, 
seals and 0.2-ml tubes listed in the Equipment section perform well, and other suppliers are similarly appropriate, we 
strongly recommend performing a prior test for evaporation.
22| Set a thermocycler to 47 °C (with the lid at 57 °C) and a 1.5-ml tube heat block to 95 °C. If required or available,  
set a second thermocycler or 0.2-ml tube heat block to 47 °C. Thaw Cot-1 DNA, as well as the 2× hybridization buffer and 
hybridization component A (from the NimbleGen SeqCap EZ hybridization and wash kit) at room temperature and place the 
reagents on ice once thawed.
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23| Thaw the required number of 4.5-µl aliquots of SeqCap EZ capture oligonucleotide probes on ice.
24| Thaw the required precapture LMPCR libraries on ice.
25| Thaw 1,000 µM Universal HE oligo and required 100 µM index HE oligo(s) on ice.
 crItIcal step If multiple libraries are being captured in the same multiplex hybridization, it is crucial to ensure that  
each library has a different index and that matched HE index oligonucleotides are used in Step 29.
26| Prepare the libraries; a total of 1.15 µg per capture is recommended (1 µg for capture hybridization and 150 ng for 
qPCR). When you are multiplexing libraries in capture hybridization, mix the library aliquots together to obtain 1.15 µg.  
Adding equal nanogram amounts of each library is recommended.
27| Add 1 µg of prepared library DNA to a 1.5-ml tube. Add 5 µg of Cot-1 DNA.
28| Add 1 µl of 1,000 µM Universal HE oligo to the tube.
29| Add 10 µl (in total) of 100 µM index HE oligos to the tube. When the capture contains multiplexed libraries, ensure that 
index HE oligos match indexes on DNA libraries and are added in the same proportions. For example, if the multiplexed pool 
of libraries contains 200 ng of five libraries, add 2 µl of the correct five index HE oligos at 100 µM.
30| Close the 1.5-ml tube and use an 18-gauge (or similar) needle to make a hole in the lid.
31| Dry the tube containing libraries, Cot-1 and indexes at 60 °C in a vacuum concentrator.
32| Once dry, add the following from the NimbleGen SeqCap EZ hybridization and wash kit to the 1.5-ml tube: 7.5 µl of  
2× hybridization buffer and 3 µl of hybridization component A. Cut the pierced cap off the 1.5-ml tube and replace it with 
the cap from another tube. Vortex the 1.5-ml tube for 10 s and centrifuge it at full speed for 10 s.
33| Denature the capture samples (precapture LMPCR library/Cot-1/HE oligo pool/hybridization cocktail) for 10 min at 95 °C 
in a heating block. If you are performing multiple capture hybridizations, consider starting the denaturation of each sample 
at intervals of 30 s−1 min. Continue with Steps 34 and 35 while the samples are denaturing.
 crItIcal step Steps 34 and 35 should be performed rapidly to prevent sample evaporation or to prevent the reaction 
from cooling. We recommend that users familiarize themselves with the protocol and localize equipment to rapidly proceed 
through protocol steps.
34| When 5 min of the 95 °C denaturation step remain, transfer 0.2-ml PCR tube(s) containing thawed 4.5-µl aliquot(s) of 
SeqCap EZ capture probes from ice to room temperature.
35| Mix the capture sample(s) with SeqCap EZ capture probe aliquot(s) to begin hybridization. This step can be performed by 
using either (option A) a 96-well plate or (option B) 0.2-ml tubes.
 crItIcal step When performing multiple capture hybridizations, consider starting hybridizations sequentially.
(a) plate, 96 wells
 (i)  Place a 96-well plate with a microseal cover in a thermocycler to equilibrate it to 47 °C during the 10-min 95 °C  
denaturation step (Step 33).
 (ii)  With ~45 s of the 95 °C denaturation remaining, remove the microseal cover and leave the thermocycler lid open  
so that the plate is ready for sample loading (Step 35A(v)).
 (iii)  At the completion of the 95 °C denaturation step, immediately transfer the 1.5-ml tube containing the capture sample 
library to a benchtop microcentrifuge and spin for 10 s at full speed (16,000g) at room temperature to  
accumulate the solution at the bottom of the tube.
 (iv)  If a second thermocycler or 0.2-ml tube heat block is available, place SeqCap EZ capture probe aliquot to warm to  
47 °C during centrifugation (Step 35A(iii)). Otherwise, leave the probe aliquot at room temperature.
 (v)  Immediately transfer the entire 10.5-µl capture sample to the 4.5-µl SeqCap EZ capture probe aliquot.  
Quickly but gently mix by pipetting (about five times) and transfer the solution to the 47 °C 96-well plate.
 (vi) Ensure that the sample is well-mixed by pipette mixing a further 5–10 times with the plate in the thermocycler.
 (vii)  Seal the plate with a microseal cover, or, if several hybridizations are being performed, seal only the column of wells 
containing the sample. Ensure that the seal is tight to prevent evaporation. If several samples are being captured,  
35
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repeat Step 35A(iii–vii) until all samples have been processed. Close the thermocycler lid and begin hybridization 
(Step 36).
(B) tube(s), 0.2 ml
 (i)  At the completion of the 95 °C denaturation, immediately transfer the 1.5-ml tube containing the capture  
sample to a benchtop microfuge and spin for 10 s at full speed (16,000g) at room temperature to accumulate  
the solution at the bottom of the tube.
 (ii)  During centrifugation (Step 35B(i)), place SeqCap EZ Capture probe aliquot in the thermocycler to warm to 47 °C.
 (iii)  Immediately transfer the entire 10.5-µl of capture sample(s) to 4.5-µl SeqCap EZ capture probe aliquot. Mix by  
pipetting (about ten times). Close the thermocycler lid. If several samples are being captured, repeat Step 35B(i–iii) 
until all samples have been processed, and then begin hybridization (Step 36).
36| Incubate the samples at 47 °C for 64–72 h in the thermocycler with the lid set to 57 °C. We recommend starting a timer 
upon hybridization to record the actual incubation time.
Binding captured Dna to Dynabeads and washing to remove nontarget Dna ● tIMInG ~2.5 h, including incubations
 crItIcal Many reagents require time to equilibrate to the required temperature. We recommend preheating the water 
baths or heat blocks to 47 °C, and equilibrating 47 °C buffers for 2 h.
 crItIcal Do not let the capture sample temperature drop below 47 °C during binding and washing steps. Keep the  
sample tubes in a heated block at 47 °C if they need to be transferred between equipment. This protocol is designed  
for the concurrent washing of one or two capture reactions. If you are performing more reactions, consider mixing each  
sample with Dynabeads consecutively and staggering the start of the wash steps.
37| Assemble the following solutions (per reaction) by using the buffer concentrates from the SeqCap EZ hybridization and wash kit:
Buffer amount (l) Water (l) total (l) temperature (°c)
Stringent wash buffer  44 396 440 47
Wash buffer I, 10×  11  99 110 47
Wash buffer I, 10×  20 180 200 Room temperature
Wash buffer II, 10×  20 180 200 Room temperature
Wash buffer III, 10×  20 180 200 Room temperature
Bead wash buffer, 2.5× 210 315 525 Room temperature
Split the stringent wash buffer into two tubes of 220 µl. Equilibrate the 47 °C buffers for 2 h in a water bath or heat block.
38| At 40 min into the 2-h buffer equilibration, place the streptavidin Dynabeads at room temperature. Allow the beads to 
warm for 30 min before use.
39| Prepare and wash the Dynabeads. Resuspend the beads by vortexing for 15 s to ensure a homogeneous mixture.  
For each capture to be performed, transfer 100 µl of resuspended beads to a 1.5-ml tube (the beads for up to six captures 
can be prepared and washed in a single tube).
40| Place the tube on a magnetic plate or stand. Once the beads have bound and the solution has cleared, without  
disturbing the beads, remove the supernatant and discard it. While keeping the tubes on the magnetic stand, add 200 µl of 
1× bead wash buffer for each capture being performed.
41| Remove the tube from the magnetic stand and resuspend it thoroughly by medium-speed vortexing for 10 s or by  
pipette mixing.
 crItIcal step Dynabeads can adhere to the walls of some tubes under certain buffer conditions. This can be minimized 
by pipette mixing rather than by vortexing.
42| Perform Steps 40 and 41 a second time with 200 μl of 1× bead wash buffer per capture and then a third time with  
100 µl of 1× bead wash buffer per capture, leaving the Dynabeads resuspended in 100 μl of 1× bead wash buffer per capture 
being performed.
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43| Transfer 100-µl aliquots of the resuspended beads into 0.2-ml tubes.
 crItIcal step It is crucial that the following steps (Steps 44 and 45, 48–52) be carried out quickly so that Dynabeads  
do not dry out and the sample temperature remains as close to 47 °C as possible. Allowing the sample to cool decreases  
the capture efficiency and hence enrichment. When multiple hybridizations are conducted, we recommend performing  
Step 45 (binding captured DNA to Dynabeads) one hybridization at a time, as small variations in incubation time (Step 46) 
are acceptable.
44| Place the 0.2-ml tube(s) containing 100 µl of Dynabeads on a magnetic plate or stand to clear the beads.
45| Remove the supernatant and resuspend Dynabeads with hybridization samples containing captured cDNA. If the  
hybridization was performed with a 96-well plate, follow option A, and if 0.2-ml tubes were used, follow option B.
(a) plate (96 wells) hybridization
 (i)  Remove as much supernatant from the Dynabeads as possible (a residual amount of supernatant remaining is  
acceptable) and close the tube cap to prevent desiccation.
 (ii) Remove the adhesive seal from the 96-well plate.
 (iii)  If a second thermocycler or 0.2-ml tube heat block is available, remove the 0.2-ml tube with Dynabeads from the  
magnetic stand and place it at 47 °C in the thermocycler or 0.2-ml tube heat block. Otherwise, remove it from the  
magnetic stand and leave it at room temperature.
 (iv)  Immediately add the hybridization sample to the Dynabeads. Note whether evaporation was substantial. Place the 0.2-ml  
tube at 47 °C in a thermocycler (if it is not there already) with the lid open and set the temperature to 57 °C. Mix by 
pipetting gently but thoroughly (about ten times). Optionally, if the hybridization sample and beads are not mixing 
well, vortex the 0.2-ml tube for 1 s, pulse-spin it for 1 s and return it to a 47 °C thermocycler and gently resuspend by 
pipette mixing. This needs to be completed within a few seconds to prevent the sample from cooling below 47 °C.
 (v) Close the lid and begin incubation.
(B) tube(s) (0.2 ml) hybridization
 (i)  Remove as much supernatant from the Dynabeads as possible (a residual amount of supernatant remaining is  
acceptable), and close the tube cap to prevent desiccation.
 (ii)  Transfer the 0.2-ml tube with Dynabeads to the 47 °C thermocycler (with the open lid set to 57 °C).
 (iii)  Immediately add the hybridization sample to Dynabeads and mix by pipetting gently but thoroughly (about ten times) 
in the thermocycler with the lid open. Note whether evaporation was substantial. Optionally, if the hybridization 
sample and beads are not mixing well, vortex the 0.2-ml tube for 1 s, pulse-spin it for 1 s and return it to the 47 °C 
thermocycler; gently resuspend the mixture by pipette mixing. This needs to be completed within a few seconds to 
prevent the sample from cooling below 47 °C.
 (iv)  Close the lid and begin incubation. 
? trouBlesHootInG
46| Incubate the beads with the hybridization sample for 45 min at 47 °C in a thermocycler (lid, 57 °C). Resuspend 5–10 
times every 15 min by pipette mixing with the tube lid open while the tube is still in the thermocycler.
47| During the 45-min incubation (Step 46), label and warm a 1.5-ml tube for each capture sample and place them in the 
47 °C water bath or heat block.
48| After 45 min of incubation, add 100 µl of wash buffer I (preheated to 47 °C) to the 0.2-ml tube containing the  
hybridization sample and Dynabeads while the tube is still in the thermocycler. Mix the entire volume by gentle  
pipetting (about ten times) in the thermocycler block set to 47 °C.
49| Transfer the contents of the 0.2-ml tube(s) to the 1.5-ml tube(s) preheated in a 47 °C water bath or heat block (from Step 47).
50| Transfer the 1.5-ml tube to the magnetic stand to bind Dynabeads with a magnet. Remove the buffer once it is clear.
51| Return the 1.5-ml tube to a 47 °C water bath or heat block. Immediately add 200 µl of 1× stringent wash buffer  
(preheated to 47 °C) to the beads. Mix the entire volume by gentle pipetting (about ten times) while at 47 °C, and  
incubate it for 5 min at 47 °C.
52| Place the tube on a magnetic stand and remove the buffer once it is clear. If some Dynabeads do not initially aggregate 
to the tube side nearest the magnet, but accumulate at the bottom of the tube, use a pipette tip to gently blow the beads 
from the bottom of the tube to the side nearest to the magnet.
37
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53| Repeat the washing step with 1× stringent wash buffer (Steps 51 and 52) for a total of two washes.
54| Perform the following washes at room temperature; each wash is followed by binding of Dynabeads with the magnet and 
removal of buffer on the magnetic stand.
Buffer amount (l) Mix
Wash buffer I 200 2 min vortexing
Wash buffer II 200 1 min vortexing
Wash buffer III 200 30 s pipette mix
 crItIcal step Ensure that the Dynabeads do not stick to the sides of the tube and dry out, especially in buffers II and III. 
If necessary, decrease the speed of vortexing or use the pipette tip to push the Dynabeads back into the buffer.
55| After the final wash, remove the buffer and resuspend the Dynabeads (containing captured cDNA) in 50 µl of PCR-grade water.
 pause poInt Dynabeads containing captured cDNA can be stored at −20 °C for at least 2 weeks.
postcapture lMpcr ● tIMInG ~3 h
 crItIcal To prevent cross-contamination, postcapture LMPCR should be performed with separate aliquots of reagents 
from those used for precapture LMPCR.
 crItIcal To minimize amplification artifacts, it is important to perform as few cycles of PCR as possible when generating 
the postcapture LMPCR library. We recommend optimizing the number of PCR cycles required; however, if this is not possible, 
we recommend performing 17 cycles.
56| Thaw the PCR components and prepare LMPCR reactions on ice. For each sample, two reactions are performed that are  
subsequently combined. A water control is required for each postcapture LMPCR, and thus a single capture reaction will require 
a 3× master mix. Preparing additional PCR master mix (5–10%) is recommended. Assemble the following (for a 1× mix):
component amount (l) Final concentration
Phusion HF buffer, 5× 20 1×
dNTPs, 10 mM  2 200 µM
TS-PCR oligo1, 100 µM  2 2 µM
TS-PCR oligo2, 100 µM  2 2 µM
Nuclease-free water 53
Phusion DNA polymerase, 2U/µl  1 2 U
Total 80
57| Resuspend the Dynabeads from Step 55 (containing captured cDNA) by pipette mixing. Add 20 µl of resuspended beads 
into two PCR tubes or wells. Add 20 µl of the nuclease-free water to a third tube or well (for a negative control).
58| Pipette 80 µl of postcapture LMPCR master mix into each tube or well. Mix by gentle pipetting (about five times).  
Proceed with postcapture LMPCR by using the following cycling conditions:
cycle number Denature anneal extend
1 98 °C, 30 s
2–user defined 98 °C, 30 s 60 °C, 30 s 72 °C, 30 s
Final 72 °C, 5 min
4 °C, hold
 pause poInt Amplified LMPCR DNA can be stored for 3 d at 4 °C, or at least for 1 week at −20 °C.
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59| Clean up each postcapture LMPCR library and negative control by using either the QIAquick PCR purification kit  
(option A) or AMPure XP beads (option B).
(a) QIaquick pcr purification kit
 (i)  Pool the two reactions from each sample into 1.5-ml tubes.
 (ii)  Follow the QIAquick PCR purification kit user guide to purify DNA, noting that the maximum volume that can be added 
to a spin column at one time is 750 µl. To elute DNA, add 50 µl of EB (included in the kit) to each spin column and 
incubate it for 1 min before centrifugation.
(B) aMpure Xp beads
 (i)  Place AMPure XP beads at room temperature. Allow them to warm for 30 min before use.
 (ii)  While the beads from Step 59B(i) are warming, prepare fresh 80% (vol/vol) ethanol sufficient for Step 59B(vii–ix) below.
 (iii)  While the beads from Step 59B(i) are warming, pool the two reactions from each sample into 1.5-ml tubes.
 (iv)  Resuspend the room temperature beads by vortexing to ensure a homogeneous mixture.
 (v)  Add a 1.8× volume of beads to each PCR reaction (i.e., add 360 µl to 200 µl of pooled PCR reactions), mix them by 
brief vortexing and then incubate them for 15 min at room temperature.
 (vi)  Place the tubes on a magnetic plate or stand. Once the solution has cleared, without disturbing the beads, remove the 
supernatant and discard it.
 (vii) While keeping the tubes on the magnetic stand, add 200 µl of 80% (vol/vol) ethanol (from Step 59B(ii)) to each tube.
 (viii) Incubate the tubes for 30 s, and then, without disturbing the beads, remove all of the ethanol.
 (ix) Repeat Step 59B(vii, viii) for a total of two ethanol washes.
 (x)  Leave the tubes in the magnetic stand with lids open for up to 15 min to remove all ethanol traces and to dry the 
beads. Once the beads are dry, continue with the next step. Do not overdry the beads (the bead cluster appears 
cracked), as this inhibits elution of DNA from the beads.
 (xi)  Remove the tubes from the magnetic stand and resuspend the beads in 52 µl of nuclease-free water by pipette-mixing 
ten times. If the beads were overdried, perform extra pipette mixes.
 (xii)  Incubate the beads for 2 min at room temperature, and then place the tubes on a magnetic stand. Once the solution 
has cleared, collect 50 µl of the supernatant (contains amplified capture DNA) and transfer it to a new 1.5-ml tube.
 pause poInt The purified library can be stored for at least 3 months at −20 °C.
60| Validate successful postcapture LMPCR with 1 µl of purified captured DNA on Agilent Bioanalyzer according to the  
Agilent high-sensitivity DNA kit guide. The library size should range from 180 to 500 nt, with a peak at 260–280 nt  
(Fig. 5c,d). Negative-control PCRs should show no signal between 180 and 500 nt. The expected yield is greater than  
250 ng, and typical yields range from 250 ng to 1 µg.
 crItIcal step Samples containing a peak of unincorporated primers (extra peaks partially overlapping or near to the 
lower marker) will require an additional round of purification (repeat Step 59) before sequencing.
? trouBlesHootInG
qpcr for capture enrichment ● tIMInG ~3 h, including qpcr run time
 crItIcal Ensure that each primer used for qPCR has been efficiency-tested under the reaction conditions used in the  
experiment (including Roche/NimbleGen control primers). We recommend only using primers with primer efficiency (PE) 
above 1.9 (see Step 62 for further details).
61| Determine the capture enrichment by comparing transcript abundance between pre- and postcapture LMPCR samples 
by qPCR. We recommend testing 6–8 amplicons in triplicate and testing both enrichment of captured transcripts and the 
depletion of nontarget transcripts. The Roche/NimbleGen control amplicons 237, 268 and 272 are suitable for cDNA capture 
enrichment analysis, as are ERCC controls and design-specific capture transcripts. 3–5 ng of cDNA per well is generally  
sufficient for qPCR analysis of a wide range of targets. Users should consult the product literature for the qPCR machine  
available to them because reaction components, concentrations and volumes can vary substantially between qPCR models. 
For an introduction to qPCR, consult Derveaux et al.32 or the qPCR handbook (Life Technologies).
62| For each enrichment amplicon tested, determine the relative fold enrichment. For CaptureSeq, the ‘delta Ct’ method  
is sufficient where enrichment = PE∆Ct. Briefly, average the cycle threshold (Ct) for the triplicate samples and calculate  
the ∆Ct value (average postcapture Ct value − average precapture Ct value). PE values can be measured by using the  
Ct slope method, where PE = 10(−1/slope), with a perfect efficiency giving a value of 2. Depletion ratios are calculated  
similarly. Depletion = −1/(PE∆Ct). Additional details for calculating qPCR fold enrichments and testing the PE are  
available47. Although it is dependent on user requirements and probe design, we aim for a minimum tenfold enrichment 
value, and we routinely achieve greater than 50-fold enrichment.
? trouBlesHootInG
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library sequencing (Illumina Hiseq 2000) ● tIMInG ~11 d
63| Having established successful enrichment and that libraries pass Agilent Bioanalyzer quality control (Step 60),  
subject libraries to sequencing by using the Illumina platform. Please refer to the ‘Estimation of fold enrichment’ section 
(INTRODUCTION) for guidance on sequencing type and depth.
captureseq data analysis ● tIMInG 24 h
64| Sequence reads are provided as a FASTQ-format file. To align sequenced reads from each sample to reference the human 
genome, type the following in the command line:
$ tophat2 --library-type fr-firststrand \
-G gencode.v17.annotation.gtf –o tophat_output \
hg19_index reads_1.fastq reads_2.fastq
 crItIcal step Optional quality control of sequenced reads can be performed by using a range of tools, including FastQC 
and FASTX, before analysis to confirm successful sequencing. Refer to associated documentation for detail.
65| Assemble the aligned reads into full-length transcript models:
$ cufflinks –g gencode.v18.annotation.gtf -o cufflinks_output \ 
tophat_output/accepted_hits.bam
The inclusion of a reference annotation (‘-g/--GTF-guide’) aids in transcript assembly.
 crItIcal step Cufflinks has an option ‘-F/--min-isoform-fraction’ that suppresses isoforms expressed below this  
abundance relative to dominant expressed isoform. To identify novel isoforms, we recommend lowering the value of this 
option (0.1 by default) so that weakly expressed isoforms that may be of interest are not omitted.
 crItIcal step Optional quality control of RNAseq reads and alignment can be performed by using RNA-SeQC28.  
Refer to the associated documentation for details.
66| Remove off-target transcripts that do not overlap the probe design:
$ intersectBed –u –a transcripts.gtf –b probed_regions.bed \
>captured_transcripts.gtf
This step reports all transcripts that have exonic sequence overlapping of any of the regions targeted for capture.
 crItIcal step The ‘–u’ option returns the entire transcript entry that overlaps the probe, rather than only the region  
that directly overlaps the probe design. This permits the user to identify all exons that are spliced into the mature mRNA  
(of which only part may be targeted) and thereby identify novel exons and isoforms.
67| If you are visualizing transcript assemblies in the UCSC Genome browser (http://genome.ucsc.edu/FAQ/FAQcustom.html), 
transcripts corresponding to ERCC RNA spike-ins must first be removed.
$ grep –v ERCC capture_transcripts.gtf 
>captured_transcripts_noERCC.gtf
Optionally, the number of reads overlapping the captured genes can be determined for estimating the fold enrichment 
achieved (as described in Box 1). By comparing the number of overlapping reads after capture to matched RNAseq, the fold 
enrichment and target specificity can be ascertained.
? trouBlesHootInG
Troubleshooting advice can be found in table 1.
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 TRANSCRIPTIONAL DIVERSITY OF 
CHROMOSOME 21  
 
3.1 Introduction 
 
In the previous Chapter, we report the development of RNA CaptureSeq, a 
technique developed to overcome the limitations of standard RNAseq, to 
investigate with saturating coverage a defined genomic output. In this Chapter, 
we apply RNA CaptureSeq to investigate the complete catalogue of transcripts 
produced from human chromosome 21 (Hsa 21) in four different contexts: a 
human cell line and three human primary tissues.  
 
The human genome is pervasively transcribed into a complex collection of 
coding and noncoding genes (Carninci et al., 2005a; Kapranov et al., 2007a). 
Recent concerted work has attempted to achieve a catalogue of these elements 
at the scale of the global genome (Djebali et al., 2012). However, these efforts 
are confounded by a wide dynamic range in expression levels between the 
most and least abundant transcripts within a cell (see Chapter 1). This 
characteristic limits the depth achievable with conventional RNAseq (Chapters 
42
  
1 & 2). We have developed a technique that permits to overcome this constraint 
by focusing sequencing on target regions of the genome (Mercer et al., 2012b; 
Mercer et al., 2014). Here, we target RNAseq across Hsa 21, capturing the full 
transcriptional output of this chromosome to achieve the deepest profile of a 
human transcriptome to date. 
 
Comprising 48 Mb, Hsa 21 is one of the smallest chromosomes in the human 
genome. Non-disjunction of Hsa 21 results in trisomy 21, the most common 
aneuploidy in live-born infants (Korenberg et al., 1994). Currently, annotations 
of Hsa 21 define 242 protein-coding genes, and 147 lncRNAs, spliced into 
1,413 and 239 isoforms respectively (GENCODE v19, (Harrow et al., 2012)). 
Hsa 21 is very similar to the rest of the genome, in terms of the number and 
density of coding and noncoding genes, splicing complexity, and additional 
features such as repeat elements content (Figure 8). These representative 
characteristics, combined to the small size of Hsa 21, explain previous 
investigations of Hsa 21 to infer global features about the whole genome 
architecture and transcriptional activity (Kapranov et al., 2002; Rinn et al., 
2003). 
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Figure 8: Hsa 21 is a representative cross section of the genome. 
Fractionating the human genome (black columns) according to (a) the number of coding genes, 
(b) noncoding genes and (c) repeat elements, and according to the size of each chromosome 
demonstrates that Hsa 21 exhibits an average, representative display of the whole human 
genome (GENCODE v19).  
 
3.2 Results and Discussion 
3.2.1 RNA CaptureSeq improves targeted sequencing 
coverage 
 
We utilized targeted RNA CaptureSeq to profile the Hsa 21-derived 
transcriptome of the human immortalized myelogenous leukemia (CML) cell 
line K562, in triplicate. Oligonucleotide probes were designed to target all non-
repetitive sequences in Hsa 21, comprising a total of 23.5 Mb.  
 
Sequencing of genomic DNA (gDNA)-containing RNA is an issue. Fragmented 
DNA may exhibit an “RNA-like” profile on quantifying instruments such as the 
44
  
Nanodrop (Thermo Scientific) or the Bioanalyzer (Agilent). Therefore, without 
assessing the presence of gDNA using PCR, the amount of nucleic acids 
processed may not match the amount of RNA contained in the sample, and the 
extent of gDNA contamination can be inconsistent across processed samples. 
Furthermore, gDNA sequencing yields reads aligning to intronic sequences. 
These false positive reads confuse results interpretation, as the pervasive 
nature of transcription has involved transcription originating in intronic loci 
(Louro et al., 2008). Finally, because RNA CaptureSeq probes hybridize with 
DNA library fragments, gDNA complementary to designed probes would be 
enriched alongside dynamically transcribed cDNA, amplifying the impact of 
false positive reads and confusing result interpretation. All RNA samples were 
therefore pre-treated with DNase and the absence of DNA contamination was 
confirmed by PCR (Figure 9a), and by no reads aligning to negative intergenic 
controls. About 80 ng RNA (post-PCR product) were loaded per lane, therefore 
degraded RNA can be visualized smearing through lanes 1-9. 
 
Conventional RNAseq was performed in parallel to RNA CaptureSeq for 
technologies comparison, and ERCC RNA Spike-In controls were added to all 
libraries to provide a quantitative standard, allowing the assessment of the 
performance of CaptureSeq experiments (Figure 9b). Libraries were 
sequenced with a minimum of 63 million reads. 
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Figure 9: Controls included in the CaptureSeq protocol 
(a) Prior to library preparation, absence of gDNA was assessed by using primers specific for a 
182 bp intronic DNA region (see Appendix A) with 200 ng RNA template, and CD34+ gDNA as 
positive control (right lane), or absence of template (second last lane). This gel validates the 
absence of gDNA in mouse tissues (Chapter 4) as well as human tissues, as experiments for 
Chapters 3 & 4 were performed in parallel. (b) Enrichment of target regions was validated by 
comparing the coverage of captured and non-captured ERCC Spike-In RNAs. 
 
Spike-In transcripts included at the lowest concentration (1.4 x 10-4 
attomoles/μl) were detected with 14.5-fold coverage in CaptureSeq replicates. 
Across all Spike-Ins, a mean 118-fold enrichment was achieved via 
CaptureSeq (Figure 10a-b). These results imply that 7.4 billion reads per 
sample would be required to obtain a similar coverage of Hsa 21 using standard 
RNAseq. As previously observed (Chapter 2), the enrichment achieved by 
CaptureSeq progressively diminish with increasing Spike-In concentrations, 
indicating progressive probe saturation limiting transcript capture ((Figure 10c, 
(Mercer et al., 2014)). This collectively indicates the achievement of saturating 
coverage for transcripts of extremely low concentrations. Therefore this 
experiment profiled the complete transcriptional output derived from Hsa 21. 
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Figure 10: Enrichment of ERCC Spike-Ins for K562 CaptureSeq experiments. 
The number of sequenced fragments for a given transcript is proportional to the abundance of 
this transcript in the original sample. The concentrations of ERCC Spike-In transcripts in a 
sample are known. The average numbers of fragments per kilobase of transcript per million 
mapped reads (FPKM) for the 3 replicate K562 libraries are graphed against each known ERCC 
Spike-In transcripts concentrations before CaptureSeq (a), and post-CaptureSeq (b), and the 
relative coverage enrichment (before CaptureSeq / after CaptureSeq) is plotted for each ERCC 
Spike-In transcript concentration (c). Note FPKM axis spans 10-3 to 105 for panel a, versus 10-
1 to 105 for panel b. 
 
3.2.2 Global detection of Hsa 21 transcriptional activity in 
K562 cells 
 
Transcripts detected in K562 cells covered 50.1% of captured nucleotides, 
compared to 29.0% for the same regions sequenced using conventional 
RNAseq (Figure 11). This drastic increase in detected transcription in a single 
cell line supports the concept of genome-wide pervasive transcription recently 
described (Clark et al., 2011b; Djebali et al., 2012), and further demonstrate the 
capability of RNA CaptureSeq to harness the full potential of sequencing 
technologies. 
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Figure 11: Detection of Hsa 21 transcriptional activity. 
Reads were mapped to the Hsa 21 genome which revealed the improved detection of 
transcripts using RNA CaptureSeq in K562 cells (orange), compared to standard RNAseq 
performed on matched samples (blue), and surpass the current GENCODE annotations (grey). 
Prevalent transcription in human testis (red), is discussed later in this chapter. 
 
In order to discriminate mature mRNA transcripts from nascent transcription, 
downstream analysis was focused towards multi-exon transcripts only. We 
identified 3,895 transcripts across all CaptureSeq replicates, more than twice 
the detection achieved by conventional RNAseq (1,552) or the full, current Hsa 
21 transcriptome annotated by the ENCODE consortium (1,801; Figure 11). 
The latter comparison is particularly striking considering the discussed 
experiment investigates a single cell line, compared to the 147 surveyed as part 
of the ENCODE project (Dunham et al., 2012). Therefore the CaptureSeq-
facilitated coverage of detected transcripts delivers the most comprehensive 
profile of the architecture of genes on Hsa 21 in human cells to date. 
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3.2.3 Isoforms and ORFs 
 
More than half (2,382) of the identified transcripts are novel isoforms of 
annotated coding genes, including 285 transcripts incorporating exons from 
multiple, distinct protein-coding genes. Current GENCODE annotations report 
643 ORFs derived from Hsa 21. Analysis of CaptureSeq-derived reads reveals 
that ~60% (1,374) of the reported novel isoforms contain ORFs and therefore 
encode putative novel proteins. These include 114 transcripts spanning 
multiple annotated protein-coding genes through long distance splicing (Figure 
12). Finally, we also reveal four loci of entirely novel, putative protein-coding 
genes. We validated the existence of nine of these novel transcripts through 
RT-PCR (Appendix A). The substantial increase in the number of encoded 
ORFs evidenced by this experiment indicates that the proteome may be 
significantly more diverse than proposed by current estimates. Conflicting 
results have been reported, relating to the correlation between mRNA and 
corresponding transcript abundance. In yeast, there has been reports showing 
no or little correlations (Greenbaum et al., 2003; Gygi et al., 1999), and varying 
degrees of correlation in different differentiated human cells (Ponomarenko et 
al., 2014). Collectively, studies suggest that additional factors including the half-
life of each molecule must be considered to accurately investigate correlations 
(Maier et al., 2009; Schwanhüusser et al., 2011). We are presently performing 
directed analysis of K562 digested peptides, using information dependant 
acquisition (IDA) mass spectrometry, to investigate whether these ORFs are 
truthfully translated into stable proteins.  
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Figure 12: RNA CaptureSeq evidences long distance splicing events generating 
conjoined transcripts. 
CaptureSeq reveal transcripts which originate from long range splicing (red), creating novel 
conjoined transcripts between genes located hundreds of bp apart on Hsa21 (blue). Some of 
these novel transcripts appear to encode ORFs (grey). 
 
CaptureSeq therefore revealed a large and complex set of novel transcripts. 
Using measures of ORFs length, and synonymous / non-synonymous 
conservation (Yin & Yau, 2007), we predicted the majority (94%) of these 
transcripts to be lncRNAs. We find almost four-fold as many lncRNA isoforms 
(818) than previously annotated (239). Furthermore, the use of CaptureSeq 
permits to resolve many currently annotated lncRNAs as fragments of larger 
lncRNA loci (Figure 13). Therefore, many partially annotated lncRNA genes in 
fact integrate into a unified locus (Figure 13b). In consequence, we report a 
similar number of lncRNA loci to GENCODE (149 and 147, respectively), while 
our analysis reveals a greater average number of isoforms (5.4 vs 1.6) and 
unique exons (8.8 vs 4.3) per locus.  
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Figure 13: Examples of partially annotated transcripts resolved using RNA 
CaptureSeq.  
Two examples of complex transcripts evidenced by RNA CaptureSeq in human brain (red) to 
comprise several transcripts according to current annotations, such as lncRNAs (green) or 
coding sequences (blue) (a). Novel exons were also evidenced within these novel transcripts 
(b). Both shown examples were validated by RT-PCR followed by Sanger sequencing 
(Appendix A). 
 
3.2.4 Splicing 
 
The precise assembly of full-length and alternatively spliced transcripts is 
difficult, and splicing diversity can be more reliably described by unique exon 
and intron count and structure. Therefore, we de-assembled multi-exonic 
transcripts into 6,997 unique exons (more than twice the numbers recovered 
by conventional RNAseq (3,471) or previous annotations (3,474); Figure 14). 
A third of individual exons (2,343) were entirely novel and half (3,282) were 
novel while sharing sequence with one or more annotated exons. Notably, 
exons recovered from noncoding transcripts were almost entirely novel (79% 
entirely novel exons, and overall 96% including the exons sharing annotated 
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sequence), emphasizing the current lack of annotation of the noncoding 
transcriptome.  
 
 
Figure 14: Classification of elements identified in the K562 transcriptome using RNA 
CaptureSeq. 
Multi-exonic transcripts were de-assembled and individual introns and exons were classified 
according to novelty and coding potential (the x-axis displays the number of identified 
elements x103). This analysis was performed for standard RNAseq and CaptureSeq K562 
mapped reads, and for GENCODE annotated transcripts. 
 
Similarly, CaptureSeq evidences almost twice as many introns (6,054) as 
standard RNAseq (2,967) or current GENCODE annotations (3,382) (Figure 
14). Interestingly, a subset (99) of introns spans vast genomic distances, 
sometimes over 100Kb, to connect two otherwise distinct coding genes, which 
often generates an extended ORF. It will be interesting to compare these results 
with datasets from chromosome conformation capture to investigate whether 
spatial proximity is correlated with this long-range transcription (Lieberman-
Aiden et al., 2009). Similarly to noncoding RNA-derived exons, a greater 
proportion of introns contained within noncoding transcript isoforms are novel, 
mostly overlapping annotated sequences (75%), but also significantly entirely 
novel (32%). Again, this is a remarkable increase compared to introns 
contained in protein-coding isoforms (53% and 5%, respectively-Figure 14). 
While the pervasive splicing of human protein-coding genes has been reported, 
with 95% of coding genes expressed as multiple isoforms (Djebali et al., 2012; 
Wang et al., 2008), the identification of so many novel noncoding introns 
suggests splicing is similarly widespread within the noncoding transcriptome, 
and is more complex than presently appreciated.  
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Next, we classified exons as either constitutive or alternative, by investigating 
the retention of individual exons within intron sequences. This analysis revealed 
that 61% of exons may be incorporated within an intronic sequence, and are 
therefore alternatively spliced in K562 cells. By comparison, GENCODE report 
45% of alternative exons. This large proportion of alternative exons translates 
into widespread splicing, generating diverse isoforms. The distinct biological 
functions of these novel isoforms remain to be investigated. 
 
3.2.5 Differential transcription of Hsa 21 in human primary 
tissues 
 
To explore the extent of tissue-specific transcription generated by Hsa 21, we 
performed CaptureSeq across Hsa 21 from human brain, kidney and testes 
RNA. Samples were captured, aligned and analyzed as described for K562, 
and a replicate K562 sample was captured alongside these tissues as an 
additional control for reliable performance. Overall, the performance of RNA 
CaptureSeq applied to the Hsa 21 transcriptome in primary tissues was 
successful, according to the ratio of captured versus non-captured ERCC 
Spike-Ins for each experiment (data not shown). However, the scarcity of 
primary tissue RNA did not allow to perform matched standard RNAseq, as 
performed with K562 cells, to investigate the enrichment over the non-enriched, 
standard RNAseq baseline. 
 
Preliminary analysis suggests the Hsa 21 transcriptomes of brain and kidney 
tissues are globally similar in size and complexity to K562 findings, collectively 
exhibiting an average of 3,175 transcripts, comprising 6,901 exons and 6,166 
introns. The proportions of different transcript types, including 
coding/noncoding predictions, and the degree of novelty, all unearthed in each 
category (Figure 15).  
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Figure 15: Classification of transcripts revealed by RNA CaptureSeq in K562 and 
human primary tissues. 
Transcripts from replicate experiments were pooled and classified according to coding 
potential, and counted for K562, and human brain, kidney and testis CaptureSeq experiments. 
GENCODE current annotations (v19) are also detailed for comparative purposes.  
 
More than half of identified transcripts (1,796) are novel isoforms to known 
coding genes, 756 are novel intergenic transcripts and 233 are novel antisense 
RNAs. By comparison, the Hsa 21 transcriptome is massively expanded in 
testes (Figures 11, 15-16). We found 7,587 transcripts, composed of 14,154 
unique exons and 12,399 unique introns, which is roughly twice the size of brain 
or kidney and four-fold higher than what is presently annotated on Hsa 21. This 
huge transcriptional activity results in a remaining 0.8% of the Hsa 21 in human 
testes comprising intergenic regions. The prevalent transcription of the genome 
in testes has been reported, and is believed to allow the generation of new 
genes, which may be relevant from an evolutionary perspective (Soumillon et 
al., 2013). 
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Introns were used to measure the extent of tissue-specific splicing (Figure 17). 
About 14% of splicing events are tissue-specific in both brain and kidney. In 
addition, lncRNAs exhibit relatively more tissue-specific splicing than coding 
transcripts. For example, 29% of noncoding splicing events are brain specific, 
compared to 12% of coding transcript splicing (Figure 17). 
 
 
 
Figure 16: RNA CaptureSeq uncovers an expanded catalogue of transcriptional events 
occurring along Hsa 21 in human testes.  
Human testis-generated datasets demonstrate the pervasive transcription occurring across 
Hsa 21, which expands annotations of the coding genome (a), and exposes an unanticipated, 
large population of noncoding transcripts (b) compared to current GENCODE annotations. The 
y-axes represent the number of transcripts mapped. 
 
This analysis revealed the prevalence of testis-restricted transcription. Testis 
transcripts are distinguished by a far higher proportion and absolute number of 
tissue-specific introns compared to brain and kidney-derived transcripts 
(Figures 17a). About 42% of all introns identified were found exclusively in 
testis, comprising 67% of noncoding introns, and 36% for coding transcripts. 
We found that almost all GENCODE annotated genes were expressed in 
testes. This includes many genes lacking biological significance for their 
transcription in this tissue, such as Olig1 and 2 transcription factors that 
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regulate oligodendrogenesis, although others have also observed Olig genes 
transcription in testis (Takebayashi et al., 2000).  This suggests that the huge 
transcription-specificity observed in testes results from an almost complete 
transcription of Hsa 21, regardless of extremely specific, testis-irrelevant 
function of some transcripts. Given this breadth of expression, testes are 
therefore an ideal medium to profile the extent of transcriptional diversity. 
 
Figure 17: Venn diagram of intron distribution in human primary tissues. 
Human assemblies were deconstructed into single elements and all introns were classified 
according to the sample source (a). Sub-classification of introns was performed according to 
coding (b) and noncoding (c) transcript occupancy. Introns could be shared by coding and 
noncoding sequences. 
 
3.2.6 Extrapolation to the complete human genome 
 
By area, the probed regions constitute 23.5 Mb, corresponding to ~0.8% of the 
full genome, or 1.72% when excluding repetitive regions, as demonstrated by 
standard RNAseq data. Therefore Hsa 21 exhibits a similar gene and repeat 
sequence density to the rest of the genome (Figure 8). By assuming the probed 
regions are representative of the broader genome, we can infer the total scale 
and composition of the human transcriptome by multiplying the number of 
transcripts by the total area of the genome. 
 
56
  
We identified the majority of probed bases transcribed in all tissues. In testes 
alone, 98.6% of nucleotides were transcribed (as either exon or intron), and 
combining transcription occurring from the three tissues investigated increased 
this number to 99.1% (Figures 11, 16). By pooling the results obtained from 
the three tissues investigated, we find that globally 20.6% of bases are 
transcribed into spliced transcripts, while only 2.0% of bases are comprised in 
a known or predicted ORF. Therefore, there is almost 9-times more noncoding 
transcripts than protein-coding transcripts in the human genome.  Collectively, 
this means that the majority of the genome bases are transcribed into introns, 
and most exons are spliced into mature lncRNAs and mRNAs. This alone 
suggests that there is almost twice as much gene sequence encoded within the 
genome than currently known. 
 
We combined our K562 and testes Hsa 21 datasets, and applied our findings 
to the entire content of the human genome, to provide an insight into the full 
size of the human transcriptome, and infer the nature of what remains to be 
discovered. 
 
In total, GENCODE (v19) catalogs 5.6 x 104 exons and 3.4 x 104 introns. We 
predict that the total K562 transcriptome comprises 4.7 x 104 exons and 4.1 x 
104 introns. Our study further demonstrates that lncRNAs are disproportionately 
under-represented within current catalogs, and represent the majority of the 
transcriptional diversity remaining to be discovered. Indeed, we show that just 
under half of transcripts within the cell are lncRNAs (Figure 15). Our study also 
highlights the potential of targeted sequencing to evidence these rare 
transcripts. 
 
Considering the breadth of transcription in testes, and applying our findings to 
the remainder of the genome suggests 9.5 x 104 exons and 8.3 x 104 introns 
are collectively expressed in this tissue. Therefore our estimation of the 
complete testis transcriptome is twice the size of the combined annotations for 
introns and exons. Furthermore, unlike observed in the other sampled tissues, 
the majority (76%) of expressed transcripts represent lncRNAs. When all three 
investigated tissues are considered collectively, this suggests that only 37% of 
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exons and 29% of introns have been discovered to date, effectively meaning 
that the human transcriptome is considerably larger and more complex than 
currently appreciated.  
 
In this Chapter, the prevalent transcription of Hsa 21 is revealed to an 
unexpectedly vast extent, surpassing all previous annotations. Notably, by 
demonstrating the transcription of numerous low abundance noncoding 
transcripts, we raise the question of their biological significance, a recurrent 
query for the ENCODE consortium, as discussed in Chapter 1. In the next 
Chapter, we investigate the conservation of these transcripts in syntenic loci in 
the mouse, in an attempt to test the spurious nature of this novel transcription 
and investigate the evolution of transcriptional regulation. 
3.3 Material and Methods 
 
Hsa 21 CaptureSeq custom array design 
The non-repetitive sequence of Hsa 21, comprising a total of 23.5 Mb, was 
targeted for the design of contiguous tiling probes for solution based capture 
(SeqCap EZ choice library, NimbleGen), as described in Chapter 2. 
 
K562 RNA isolation 
K562 cells (passage 9 or 10) were grown to ~80% confluence, and total RNA 
was extracted in 3 mL TRIzol reagent (Ambion). Briefly, extraction of the 
aqueous phase was performed using chlorophorm, and RNA precipitation was 
catalyzed with isopropanol. RNA pellets were washed in ice-cold 75% EtOH 
and allowed to dry before resuspension in DEPC-treated H2O. 
 
Human tissues 
Two independent samples for each normal human tissue (testis, brain and 
kidney) were obtained either as total RNA from a single biological replicate, or 
as a pool of total RNA from several biological samples. Sequencing results 
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encompass  4 biological samples for each human tissue. Total RNA samples 
were obtained from the Ambion RNA Survey Panel or from OriGene 
Technologies. 
 
Dnase Treatment 
The presence of contaminating gDNA in total RNA samples was investigated 
by performing a PCR according to Chapter 2, with primers designed to amplify 
a small intronic DNA sequence (Appendix A) and Phusion Hot Start Flex DNA 
polymerase (New England BioLabs). gDNA, from mouse toe (see Chapter 4) 
or human hematopoietic cells, was used as a positive control. gDNA-
contaminated samples were treated with Turbo DNAse (Ambion) for 20 min at 
37 C before on-column RNA purification (Zymo Research) and re-suspension 
in nuclease-free H2O (Gibco) containing of 2U/L of RNAse out (Invitrogen). 
 
rRNA removal 
gDNA-free total RNA samples were analyzed using an RNA 6000 nano kit 
(Agilent Technologies) with the total eukaryotic RNA assay on a Bioanalyzer 
(Agilent Technologies) which provided RIN and nucleic acid concentration. 
Samples with RINs ≥ 5 were prepared in aliquots ≤ 5 µg and ERCC spike-in 
control mix 2 was added to a final 1% concentration. rRNA was depleted 
according to the Ribo-Zero rRNA removal magnetic kit (Human/Mouse/Rat, 
Epicentre). Successful rRNA depletion was validated using an RNA 6000 pico 
kit (Agilent Technologies) with the mRNA assay on a Bioanalyser (Agilent). 
 
Pre-Capture library preparation 
cDNA libraries were prepared from rRNA-depleted samples using the Illumina 
TruSeq stranded mRNA low-template kit, as described in Chapter 2 (Mercer et 
al., 2014). Pre-capture LMPCR amplified libraries were purified using AMPure 
XP beads (Beckman Coulter Genomics), and successful library preparation 
was validated using a DNA 1000 kit (Agilent) on a Bioanalyser. Average library 
sizes were ~280-310 bp.  
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Amplified libraries were combined in equal amounts into triplex pools according 
to the Illumina adapter indexes pooling guideline. Index adapters 4 (TGACCA), 
6 (GCCAAT) and 12 (CTTGTA) were used together for most of the 
experiments. Because some human samples were provided in single 5 µg total 
RNA aliquots, it was not possible to perform multiple rounds of sample 
preparation to pool a total ≥ 384 ng post-LMPCR single library, as described in 
Chapter 2, in order to retain 150 ng of pre-capture pool for enrichment 
validation and capture on a triplex pool totalling 1 µg combined libraries. 
Preliminary experiments validated sufficient enrichment from sequencing reads 
when capturing down to 100 ng of each library, therefore for subsequent 
experiments, libraries were combined totalling ≥ 450 ng, and captures were 
performed on ≥ 300 ng pools. 
 
Capture by hybridization to Hsa 21 in-solution probes array 
Hybridization was performed in 96-well plates, and up to 3 captures were set-
up sequentially over a 5-10 min period, and hybridized in parallel. Pooled 
libraries and hybridization probes were incubated at 47 C between 64 and 77 
h. Off-target removal and amplification of captured libraries were performed as 
described in Chapter 2, with post-capture LMPCR amplified over 17 cycles. 
Amplified post-capture libraries were purified using AMPure XP beads, and 
validated using a DNA 1000 kit on a Bioanalyzer. Samples that retained 
unincorporated primers were cleaned a second time using a QIAquick PCR 
purification kit (Qiagen), and successful primer removal was validated on the 
bioanalyzer. 
 
Enrichment validation 
qPCR was performed as per Chapter 2 on a BioRad CFX96 real-time cycler 
with the SsoAdvanced SYBR green qPCR reagents (BioRad), using 4 primer 
pairs targeting: (1) a NimbleGen control enriched by the array, (2) a Spike-In 
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ERCC transcript, (3) an enriched transcript, and (4) a depleted transcript (see 
Appendix A).  
 
Sequencing, mapping and normalization 
Enriched libraries were sequenced on the Illumina HiSeq2000 using paired-end 
sequencing 2 x 101 bp. Reads were mapped against the human (hg19) genome 
using TopHat (Trapnell et al., 2009), and assembled into full-length transcripts 
using a combination of Cufflinks (Trapnell et al., 2013) and Trinity (Haas et al., 
2013b) to detect novel transcripts and isoforms. Bowtie 2 (Langmead & 
Salzberg, 2012) was used to estimate the fold enrichment. Analysis of 
transcripts was performed using various softwares including CPAT (Wang et 
al., 2013), all through the UNIX shell command line.  
 
Validation of novel transcripts by RT-PCR.  
K562 cDNA was produced using the Protoscript first strand cDNA synthesis kit 
(New England Biolab), or the Tetro cDNA synthesis kit (Bioline). Long range 
splicing events were validated by RT-PCR followed by Sanger sequencing, 
using primers as per Appendix A. 
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Chapter 4
Evolutionary Dynamics
of the Mammalian Transcriptome
     Nothing in biology makes sense except
in the light of evolution
- Theodosius Dobzhansky 1973 -“ ”
62
  
 
 
 
 
 
 
 
 
 
 
 EVOLUTIONARY DYNAMICS OF THE 
MAMMALIAN TRANSCRIPTOME 
4.1 Introduction 
 
The domestic mouse (Mus musculus) is the predominant model organism to 
study mammalian biology, and has provided extensive insights into human 
biology, development and disease. The mouse genome exhibits a similar size to 
the human genome (2.7 Gb and 3.3 Gb, respectively), and more than 80% of 
mouse protein-coding genes have clear human orthologs (Waterston et al., 
2002). However, mouse and human have undergone divergent evolutionary 
innovations and, as such, are a well-studied context in which to examine 
mammalian evolution (Pevzner & Tesler, 2003). 
 
A comprehensive profiling of transcription originating from Hsa 21, at 
unprecedented detail, is described in Chapter 3. This analysis provides both fine 
details of gene transcription and splicing, whilst also enabling the extrapolation 
of global properties of the human transcriptome. A matched analysis of 
transcription in syntenic regions of the mouse genome would enable a 
comparative analysis of the reported features. For instance, by comparing 
transcripts generated from a defined Hsa 21 region, and its syntenic mouse locus, 
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its is possible to infer conserved and divergent transcripts between human and 
mouse, thereby providing an insight into the evolutionary forces shaping the 
mammalian transcriptional landscape (Dehal et al., 2001). Therefore, to assess 
whether the noncoding transcription that is expanded within humans (Chapter 3) 
is a spurious transcriptional process, we considered whether the regulation of 
lncRNA expression and splicing is conserved in the mouse. 
 
The syntenic regions to Hsa 21 mostly occur on mouse chromosome (Mmu) 16, 
with the remainder on Mmu 10 and 17 (Figure 18). We designed capture probes 
that targeted all non-repetitive sequences within these syntenic regions of the 
mouse genome. The transcription of target regions was interrogated in brain, 
kidney and testis tissues, in order to match the human tissues previously 
characterised in Chapter 3.  
 
Figure 18: Overview of wild-type and Tc1 mice genome sequences targeted for RNA 
CaptureSeq. 
Probes were designed to tile across the non-repetitive portions of the long and short arms of 
Hsa 21 (short arm targets not represented here for aesthetic reasons), and corresponding 
syntenic regions in the mouse genome on chromosomes 10, 16 and 17. Experiments from 
Chapter 3 were performed using this array design. The nuclei of Tc1 mice contain an additional 
copy of Hsa 21, and therefore Tc1 cDNA will hybridize to both human and mouse-specific 
probes. 
 
The extent to which evolutionary change in cis-regulation accounts for divergent 
features in mouse and human transcriptomes is unknown. In an attempt to 
resolve evolutionary conservation of novel transcripts to the greatest definition, 
we sought to investigate the contribution of the cis-regulatory sequence in 
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regulating the human transcriptome. Therefore we elected to apply the RNA 
CaptureSeq protocol to the transchromosomic Tc1 mouse that bears a near-
complete copy of Hsa 21 (Figure 18, (O'Doherty et al., 2005a)). This model 
allows to question the relative input of the mouse nuclear environment, and the 
Hsa 21 cis-encoded sequence, in Hsa 21 transcriptional activity (Wilson et al., 
2008). Breeding of the Tc1 strain generates ~50% Hsa 21-negative progeny, 
which exhibit a normal karyotype and could therefore be used as control WT 
mice. Hence, to explore the regulatory evolution of Hsa 21, we performed 
CaptureSeq across Hsa 21 syntenic regions of the mouse genome in Tc1 and 
WT mice, and compared the yielded transcripts to human results presented in 
Chapter 3. 
 
4.2 Results and Discussion 
 
4.2.1 RNA CaptureSeq 
 
Quality control check points are implemented throughout the RNA CaptureSeq 
sample preparation process, as delineated in Chapter 2. These tests are 
performed using a Bioanalyzer instrument (Agilent), providing nucleic acid 
quantification and validating the expected nucleic acid profile. The successive 
bioanalyzer-generated traces for the sample “mouse 6 brain” a WT littermate, 
is provided here as a representative example, as Chapter 2 only described the 
library-generated traces (Figure 19). 
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Figure 19: A representative example of sample validation controls performed 
throughout the RNA CaptureSeq protocol using multiple arrays on the Bioanalyser. 
Mouse brain total RNA was analysed on an RNA 6000 nano chip, using the eukaryote total 
RNA assay to obtain concentration and RIN. The 18S and 28S rRNA peaks are clearly visible 
around 2kb and 4kb (a). After rRNA depletion, the sample was assayed on an RNA 6000 pico 
chip using the eukaryote mRNA assay to validate absence of 18S and 28S rRNA (b). A test 
library was amplified and inspected using a DNA 1000 chip, to obtain cDNA fragment yield, 
which dictates the minimum required number of cycles to amplify the full cDNA library to 
sufficient yield, as per Chapter 2 (c). The pre-captured amplified cDNA library was then 
validated on a DNA 1000 chip prior to pooling for multiplexing (d). The captured triplex library 
pool comprising the original sample analysed in (a) was amplified a last time and examined on 
a High-sensitivity DNA chip, to confirm successful amplification, and obtain yield and average 
fragment size to prepare the sequencing aliquot (e). Here an additional peak is visible next to 
the small marker, representing unincorporated primers, which dictates an additional purification 
prior to sequencing. All PCR products examinations (c-e) included the analysis of a H2O 
template product to validate absence of contamination. The y-axes show the fluorescence 
units (FU) and the x-axes represent the runtime in seconds (s); these axes are standard 
for representing output from nucleic acid analysis on the Bioanalyzer. 
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Before initiating sequencing of captured libraries, an estimation of the success 
of each CaptureSeq experiment was performed for each sample. Enrichment 
of selected RNA CaptureSeq target sequences was validated using qPCR. 
Representative results are shown in Figure 20. As expected, the target 
sequences corresponding to ERCC transcripts, spiked-in prior to library 
preparation, were systematically enriched. Primers used to test the Roche 
internal control 237 amplify an 80 bp fragment on Hsa 6 and Mmu 17, and 
consistently exhibited the higher fold enrichment compared to all primers used. 
In addition, the mouse YBEY sequence, located on Mmu 10 on a syntenic locus 
to Hsa 21 was enriched for both captures, and the human DSCR3 gene, 
present on Hsa 21q, was enriched for the tested Sample Capture 1. Sample 
Capture 2 was not tested for human DSCR3, but assayed instead for the 
ALAS1 gene located on Hsa 3 and therefore not targeted by hybridization 
probes, and qPCR results show depletion of this gene.  
 
Figure 20: qPCR estimated fold-enrichment of two representative mouse cDNA triplex 
pools, performed after the RNA CaptureSeq procedure. 
Representative results obtained from qPCR of pre-capture and post-capture matching pools 
using 4 ng cDNA template per well, in triplicate for each primer pair tested, including a primer 
pair specific for the External RNA Controls Consortium (ERCC) transcript 31, which was spiked 
into samples at a known concentration. Both experiments were performed on different days, 
with mice 8 and 21 exhibiting the Tc1 genotype while mouse 6 is WT. Ct values were averaged 
for each triplicate and fold enrichments calculated as described in Chapter 2. As expected, 
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captured genes exhibit enrichment while non-targeted genes are depleted post-RNA 
CaptureSeq. 
 
4.2.2 Transcription from Hsa 21 syntenic regions in the WT 
mouse 
 
Each tissue was processed in biological triplicates using the RNA CaptureSeq 
protocol as previously described (Chapter 3, Figure 9a, and Material and 
Methods). A minimum of 99 million reads was obtained for each sequenced 
sample. Sample spiked-in ERCC transcripts were used to assess the RNA 
CaptureSeq performance, as per Chapter 3. Using this analysis, we show on 
average ~68-fold enrichment obtained in mouse tissues processed with 
CaptureSeq (Figure 21). Sequence reads were aligned and assembled to the 
mouse genome as previously described. The obtained coverage provided a 
comprehensive profile of transcription in the WT mouse. 
 
Figure 21: Representative example of the enrichment of probe-targeted ERCC Spike-In 
transcripts in a WT mouse brain CaptureSeq sample. 
Successful enrichment in captured mouse samples can be assessed by comparing the 
coverage of captured versus non-captured ERCC Spike-In RNAs. 
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Within the mouse brain, we identify 2,766 transcripts incorporating 6,169 unique 
exons and 5,233 unique introns, each of which far exceeds current annotation by 
at least 2.5-fold (Figure 22, mouse GENCODE vM3: 524 transcripts, 2,551 
exons, 2,076 introns). Similarly to observed in human, the majority of exons 
(93%) are alternatively spliced and transcripts are similarly divided between 
coding (57% or 1,580) and noncoding transcripts (43% or 1,186).  
 
By comparison to the mouse brain, the human brain expressed a similar number 
of genes (Figures 15, 22), with a similar density (295.7 and 296.8 exons per Mb, 
respectively) to syntenic regions, which contrasts with the genetic loss reported 
in the murine lineage (Waterston et al., 2002). Furthermore, human probed 
regions exhibit a 15.2% higher number and density of lncRNAs relative to mouse. 
This was not specific to the human brain, with human kidney samples showing 
similar proportional increases in noncoding transcripts relative to mouse (Figure 
23). This suggests that noncoding transcription and alternative splicing are both 
higher in human than in the mouse, while the coding gene complement has 
remained relatively stable. These results are in agreement with the literature 
correlating an organism’s level of complexity to its noncoding genome (Chen et 
al., 2014; Taft et al., 2007). 
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Figure 22: Quantification of transcripts revealed by CaptureSeq in mouse primary 
tissues. 
Transcripts evidenced from three biological replicate experiments for each tissue were pooled 
and classified according to coding potential. GENCODE mouse current annotations (vM3) are 
also detailed for comparative purposes.  
 
Overall, CaptureSeq revealed a transcriptome of far greater complexity than is 
currently annotated across syntenic regions in each mouse tissue (Figure 23). 
Transcriptome-wide, we observe an increased number of introns in human, 
indicating a higher degree of alternative splicing in the human transcriptome 
relative to mouse (Figure 23D). 
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Figure 23: Proportions of intronic and exonic features in human and mouse 
transcriptomes revealed using RNA CaptureSeq. 
Venn diagrams indicate the proportion of coding/noncoding introns and internal exons that were 
detected in brain, kidney and/or testis libraries from both human (A) and mouse (B). In both 
species, testis was characterized by a disproportionate diversity of noncoding RNAs, largely 
encompassing the noncoding transcriptomes of the other two tissues. (C) The number of coding 
and noncoding transcript isoforms, introns and internal exons identified and (D) the proportion 
of profiled bases that fall within an exon/intron of one or more mature spliced transcripts on Hsa 
21 and its syntenic regions in mouse, compared to Gencode v19 and mouse Gencode M3. 
 
4.2.3 Conservation of Hsa 21-derived transcription 
 
To compare the relative conservation of coding and noncoding genes across the 
vertebrate lineage, we mapped known and novel transcripts back across 15 
vertebrate genomes that represent a range of lineages (Figure 24). To 
investigate the evolutionary history of Hsa 21 exons, we used the UCSC Genome 
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Browser liftOver tool to determine their syntenic positions in the chimp, gorilla, 
orangutan, gibbon, macaque, mouse, opossum, platypus, chicken, frog, fish and 
lamprey reference genomes, obtained from the UCSC Genome Browser. We 
calculated the percentage sequence conservation at these positions, using 
EMBL-EBI Muscle tool (Edgar, 2004) to measure sequence similarity to their 
original positions in Hg19. Coding genes are relatively stable across vertebrate 
lineages, with 81% of assembled coding exons successfully mapping to mouse 
syntenic regions. By contrast, only 21% of noncoding genes are successfully 
aligned to syntenic regions of the mouse genome, and less than 67% of these 
exhibit expression in matched mouse tissues. This indicates that noncoding 
genes have undergone substantially more evolutionary divergence between the 
human and mouse lineages.
 
Figure 24: Conservation of Hsa 21, and syntenic mouse-derived exons accross 15 
genomes. 
The liftOver tool available through the UCSC genome browser was used to investigate 
coding and noncoding exonic sequence conservation across 15 species. The left panel 
was constructed according to human conservation while the right panel exhibits 
conservation relative to mouse exons. Indexing of the x-axis was performed according 
to decreasing noncoding exon conservation. Because of the current sparse annotation 
of the noncoding mouse genome, the right panel x-axis was indexed according to 
conservation of the CaptureSeq generated dataset. 
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We previously observed a massive expansion of gene expression within human 
testes. This transcriptional phenomenon was similarly observed in mouse testes 
(Figure 25), which express a total of 6,593 transcripts, comprising 11,740 unique 
exons and 9,991 unique introns, twice as much as for either brain or kidney. 
Whilst a relatively similar number of coding transcripts were found in each tissue 
(1,580 brain, 1,460 kidney and 1,888 testis), the noncoding transcript population 
was dramatically expanded in testes (1,186 brain, 1,257 kidney, 4,705 testis), 
with ncRNAs comprising 71% of unique expressed transcripts. The majority of 
exons and introns belonging to these non-coding transcripts were novel (94% of 
exons, 91% or introns), with 81% and 75% sharing no sequence overlap with any 
known exon or intron respectively, indicating the almost entirely unknown function 
of this massively expanded testes-derived noncoding transcriptome. 
 
 
 
Figure 25: CaptureSeq-evidenced human and WT mouse pervasive transcription in 
testes. 
Transcripts derived from Hsa 21 (black, top panel) and syntenic mouse regions (black, bottom 
panel) in testis are revealed by RNA CaptureSeq and compared to current GENCODE 
annotations (blue). 
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The syntenic regions mouse cDNA sequences profiled with CaptureSeq are 
largely representative of the broader mouse genome, with a similar gene and 
repeat density. Probed regions constitute 20.8 Mb, corresponding to ~0.7% of 
the full genome, or 1.69% when excluding repetitive regions. 
 
As performed in Chapter 3 for the human genome, it is possible to infer a more 
accurate size and complexity of the mouse transcriptome by extrapolating the 
obtained results across the broader mouse genome. For example, we predict that 
the mouse brain expresses a total of 161,350 different transcripts (92,167 coding 
and 69,183 noncoding) constituting 359,858 and 305,258 unique introns and 
exons respectively. By comparison, we anticipate the human brain to express 
30% more unique exons, and 27% more unique introns than revealed after this 
experiment. 
 
To obtain a full-complement of genic information encoded within the human and 
mouse genomes requires the analysis of an exhaustive range of cell types and 
tissues. While this is beyond the scope of this study, we combined all profiled 
tissues to estimate a lower limit to this full genic complement. In total, we estimate 
the mouse genome encodes 6.8x104 exons, 5.8x104 introns, 1.1x104 coding 
transcripts and 2.7x104 noncoding transcripts. This is about 40% less than human 
predictions, with alternative splicing and noncoding transcription being 
preferentially expanded in human relative to mouse.  
 
This estimation also measures the status of current efforts to annotate the mouse 
genome (Stamatoyannopoulos et al., 2012). We estimate that 36% of mouse 
exons and 33% of introns are currently annotated (GENCODE Version M3 April 
2014 freeze, GRCm38), with preferential annotation of coding sequences, as we 
identify 66% of annotated protein-coding transcripts, but only 2.9% of mouse 
lncRNAs. 
 
The functional significance of pervasive transcription has been intensely debated 
(Clark et al., 2011a; van Bakel et al., 2010a; van Bakel et al., 2011b). We 
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investigated whether, like in humans, the mouse genome is pervasively 
transcribed. In each tissue, more than half of all captured bases were detected 
as being transcribed, this figure reaching 90% in testis alone (Figure 25). Across 
all tissues, 95% of bases are transcribed, with 84% falling within the boundaries 
of multi-exonic transcripts. However, much of these transcripts were intronic, and 
in total we found 29% of all profiled bases are expressed as mature mRNAs and 
2% within ORFs. Therefore, pervasive genome-wide transcription also occurs in 
mice, albeit at a slightly reduced breadth, and is likely a conserved feature of 
mammalian genomes. 
 
4.2.4 Insight into transcriptional regulation by analysing the 
transcription of Hsa 21 from Tc1 mouse tissues 
 
Our analysis of transcription suggests that both ncRNAs and alternative splicing 
events are enriched in the human transcriptome relative to the mouse. To 
determine whether conserved lncRNAs are actually expressed in mouse, we 
quantified transcription at their syntenic positions in the mouse genome. 
Increased coverage coinciding with human lncRNA exon boundaries was 
apparent and by parsing exons into those that possessed a conserved canonical 
splice acceptor site in mouse and those that did not we demonstrated that the 
former but not the latter were demarked by a spike in coverage at their 5’ border. 
Whilst evidencing functional relevance among lncRNA splice sites conserved 
between human and mouse, this finding encompasses only a small subset of 
lncRNA exons detected on Hsa 21 (11%) and, in general, the sequence and 
structure of lncRNAs is substantially diverged between human and mouse. The 
majority of ncRNAs are not conserved between mouse and human genomes 
when considering either sequence conservations (ie. nucleotide base changes 
between noncoding exons) or position / syntenic conservation (ie. intron/exon 
structure and location) (Chodroff et al., 2010). This lack of conservation of 
ncRNAs is often cited as evidence that noncoding transcripts represent spurious 
gene expression, with little biological consequence.  
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To further investigate whether the noncoding transcription that is expanded within 
humans is a spurious transcriptional process, we considered whether the 
regulation of lncRNA expression and splicing is conserved in the mouse 
microenvironment. Therefore, we sought to apply the RNA CaptureSeq protocol 
to brain, kidney and testis RNA obtained from transchromosomic Tc1 mice that 
contains a near-complete copy of the Hsa 21(O'Doherty et al., 2005a). 
 
Backcrossing Tc1 females with (C57BL/6J x 129S8/SvEv) F1 males yields > 
40% pups carrying a copy of Hsa 21 (O'Doherty et al., 2005b). Three breeding 
pairs were obtained from the Jackson Laboratory (Maine, USA), mated and the 
identification of offspring carrying Hsa 21 was performed using PCR. Mouse 
toe gDNA was amplified using mouse (Figure 26a) and human (Figure 26b) 
primers for an intronic fragment of the Jam2 gene, which encodes a type I 
membrane protein conserved in human and mouse, and located on Hsa 21q 
and Mmu 16q. Samples yielding both human and mouse amplicons were Tc1 
(Figure 26b, lanes 1, 4-7), while samples only yielding the mouse amplicon (2-
3, and 8-9) were WT. Sequenced transcripts confirmed this result, with very few 
reads mapping to Hsa 21 for WT-genotyped mice, compared to an even split 
between Hsa 21 and Mmu for Tc1 mice. Out of 24 offspring produced, 11 were 
Tc1, in agreement with the proportion described in the original publication 
(O'Doherty et al., 2005b). A Tc1 male and littermate WT male produced from 
each breeding pair were used for RNA CaptureSeq. Males were selected to 
examine inter-species differences in the transcriptional complexity exposed in 
Chapter 3 in humans (Soumillon et al., 2013). 
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Figure 26: Genotyping Tc1 mice resulting from [(C57BL/6J x 129S8/SvEv) F1 x Tc1] 
breeding.  
Representative gel electrophoresis of a genotyping experiment. Amplification of 181 bp mouse 
Jam2 fragments (a), and 228 bp human Jam2 amplicons (b), with matching sample/lane on 
both gels. C57BL/6J mouse tail gDNA and CD34+ human cells gDNA were included as PCR 
template as positive controls for mouse and human Jam2, respectively (P). These templates 
were also used with primers of the other species (e.g mouse Jam2 primers with CD34+ human 
cells gDNA template) as a negative control (N). A no template control (H2O) was also included. 
 
We profiled triplicate samples for brain, kidney and testis in Tc1 mice, obtaining 
at least 185 million reads in total for each tissue. Strikingly, comparing the amount 
of transcript assemblies between species suggests the transcription of Hsa 21 in 
the mouse microenvironment is more pervasive than in human for kidney and 
brain tissues (Figure 27). Further investigations are required to identify the 
portion of Hsa 21 that is expanded in the mouse, and preliminary analysis 
suggest a more expansive population of lncRNAs (data not shown). This dataset 
expands on previous work interrogating 105 genes in human and Tc1 
hepatocytes, demonstrating Hsa 21 transcription to be recapitulated in Tc1 cells, 
and concluding that the cis-regulatory sequence contains sufficient information 
for transcription (Wilson et al., 2008). The RNA CaptureSeq–generated dataset 
is much more comprehensive, however, with three tissue types sampled and 
more than 2000 transcripts identified in each tissue. 
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Figure 27:Transcription of Hsa 21 in human and mouse microenvironment. 
RNA CaptureSeq derived datasets were aligned and assembled into transcripts. 
Transcripts from biological replicates were pooled for qualitative investigation of 
transcription. The matching of orthologs between mouse and human CaptureSeq-
evidenced transcripts is currently being performed. Current results highlight the 
expanded Hsa 21-derived transcript population originating from brain and kidney Tc1 
mouse compared to human, while human testis originates more Hsa 21-derived 
transcripts than Tc1 testis. 
 
The CaptureSeq-derived dataset highlighted complex transcription and splicing 
events, including long-range splicing across several annotated genes to produce 
long transcripts. These complex events were identified in human and mouse 
tissues (Figure 28), and remain to be quantified and analysed in greater depth. 
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Figure 28: An example of complex transcriptional events originating from a locus on 
Hsa 21 in human and Tc1 mouse brain, as evidenced using RNA CaptureSeq. 
 
4.2.5 Altered gene expression caused by the additional Hsa 
21 in Tc1 mice 
 
The Tc1 mouse strain is a model of trisomy 21, which underlies Down Syndrome, 
the most common genetic defect in human live births (Rueda et al., 2012). The 
Tc1 mouse recapitulates many phenotypic features of Down Syndrome in 
behaviour, synaptic plasticity, cerebellum neuronal number, heart development, 
and mandible size (O'Doherty et al., 2005a; Rueda et al., 2012). These 
phenotypic symptoms are thought to result from Hsa 21 genes over-expression, 
caused by increased copy number without compensatory gene dosage. 
Therefore, characterising the impact of trisomy 21 on the expression of both 
endogenous and transchromosomic genes may provide an insight into the altered 
gene expression profile underlying trisomy 21.  
 
To explore this avenue, we compared the transcription occurring from mouse loci 
syntenic to Hsa 21 between the aneuploid Tc1 mouse and the diploid WT mouse. 
We did not observe major differences between gene expression in kidney and 
testis, with similar number and expression of endogenous mouse genes. 
However, there were significant differences between endogenous mouse gene 
expression patterns in the brain. Tc1 mice brain transcriptomes exhibit a 
significantly expanded population of 2,461 noncoding transcripts (composed of 
4,660 exons and 3,703 introns), relative to WT mice transcriptomes, almost two-
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fold higher for genetic element (1,186 transcripts, 2,563 exons, 1,959 introns). 
While 85% and 79% of coding introns identified in WT and Tc1 brain 
transcriptomes were shared, 61% of noncoding introns in Tc1 were absent from 
WT, the reverse being true for only 34%. Hence, the presence of the Hsa 21 in 
the Tc1 mouse appears to deregulate expression of ncRNAs within syntenic 
regions in a brain-specific fashion.  
 
This increased expression of ncRNAs was similarly observed in Hsa 21 
transcription between the Tc1 mouse and human brain samples. Whilst similar 
number and complexity of coding genes was observed between Tc1 and human 
brain, preliminary analysis suggest almost twice as many ncRNAs (2,752 
noncoding transcripts, comprising 5,201 exons and 3,986 introns) were found in 
Tc1 brain compared human brain (data not shown). This disproportionate 
expansion of the noncoding transcriptome on Hsa 21 was not observed in other 
Tc1 tissues. These results are currently being investigated in greater details to 
identify transcripts with the most significant differential expression between WT 
and Tc1 brain. 
 
4.2.6 Cis- and Trans- regulatory principles of transcription 
and splicing in mammals 
 
The Tc1 mouse strain carries a stable, near-complete copy of Hsa 21, and can 
hence be used to distinguish the contribution of regulatory cis-elements 
encoded on Has 21, from trans-regulation of the species-specific nuclear 
milieu.  RNA CaptureSeq was performed across Hsa 21 and the mouse 
syntenic regions of the in Tc1 mouse tissue libraries (brain, kidney and testis), 
assessed as above, allowing to profile the expression and splicing of transcripts 
originating from the human chromosome (Tc1-Hsa 21) and mouse syntenic 
regions (Tc1-Mmu) in parallel within each tissue. We derived Percent Spliced 
Introns (PSI) values across a comprehensive set of conserved splice sites in 
human, mouse and Tc1 libraries.  
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Figure 29: Splicing profile of Hsa 21 in the Tc1 mouse. 
(A) Annotated intron/exon structure the Dyrk1A gene in human and mouse and that which was 
resolved via CaptureSeq in human, mouse, Tc1-HsaChr21 and Tc1-Mmu brain samples. Aligned below 
each gene model are Percentage Spliced In (PSI) values for the splice acceptor site of each internal exon 
in the same samples. (B) Proportion of conserved HsaChr21 splice sites that were classified as 
constitutive  (in orange) (PSI > 95) or alternative (in blue) (5 < PSI < 95) in human, mouse, Tc1-HsaChr21 
and Tc1-Mmu and the proportion of sites that were classified concordantly between samples. 
 
The increased frequency of alternative splicing observed across human tissues 
(73% alternative), relative to mouse (35% alternative) (Figure 29B), was 
somewhat diminished among Tc1-Hsa 21 splice sites (61% alternative) but was 
considerably higher than for Tc1-Mmu sites (34% alternative). Likewise, for all 
sites classified as alternative in Tc1-Hsa 21, 88% were also alternative in 
human, compared to just 39% of mouse or Tc1-Mmu sites, suggesting Hsa 21’s 
endogenous splicing patterns were largely maintained in the mouse cell 
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(Figure 29B). This effect could be clearly observed at the Dyrk1A locus, where 
the human-specific exon-intron structure and alternative splicing profile was 
faithfully recapitulated on Hsa 21 in the Tc1 mouse (Figure 29A). To confirm 
this phenomenon globally, we evaluated human, mouse and Tc1 libraries 
based on ranked correlation of PSI profiles across all orthologous splice sites, 
with samples clustering principally according to chromosome, rather than 
organism, of origin (data not shown). In sum, the specific position of a splice 
site and the degree to which it is spliced, appear to be largely encoded in the 
local chromosome sequence of Hsa 21.  
 
 
 
Figure 30: Gene expression profile in human, mouse and Tc1 tissue samples. 
A general deregulation of expression, encompassing both coding and noncoding genes, was observed 
across Hsa 21 in the Tc1 mouse and is illustrated via two examples; (i) the coding gene ICOSLG and (ii) 
lncRNA loci assembled upstream of NCAM2 (natural-log scale). In each, normalized expression is 
compared between human and Tc1-Hsa 21, and between mouse and Tc1-Mmu. 
 
By contrast, there was a general deregulation of gene expression to occur on 
Hsa 21 in the Tc1 mouse. This broad deregulation applied to both coding and 
noncoding genes (Figure 30), providing no indication that their expression is 
subject to fundamentally distinct regulatory regimes. Thus, while a similar 
pattern of expression has been maintained among orthologous genes in human 
and mouse (Figure 30) the isolated regulatory systems appear to have become 
mechanistically distinct, such that cis-regulatory elements of Hsa 21 are 
incompatible with the trans-regulatory environment of the mouse nucleus. Yet, 
despite broad deregulation of gene expression, the splicing machinery is able 
to decipher information encoded in cis on Hsa 21 with remarkable accuracy. 
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The complex human-specific splicing profiles resolved via CaptureSeq being 
precisely and robustly encoded in the Hsa 21 genome sequence strongly 
argues for their functional relevance.  
 
4.3 Material and Methods 
 
Ch21 CaptureSeq custom array design 
In addition to the non-repetitive sequence of Hsa 21, contiguous tiling probes 
for solution based capture (SeqCap EZ choice library, NimbleGen) were 
designed to target syntenic mouse regions, located on chromosome 16 and to 
a lesser extent on chromosomes 10 and 17. Syntenic regions were obtained by 
using the liftOver tool through the UCSC genome browser. In total, the array 
targetted 25.3 Mb comprising 0.87% of the human genome and 20.3 Mb 
comprising 0.77% of the mouse genome 
 
Mice  
All procedures were approved by the Animal Ethics Committee of The 
University of Queensland, Brisbane, Australia. Three males (C57BL/6J x 
129S8/SvEv) F1 and 3 Tc1 females breeders were imported from the Jackson 
Laboratory, Maine, USA. F1 pups produced from paired mating were toed for 
identification and genotyping.  
 
Genotyping 
gDNA was extracted on-column from toe tissues using the MoBio UltraClean 
Tissue&Cell DNA extraction kit (MoBio) according to the tough tissue protocol 
preparation, using 0.5 mg / mL proteinase K and homogenized using 3 cycles 
of 6500 rpm for 20 sec on a Precellys tissue homogenizer, connected to a 
cooling system (Cryolis) keeping the samples temperature < 4C during the cell 
lysis procedure. Genotyping was performed using primers specific to human 
and mouse Jam2 genes (Appendix A). PCR was performed over 35 cycles 
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using the Phusion Hot-Start Flex DNA polymerase (New England Biolabs) 
according to recommended cycling conditions with 60C annealing 
temperature, and amplified fragments were separated by 1% agarose gel 
electrophoresis. 
 
Mouse Tissue RNA isolation 
Three Tc1 F1 males and 3 WT littermates were sacrificed between 6 and 9 
weeks of age, and testis, kidney and brain tissues immediately harvested in 
TRIzol reagent (Ambion), snap-frozen on dry ice and stored at -80C until 
processing. To isolate RNA from tissues, samples were defrosted on ice, and 
125 mg MicroBeads (MoBio) were added to sample tubes. Tissues and cells 
were disrupted by 2 cycles of 45 sec at 6500 rpm on a tissue homogenizer 
(Precellys) connected to a cooling system (Cryolis) keeping the samples 
temperature < 4C during the cell lysis procedure. Bead-free cell lysates were 
transferred to a new 1.5 mL tube and RNA was immediately harvested as per 
the K562 procedure, except for the use of 1-Bromo-3-chloropropane (Sigma-
Aldrich) instead of chlorophorm. Brain RNA was extracted a second time in 
TRIzol due to high lipid contamination present after the first extraction. 
 
The remainder of the experiment, including gDNA , rRNA removal, library 
preparation, RNA CaptureSeq, validation of CaptureSeq-mediated enrichment, 
was performed as per Chapter 2 and 3. 
 
Transcriptome Assembly and Downstream Analyses 
 
Reads were trimmed with the Trim Galore Cutadapt wrapper (Martin & Wang, 
2011) prior to mapping and assembly. Transcriptome assembly for human 
samples was performed via a combination of ab initio and genome-guided 
tools. In silico pre-normalization and ab initio assembly were performed using 
trinity/2014-04-13 (Haas et al., 2013a) and all transcripts were aligned to the 
Hg19 reference genome with the UCSC BLAT tool in order to obtain genomic 
coordinates for all putative splice junctions. Non-redundant canonical splice 
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junctions retrieved via Trinity from all libraries were pooled into a splice junction 
catalog. This catalog was used to inform a second-round of alignment for each 
sample using tophat/2.0.12 (-j option) (Trapnell et al., 2012), aligning to Hg19 
with ERCC references added. Reads mapping to ERCCs were counted using 
samtools/1.19 (Li et al., 2009) and RPKM values calculated.  
 
Mapped reads from each library were separately assembled de novo using 
cufflinks/2.2.1 (Trapnell et al., 2012). Assemblies from replicates for each tissue 
were merged using cuffmerge (Trapnell et al., 2012). Full-length transcript 
sequences were filtered to retain only those that overlapped CaptureSeq 
probed regions. Single exon transcripts and transcripts containing 
noncanonical introns were filtered from each assembly and any duplicate 
transcript isoforms distinguished only by the external border of a shared 
terminal exon were merged into single isoforms. A comprehensive assembly, 
encompassing all replicates of all tissues was also generated in this way. 
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 TARGETED ANALYSIS OF CANCER GENE 
EXPRESSION 
 
5.1 Introduction 
 
After using the RNA CaptureSeq protocol to unveil low abundance transcription 
originating from a continuous genomic region (Chapter 3 & 4), we apply here this 
technique in a hypothesis-driven scenario to investigate in great details the 
transcription of selected genes in haematological disorders. Within this chapter, 
we investigate the application of CaptureSeq to question splicing events in cancer 
samples, and profile differential gene expression and usage. Thereby we 
demonstrate the utility of RNA CaptureSeq to investigate cancer samples. 
 
Almost all human genes are spliced to generate mature mRNA, with the majority 
of genes undergoing alternative splicing to produce different mRNA isoforms and 
proteomic diversity (Boise et al., 1993; Wang et al., 2008). In recent years, a wide 
range of cancers has been found to frequently harbor driver mutations in genes 
encoding the general RNA splicing machinery (Ebert & Bernard, 2011; Harbour 
et al., 2013; Papaemmanuil et al., 2011; Quesada et al., 2012; Rossi et al., 2011; 
Wang et al., 2011; Yoshida et al., 2011). This was unexpected given that splicing 
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is fundamental to gene expression, therefore mutations within the general 
splicing machinery would be predicted to have catastrophic phenotypic 
consequences. 
 
As seen in Chapter 1, the spliceosome mediates splicing by recognizing at least 
three genetic elements within pre-spliced introns: the 5′ splice site, the 3′ splice 
site and the branchpoint (BP) (Will & Luhrmann, 2011). The U2 snRNP 
component of the spliceosome physically binds the intron to be spliced out, and 
is incidentally recurrently mutated in hematological cancers (Yoshida et al., 
2011). Within the U2 snRNP, the SF3B1 gene, involved in the recognition and 
recruitment of the U2 snRNP to the BP, is the most commonly mutated gene in 
myelodysplasia (MDS) (Figure 31a). MDS is a disorder of hematological stem 
cells characterized by an aberrant expansion of myeloblasts in the bone marrow, 
that can present various subtypes. Overall, 20.3% of MDS patients harbor an 
SF3B1 mutation, with a prevalence of up to 85% in the RARS subtype of MDS, 
characterized by the presence of abnormal erythroid cells known as ring 
sideroblasts (Papaemmanuil et al., 2011; Yoshida et al., 2011). SF3B1 is also the 
second most frequently mutated gene in chronic lymphocytic leukemias (CLL) 
(9.7%), another hematopoietic stem cell cancer characterized by an illegitimate 
over-expansion of a B cell population (Landau et al., 2013).  
 
Mutations in SF3B1 cluster within two HEAT repeats in the C-terminal domain of 
SF3B1 (Figure 31b), with one substitution, K700E, accounting for 57% of all 
alterations (Harbour et al., 2013), and the sites of mutation suggest that they are 
likely to represent a ‘gain-of function’ mutation. In MDS the SF3B1 heterozygous 
mutation is present in the majority of cells from the malignant clone, suggesting 
that it is an early initiating event during oncogenesis. Mutations to SF3B1 occur 
broadly in a range of additional hematological malignancies, in uveal melanomas 
(18.6%), and in up to 5% of a range of common cancers, including breast, 
pancreatic, melanoma and kidney cancer (Biankin et al., 2012; Harbour et al., 
2013). This prevalence across a range of cancers suggests SF3B1 mutations 
may represent a generic oncogenic pathway. While the pathological mechanisms 
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are currently unknown, SF3B1 mutations were recently associated with aberrant 
alternative splicing in uveal melanomas (Furney et al., 2013).  
 
 
Figure 31: Mutations in the splicing machinery of MDS samples. 
(a) Mutations (frequency indicated by width of circle outline) in genes for 3’ splice site selection 
occur in up to 85% of MDS. (b) Mutations (red) cluster in Heat domain in SF3B1, suggesting 
gain-of-function. Modified and reproduced with permission from Nature Publishing Group 
(Yoshida et al., 2011). 
 
In previous experiments (Appendix B), we show that RNA CaptureSeq 
performed on RNaseR-digested K562 cells exhibits the existence of RNAs that 
form closed circular loops (Figure 32a). Circular RNAs characteristically 
comprise consecutive internal mature exons ligated together to form a circle. In 
total, 213 exons were significantly enriched as circular RNAs in RNaseR-
treated libraries, affecting 62 genes. Several (12) of these circular RNAs are 
further supported by internally primed ESTs that traverse the circular junction 
and produce a perfectly antisense cDNA. Circular RNAs are found in almost all 
eukaryotes and are conserved between vertebrate species (Jeck et al., 2013; 
Salzman et al., 2012). Their function remains a mystery; however, at a 
minimum, these circular exonic RNAs were recently shown to act as sponges 
to titrate microRNAs (Hansen et al., 2013; Memczak et al., 2013). The possible 
mechanisms by which circular RNAs are produced were recently reviewed, and 
include “back-splicing” (Figure 32b) (Jeck & Sharpless, 2014) 
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In this Chapter, we hypothesize that a mutation in the SF3B1 spliceosomal 
protein causes aberrant branchpoint selection, which generate illegitimate back-
splicing events responsible for the generation of aberrant mRNA transcripts 
(Figure 32b).  
 
 
Figure 32: Evidence of exonic circular RNA derived Asxl1, and possible mechanism of 
generation through backsplicing. 
Genome browser view of consecutive RNaseR-resistant exons within the Asxl1 gene, 
which are therefore present in a circular form (a). Schematic view of the proposed 
mechanism of backsplicing, which is hypothesized to generate a circular exonic RNA, 
alongside a truncated, aberrant mRNA (b). 
 
Throughout my PhD candidature, I have pursued a parallel interest in 
hematopoiesis and associated disorders (Appendix C & D). With this work, we 
merged both fields of study, by applying the RNA CaptureSeq technology (Mercer 
90
  
et al., 2014) to target cancer-associated genes in SF3B1-mutated and -WT MDS 
samples, in order to investigate the potential impact of SF3B1 mutations on 
aberrant splicing events in oncogenes. The RNA CaptureSeq method is 
analogous to DNA exome-sequencing, previously used in cancer samples, and 
focuses sequencing depth on targeted RNA transcripts to achieve an 
unprecedented sequencing coverage, thereby permitting the analysis of rare or 
transient RNA species (Roberts & Pachter, 2011). We considered whether this 
approach could identify the pathological impact of SF3B1 mutations, by targeting 
468 cancer genes in SF3B1 mutated, and WT MDS samples. 
 
5.2 Results and Discussion 
 
5.2.1 Targeted sequencing reveals novel exons, introns and 
isoforms of cancer genes in healthy control tissues 
 
The identification of driver mutations requires a comprehensive and accurate 
annotation of cancer genes (Garraway & Lander, 2013). We have previously 
demonstrated the advantages of CaptureSeq to identify novel elements such as 
exons and isoforms within even well-described genes (Chapters 3 & 4, (Mercer 
et al., 2012a)). Therefore, we reasoned that applying CaptureSeq to cancer 
samples would provide an expanded and detailed annotation of targeted cancer 
genes. 
 
We firstly designed oligonucleoide probes targeting 468 genes causatively 
associated with cancer, as previously catalogued by the Welcome Trust Cancer 
Census (Futreal et al., 2004a). This oncogenes-specific design is referred to as 
OncoSeq. The OncoSeq design also included probes targeting intergenic control 
regions and ERCC Spike-Ins, as described for the precedent Hsa 21-specific 
array used in Chapters 3 & 4. To generate an expanded annotation of cancer 
genes, we applied OncoSeq to a sample comprising a pool from 20 healthy 
human tissues RNA. This enabled to maximise the sequence diversity within the 
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captured sample, and thereby increase our ability to identify novel exons and 
isoforms. OncoSeq was performed as previously described, and for comparison, 
matched conventional RNAseq was also performed.  
 
Figure 33: OncoSeq-enrichment of cancer-related genes from a pool of human healthy 
samples. 
OncoSeq performed on a pool of 20 human biological replicate samples evidences an increased 
number of transcripts compared to standard RNAseq (a). Dissecting transcripts into inrtons and 
exons revealed the existing overlaps between elements that were shared (red) and unique (blue) 
beween the OncoSeq-derived data and the Wellcome Trust Cancer Census genes (b). Poly-
pyrimidine tracts present in newly identified introns evidence probable splicing sites (c). 
 
Using this pool, we were able to assemble almost all (97%) previous annotations 
for targeted genes. In total, we assembled 7,812 multi-exon transcripts which 
sequence overlapped one cancer-associated genes (Figure 33a). This is more 
than four times what was retrieved via conventional RNAseq (1,857 transcripts) 
and exceeds the 5,834 annotated transcripts (according to GENCODE v19) 
associated with targeted genes (Figure 33a) (Harrow et al., 2006). 
 
Transcripts were disassembled into 21,893 unique exons and 25,358 unique 
introns (compared to 20,992 unique exons and 15,281 unique introns in initial 
annotations; Figure 33b). Almost a third (7,275) of probed exons were not 
assembled, possibly due to not being expressed in tissues interrogated. 
However, OncoSeq resolved an additional 7,378 novel exons (33.7% more) and 
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3,865 novel introns (17.7% more) (Figure 33b). Many novel exons represent 
noncoding variants, alternative 3’ and 5’ UTR exons, or result in truncated coding 
sequences that may be subject to nonsense mediated decay (Popp & Maquat, 
2013). 
 
Novel exons to cancer genes constitute a 6% expansion on current Cancer 
Census annotations (Futreal et al., 2004a). These novel exons exhibit a lower 
conservation than previous annotations, but show elevated conservation and 
three-nucleotide periodicity characteristic of coding exons maintaining an open 
reading frame (Figure 33c) (Yin & Yau, 2007). Similarly, we observe 
characteristic splicing elements, including polypryimidine tract, and canonical 3’ 
and 5’ splice sites at novel introns (Figure 33c). 
 
We identified novel isoforms for prominent genes such as RB1, PTEN, PIK3CA, 
and DNMT3A. For example, the phosphatase and tensin homolog (PTEN) is a 
tumour suppressor gene involved in the regulation of cell cycle, and mutations to 
this gene have been identified in a large numbers of cancers (Chalhoub & Baker, 
2009). There are two identified isoforms for PTEN, comprising 10 exons. Here, 
we identify 4 novel exons and evidence 3 additional alternative spliced exons. 
Similarly, PIK3 (phosphatidylinositol-4,5-bisphosphate 3-kinase) is one of the 
most commonly mutated genes in endometrial cancers (Samuels & Ericson, 
2006). Inhibition of the PIK3CA isoform of PIK3 effectively induces cancerous cell 
apoptosis in multiple myelomas (Hofmann et al., 2014). The implicated PIK3CA 
isoform sequence comprises 23 exons. We identify 3 novel exons, and 5 exons 
can be alternatively spliced generating at least 6 isoforms for PIK3CA (Figure 
34a). The retinoblastoma 1 tumour-suppressor gene (RB1) is annotated as a 
single isoform critical to oncogenesis (Goodrich, 2006). Using OncoSeq, we 
evidence 5 novel exons and 4 alternatively spliced exons for RB1 (Figure 34b).  
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Figure 34: OncoSeq unveils novel isoforms for critical oncogenes. 
Novel exons (green triangles) and alternative splicing (red triangles) are evidenced in cancer-
related genes by applying OncoSeq to a pool of healthy tissues RNA (a-b). Conjoined genes 
transcripts were also evidenced, that may encode novel proteins (c). 
 
In addition to alternative isoforms, we also found 465 isoforms (5.9%) produced 
from distal splicing to generate conjoined genes. In these cases, long distance 
splicing joined two distinct genes, resulting in the formation of a fused transcript 
including intergenic sequence present between the two partner genes. For 
example, we identified that distal splicing joined together the PPL3 and CLK1 
genes, resulting in a 554 amino acids protein-coding sequence (Figure 34c). 
About 750 conjoined genes have been identified previously within the entire 
human genome (Prakash et al., 2010), while we report 456 conjoined genes 
transcripts arising from a very small fraction of the human genome, suggesting 
there is a lot more conjoined transcripts in the genome than currently appreciated. 
The impact and significance of transcripts resulting from these distal splicing 
events is currently unknown. 
 
We next considered the impact of the splicing diversity on the encoded protein 
sequence. In total, we identified 5,386 ORFs within expanded isoform 
annotations, of which 300 novel exons in frame, resulting in a 1.1% new, 
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potentially translated, products impacting 12.2% of cancer genes. For example, 
we identified novel protein isoforms to the TET1 gene (Figure 35). TET1 
catalyzes the conversion of the modified DNA base 5-methylcytosine (5-mC) to 
5-hydroxymethylcytosine (5-hmC), which is the initial step of mammalian DNA 
demethylation (Cimmino et al., 2011). Globally these findings represent a large 
set of novel ORFs potentially associated with cancer, and highlight the sensitivity 
of the CaptureSeq protocol to resolve novel splicing events. 
 
 
Figure 35: OncoSeq-facilitated identification of novel exons in cancer-related genes, in 
healthy human. 
Examples of novel exons evidenced in the TET1 and MYH9 genes by applying 
OncoSeq to a pool of various healthy tissues from 20 human biological replicates. 
Novel exonic sequences are further supported by conservation through the vertebrate 
lineage. 
 
5.2.2 Fusion Transcripts 
 
After expanding the catalogue of genetic elements that can be identified using 
OncoSeq, we next considered the ability of OncoSeq to identify and quantify 
fusion genes. Large-scale structural variations, such as translocations and 
deletions, can cause aberrant juxtaposition of genomic elements, resulting in 
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oncogenic fusion genes and resultant chimera proteins. Fusion transcripts are 
particularly common within hematopoietic malignancies (Acunzo et al., 2014; De 
Braekeleer et al., 2014; Melo, 1997). As proof-of-principle, we employed 
OncoSeq, to profile gene expression within the immortalized myelogenous 
leukemia cells K562. K562 cells harbor a t(9;22)(q34;q11) translocation (Figure 
36a), commonly called Philadelphia chromosome, which results in the formation 
of the oncogenic BCR-ABL1 fusion transcript (p210) (Laurent et al., 2001; 
McGahon et al., 1994).  
 
We performed OncoSeq on K562 replicate RNA as previously described, 
including a matched RNAseq (Figure 36b). We were able to identify over ~3460 
reads that directly span the fusion junction, and 739 paired-end reads that 
support the fusion. This represents ~320-fold enrichment over background levels 
of negative controls, and a ~90-fold improvement over the resolution of 
conventional RNAseq that detects p210 fusion gene with only 3.5-fold enrichment 
over background. This indicates both the higher sensitivity and specificity of 
OncoSeq over RNAseq to resolve gene fusion events in cancer.  
 
Figure 36: Resolution of the BCR-ABL1 gene fusion in K562 using OncoSeq. 
The common myelogenous leukemia cell line K562, known to harbor the BCR-ABL1 gene fusion 
(a), was investigated using OncoSeq and standard RNAseq. Both OncoSeq and RNAseq 
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detected the BCR-ABL1 fusion, although OncoSeq exhibited a 90-fold greater sensitivity 
compared to RNAseq (b). 
5.2.3 Non-canonical backsplicing 
 
Given the sensitivity with which CaptureSeq can identify novel splice junctions 
and fusion transcripts, we next considered whether OncoSeq could similarly 
facilitate the identification of non-canonical, rare forms of splicing, such as 
splicing that generate circular exons (Cocquerelle et al., 1993; Jarrell, 1993; 
Jeck & Sharpless, 2014; Zaphiropoulos, 1996). We recently evidenced circular 
exon-containing RNA loops through sequencing of RNaseR digested K562 
libraries (Figure 32, Appendix B). RNAseR is a 3’ to 5´ exoribonuclease, which 
digests linear RNA but is unable to process circular RNAs. These circular 
exonic species are often accompanied by ‘abridged’ mRNAs lacking those 
exons incorporated within the circular RNA. Non-canonical splicing events, 
termed “backsplicing”, refer to the splicing of a 5’ splice site to an upstream 3’ 
splice site that generate a circular RNA and an abridged mRNA (Figure 32b) 
(Jeck & Sharpless, 2014). 
 
Within K562 samples, we identified differential exon abundance between 
RNaseR-treated and untreated RNA. 213 exons involving 62 genes were 
unaffected by RNaseR treatment and are therefore enriched as circular 
species. Non-canonical exon-exon junctions that formed circular RNAs were 
identified in K562 using OncoSeq, and we validated circular and abridged 
mRNA species for the BRAF gene (Figure 37), and an abridged mRNA for 
FOXP1, EZH1 and ASXL1 using RT-PCR and Sanger sequencing (Figure 39a-
b). 
 
Therefore, OncoSeq analysis revealed some notable cancer genes that may 
undergo this non-canoncial splicing. For example, characteristic features of 
backsplicing were observed within the BRAF gene, such as the formation of 
circular exons comprising exons 4-8 with the matched generation of abridged 
mRNAs (Figure 37). Notably, these abridged isoforms have been previously 
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detected in melanomas that have evolved resistance to the RAF-inhibitor, 
vemurafenib. In these resistant tumours, the exclusion of exons 4-8 result in 
the translation of a 61-kDa BRAF (V600E) variant form that is missing the RAS-
binding domain and undergoes aberrant dimerization, resulting in insensitivity 
to the action of vemurafenib (Poulikakos et al., 2011).  
 
 
Figure 37: RNaseR-resistant, circular exons originating from BRAF are accompanied 
by an aberrant, abridged mRNA. 
The evidenced aberrantly spliced isoforms generated from BRAF, circular and truncated, bear 
the hallmarks of backsplicing.  
 
Numerous studies have similarly reported mRNA isoforms to genes such as 
PTEN and TSG101 that are missing several consecutive internal exons in 
multiples cancer types (Kameyama et al., 2012; McLver et al., 2000; Oh et al., 
1998; Sigalas et al., 1996), suggesting this novel form of non-canonical splicing 
may provide a more generic contribution towards cancer. Given the prevalence 
of SF3B1 mutations in haematological cancers, we sought to apply OncoSeq 
to CLL and MDS samples harbouring a mutation within the SF3B1 genes to 
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investigate the impact of the mutation to the frequency of backsplicing events 
in oncogenes.  
 
5.2.4  Surveying backsplicing events in hematopoietic 
disorders using OncoSeq 
 
We obtained 26 MDS RNA samples from the Australasian Leukaemia & 
Lymphoma Group (ALLG) and 46 CLL frozen peripheral blood cell samples 
from Devinder Gill (Translational Research Institute, Brisbane, Australia). 
Samples were genotyped for the common K700E mutation in SF3B1, widely 
implicated in MDS (Yoshida et al., 2011) and CLL (Landau et al., 2013). A 
Sanger sequencing protocol was devised to obtain at least the complete 
sequence of exon 15, homing K700.  
 
Figure 38: Sanger sequencing traces validating four different heterozygous mutations 
within exon 15 of the SF3B1 sequence in genotyped MDS and CLL samples. 
Mutations (a) and (b) were found in MDS samples, (b-d) were found in CLL samples. 
 
Out of 26 MDS samples sequenced in both directions using cDNA primers for 
exons 12-17 (Appendix A), six samples exhibited the WT SF3B1 sequence, 
four samples showed the K700E mutation, and one sample exhibited the 
H662Q mutation, present in the COSMIC database for hematopoietic and 
lymphoid tissue cancers (Forbes et al., 2011)(Figure 38 & Table 1a). The 
sequencing of the remaining 15 samples did not provide unequivocal results 
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due to high background, it was therefore not possible to accurately assess 
these genotypes. In the interest of time, we did not pursue further sequencing 
and instead processed samples from explicit genotypes. From 46 CLL samples 
sequenced in both directions using gDNA primers specific for exons 15-16 
(Appendix A), 13 sampled returned a WT SF3B1 sequence, one sample 
exhibited an I704F mutation, and one sample showed a R775Q mutation, both 
reported in the COSMIC database (Figure 38), and three samples exhibited 
the K700E mutation (Table 1b), with the rest of the sequences providing 
ambiguous results requiring re-sequencing, as above. 
 
Table 1: Summary of MDS (a) and CLL (b) SF3B1 exon 15 Sanger sequencing outcomes. 
 
OncoSeq was applied to at least three SF3B1 K700E mutated and three SF3B1 
WT samples for each haematological disorder, using a different ERCC Spike-
In mixture for each sample group in order to enable subsequent analysis of 
differential gene expression. Libraries were pooled in triplexes prior to 
enrichment, and validation of enrichment using qPCR was performed prior to 
sequencing on the Illumina HiSeq 2000 using a Rapid Run with paired-end 2 x 
101 reads. Obtained reads were assembled and aligned as previously 
described (Chapters 2-4). 
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Figure 39: A trend for increased backsplicing in SF3B1 mutated samples is observable, 
although not significant. 
Backsplicing frequency, expressed as the ratio of the frequency of reads across a canonical 
exon-exon splice junction to the frequency of reads spanning an aberrant junction characteristic 
of circular RNA, was calculated for specific genes, such as Asxl1 (a) and Ezh2 (b) in MDS WT 
and SF3B1 mutated samples. Individual ratios per sample were also calculated and averaged 
across selected genes with reported evidence for abridged or circular RNA, for MDS and CLL 
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samples (c). Two replicate K562 samples were also analysed. The significance of differential 
backsplicing ratio was investigated using the unpaired t-test. 
 
Transcripts were analyzed at splice junctions to identify canonical versus 
reversed, aberrant junctions characteristic of exonic, circular RNAs. The ratio 
of aberrant versus normal splicing was referred to as the frequency of 
backsplicing events, and was observed between SF3B1 mutated and WT 
samples. The absence of significant differences in backsplicing frequency 
between SF3B1 mutated and WT samples could not allow a definite conclusion 
towards the impact of SF3B1 mutations in backsplicing due to the wide spread 
of ratios within groups (Figure 39). However, a trend was present at the single 
gene scale (Figure 39a-b) with less backsplicing events occurring in WT MDS 
samples compared to SF3B1 mutated MDS samples. We suggest increasing 
the number of samples tested may improve clustering of results and enable a 
definite conclusion. In addition, analysis of the backsplicing frequency for 
additional single genes, as performed for Figure 39a-b, may also increase the 
statistical significance of results.  
 
We are presently in the process of applying OncoSeq to control human 
samples, such as donor peripheral blood circulating B-cells for CLL, and 
healthy bone marrow aspirates CD34+ cells for MDS, in order expand this study 
to profile cancer gene expression and splicing patterns between healthy and 
cancerous phenotypes. We expect this additional experiment to evidence 
differential gene expression patterns, such as preferred splicing events and 
isoforms expression, across both hematological disorders and their respective 
controls. We anticipate this analysis to deliver further insight into 
leukemogenesis, and expect this experiment to provide proof-of-concept for the 
application of targeted capture sequencing for cancer gene profiling to the 
greatest available depth to date. 
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5.3 Material and Methods 
 
CaptureSeq “Onco” custom array design 
Annotated exons from 467 genes implicated in oncogenesis (Wellcome Trust 
Sanger Institute, 2014), and sequences surrounding branchpoints in selected 
genes exhibiting aberrant splicing patterns were targeted for the design of 
probes for solution based capture (SeqCap EZ choice library, NimbleGen). 
Overall, the array targeted a total of 5.7 Mb, or 0.4% of the human genome, 
excluding the repetitive regions. 
 
K562 
K562 cells (passage 16) were grown to ~80% confluence, and total RNA was 
extracted in 1 mL Trizol (Ambion) per 2 x 106 cells, yielding ~17 g DNAse-
treated RNA. Briefly, extraction of the aqueous phase was performed using 1-
Bromo-3-chloropropane (Sigma-Aldrich), and RNA precipitation was catalyzed 
with isopropanol. RNA pellets were washed in ice-cold 80% EtOH and allowed 
to dry before resuspension in nuclease-free H2O (Gibco).  
 
Cancer samples 
26 MDS total RNA 5g aliquots, Trizol extracted from bone marrow aspirates, 
were obtained from the Australasian Leukaemia and Lymphoma Group (ALLG). 
Samples included the following subtypes: 5 RAEB-1, 2 RARS, 18 RCMD, and 
1 RA, classified as per the WHO 2008 classification of blood neoplasms 
(Vardiman et al., 2009). Two additional MDS samples of the RCMD subtype, 
genotyped as SF3B1 K700E mutants, were kindly gifted by Dr. Meagan Wall 
(St. Vincent’s Hospital, Melbourne, Australia). 46 CLL biological samples were 
kindly provided as peripheral white blood cells, cryopreserved in 10% 
DMSO/FBS, by the laboratory of Dr. Devinder Gill’s (Translational Research 
Institute, Brisbane, Australia).  
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Screening for SF3B1 mutations was performed by Sanger sequencing of 
amplified SF3B1 mutation “hot-spot” sequences. For CLL samples, gDNA was 
extracted using the UltraClean DNA extraction kit (MoBio), and gDNA specific 
primers (see Appendix A) were used to amplify exons 15-16, the K700 mutation 
involving exon 15. For MDS samples, 0.5 L of defrosted RNA was diluted in 
10 L nuclease-free H2O, and converted into cDNA using the Tetro cDNA 
synthesis kit (Bioline). cDNA-specific primers (see Appendix A) were used to 
amplify exons 12-17. Amplified fragments were sequenced in both directions 
by Sanger sequencing, and resulting traces visually inspected to detect 
heterozygous mutations. Three SF3B1 mutants and 3 SF3B1 WT samples 
were initially selected for both leukemias and processed for RNA CaptureSeq. 
Total RNA was extracted from selected CLL cryopreserved cells, as described 
above for K562 cells.  
 
Dnase Treatment 
The presence of contaminating gDNA in total RNA samples was investigated 
by performing a PCR according to Chapter 2, with primers designed to amplify 
a small intronic DNA sequence (YWHAZ primer pair, see Appendix A) and 
Phusion Hot Start Flex DNA polymerase (New England BioLabs). gDNA from 
human hematopoietic cells was used as a positive control. gDNA-contaminated 
samples were treated with Turbo DNAse (Ambion) for 20 min at 37C before 
on-column RNA purification (Zymo Research) and resuspension in nuclease-
free H2O (Gibco) containing of 2U/L of RNAse out (Invitrogen). 
 
rRNA removal and ERCC RNA spike-in 
gDNA-free total RNA samples were analyzed using an RNA 6000 nano kit 
(Agilent Technologies) with the total eukaryotic RNA assay on a Bioanalyzer 
(Agilent Technologies) which provided RIN and nucleic acid concentration. 
rRNA was depleted according to the Ribo-Zero rRNA removal magnetic kit 
(Human/Mouse/Rat, Epicentre). Successful rRNA depletion was validated 
using an RNA 6000 pico kit (Agilent Technologies) with the mRNA assay on a 
Bioanalyser. To allow differential gene expression analysis, ERCC RNA spike-
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in ExFold mix 1 and mix 2 (Ambion) were added to 1 % final concentration to 
SF3B1 mutant and WT samples, respectively. 
 
Pre-Capture library preparation (as per Chapter 2 and 3) 
cDNA libraries were prepared from rRNA-depleted samples using the Illumina 
TruSeq stranded mRNA low-template kit, as described in Chapter 2 (Mercer et 
al., 2014). Pre-capture LMPCR amplified libraries were purified using AMPure 
XP beads (Beckman Coulter Genomics), and successful library preparation 
was validated using a DNA 1000 kit (Agilent) on a Bioanalyser. Average library 
sizes were ~280-310 bp.  
 
Amplified libraries were combined in equal amounts into triplex pools according 
to the Illumina adapter indexes pooling guideline. Index adapters 4 (TGACCA), 
6 (GCCAAT) and 12 (CTTGTA) were used together for most of the 
experiments. Because the MDS samples were provided in single 5 µg total RNA 
aliquots, it was not possible to perform multiple rounds of sample preparation 
to pool a total ≥ 384 ng post-LMPCR single library, as described in Chapter 2 
and 3. Therefore libraries were combined totaling ≥ 450 ng, and capture was 
performed on ≥ 300 ng pools. 
 
Capture by hybridization to Onco in-solution probes array (as per Chapter 
2 and 3) 
Hybridization was performed as per Chapter 2 and 3, in 96-well plates, and up 
to 3 captures were set-up sequentially over a 5-10 min period, and hybridized 
in parallel. Pooled libraries and hybridization probes were incubated at 47C 
between 64 and 77 h. Off-target removal and amplification of captured libraries 
were performed as described in Chapter 2, with post-capture LMPCR amplified 
over 17 cycles. Amplified post-capture libraries were purified using AMPure XP 
beads, and validated using a DNA 1000 kit on a Bioanalyzer. Samples that 
retained unincorporated primers were cleaned a second time using a QIAquick 
PCR purification kit (Qiagen), and re-observed on the bioanalyzer. 
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Enrichment validation 
qPCR was performed as per Chapter 2 on a BioRad CFX96 real-time cycler 
with the SsoAdvanced SYBR green qPCR reagents (BioRad), systematically 
using 4 primer pairs targeting: (1) a NimbleGen control enriched by the array, 
(2) a spiked-in ERCC transcript, (3) an enriched transcript, and (4) a depleted 
transcript (Appendix A).  
 
Sequencing, mapping and normalization 
Enriched libraries were sequenced on the Illumina HiSeq2000 using paired-end 
sequencing 2 x 101bp. Reads were assembled and mapped against the human 
(hg19) genome as previously described (Chapters 2-4). 
 
Validation of potential backsplicing events by-product by RT-PCR.  
K562 cDNA was produced using the Protoscript first strand cDNA synthesis kit 
(New England Biolab), or the Tetro cDNA synthesis kit (Biolab). Truncated 
mRNA from Asxl1, BRAF, FOXP1, EZH1 were validated by RT-PCR. 
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 DISCUSSION 
6.1 Overview 
 
Studies of the transcriptome have shaken the dogma placing RNA as a simple 
precursor to protein synthesis. First, the transcriptome is extremely dynamic, 
owing to context-specific differential gene expression (Hochheimer & Tjian, 2003) 
and to a trivial fraction of the genome generating a large amount of transcripts, 
(Jiang et al., 2011). Secondly, the principal output from mammalian genomes 
comprises ncRNAs (Carninci et al., 2005b; Djebali et al., 2012). Thirdly, the 
transcriptome is hugely complex (Mercer et al., 2012b) and alternative splicing is 
a predominant mechanism in eukaryotes that contributes to the level of 
complexity of a given organism (Chen et al., 2014; Keren et al., 2010). This novel 
appreciation for the transcriptome has not been promptly matched by the use of 
innovative experimental strategies to direct efficient sequencing and permit its full 
exploration. In fact, post-hoc normalization approaches are common to 
deconvolute complex sequencing datasets for increasing output specificity 
(Aanes et al., 2014; Chen et al., 2014; Jin et al., 2013; Tarazona et al., 2011).  
 
In this thesis, I approached the aforementioned limitations by exploring the use 
of targeted transcriptome sequencing. In Chapter 2, we detail a novel 
experimental method termed RNA CaptureSeq, designed to explore a true 
genomic output to the greatest sensitivity available, by enriching a targeted 
fraction of the transcriptome prior to sequencing. Using RNA CaptureSeq, we 
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demonstrate superior sequencing resolution while retaining accurate transcript 
quantification (Mercer et al., 2014). The saturating coverage obtained along the 
target regions reveals low abundance transcripts, such as rare novel or transient 
species.  
 
In Chapter 3, I exploit this feature to uncover the full extent of transcription 
occurring along Hsa 21. Using probes to enrich for all non-repetitive regions of 
Hsa 21, I investigate transcription in 4 different contexts (K562, brain, testis, 
kidney). RNA CaptureSeq greatly improves current annotations by increasing the 
number of proteins-coding isoforms, as well as noncoding transcripts. We also 
evidenced the transcription of rare, long-range conjoined transcripts which 
relevance remains to be investigated. By extrapolating this data to the entire 
genome, we infered the size of the transcriptome in sampled tissues, and suggest 
the transcriptome to remain vastly unappreciated.  
 
In Chapter 4, we extend this analysis by interrogating syntenic regions of Hsa 21 
in the mouse, using matched tissues to used in the human study, in order to 
question the conservation of novel transcripts. Preliminary analysis suggest 
coding transcripts to be more conserved than noncoding RNAs, although 
matching of orthologs remains to be performed for a more detailed conclusion.  
 
We extend this study by applying this RNA CaptureSeq design to matched 
tissues of the Tc1 aneuploid mouse, which contains in its nuclei an additional Hsa 
21, in order to investigate the regulation of human transcription in the mouse 
nuclear environment. This approach revealed striking mammalian regulatory 
processes, as more transcripts were found overall in the Tc1 mouse compared 
to humans. This result suggests the information directing gene expression and 
splicing is encoded in the cis-regulatory sequence of Hsa 21.  
 
Finally in Chapter 5, we use the RNA CaptureSeq method in a clinical scenario 
(OncoSeq), to investigate rare splicing events in human hematopoietic cancer 
tissues. Using OncoSeq expanded the catalogue of isoforms of cancer-related 
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genes. OncoSeq was then applied to investigate the impact of a mutation in the 
SF3B1 spliceosomal protein on aberrant splicing, and delivered promising 
results, which must be followed by additional analysis and experiments to be 
conclusive. Finally OncoSeq delivered a proof-of-concept for its utility in the 
clinic by resolving the BCR-ABL1 translocation breakpoint in K562 with greater 
sensitivity than RNAseq.  
 
Overall these results validate the huge potential of RNA CaptureSeq to discover 
novel genomic features. Therefore, implementing targeted sequencing, as part 
of approaches aiming to explore specific genome attributes will result in greater 
sensitivity in the generated data. I expect that RNA CaptureSeq enrichment will 
become a widely employed technique both in research and clinical settings. 
 
6.2 Diversity and evolution of Hsa 21 
 
The ENCODE project first evidenced the pervasive transcription of the human 
genome, sparking much controversy regarding the significance of such results 
(Graur et al., 2013). In Chapters 3 and 4, I confirm genome-wide transcription 
in multiple tissues in human and mouse. However as for its precursor studies, 
assessment of the validity of these groundbreaking results is imperative, as 
their significance would be major in multiple fields of biology, starting from the 
search for novel disease markers in unannotated regions which could lead to 
the development of novel therapeutics, to the identification of yet undiscovered 
biological mechanisms in such regions. Pervasive transcription of rare 
transcripts was true, as validated by the concomitant sequencing of spiked-in 
ERCC RNAs present in libraries at extremely low concentrations. In addition, 
novel RNA species could be independently verified using standard qRT-PCR, 
further validating our dataset as genuine and aligning our data with the 
ENCODE results. 
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Regarding functionality however, it is not sufficient to point to transcribed bases, 
as the process of reverse transcription can be leaky and spurious (Spivakov, 
2014). Conservation of coding genes was evidenced in a range of lineages, as 
expected for functional transcripts. However with regards to noncoding 
transcripts, we showed that whilst the pervasive abundance of lncRNAs and 
their limitless splicing diversity are shared features of the human and mouse 
genomes, genuine lncRNA orthologs are rare. Nonetheless, this echoes similar 
findings that much of the annotated regulatory sequences have diverged 
between mouse and human (Villar et al., 2015), and therefore cannot be used 
to disregard these transcripts as nonfunctional. 
In the Tc1 mouse, we showed broad Hsa 21 coding and noncoding sequence 
expression deregulation providing no indication that coding and noncoding 
expression is subject to fundamentally distinct regulatory regimes. 
Furthermore, despite a similar expression pattern among human and mouse 
orthologous genes, regulatory mechanisms have substantially diverged, 
yielding cis-regulatory elements encoded within Hsa 21 to be incompatible with 
the trans-regulatory environment of the mouse nucleus such as the 
transcriptional machinery. Indeed, despite broad deregulation of gene 
expression, the mouse splicing machinery is able to decode the instructions 
comprised within Hsa 21 (ie. in cis) very accurately.  Due to the biological 
complexity and effort involved in splicing, the fact that novel human-specific 
splicing profiles are recapitulated by Hsa 21 in the Tc1 mouse strongly argues 
for their functional relevance.  
As evidenced in this brief discussion, this CaptureSeq discovery study is 
unlocking multiple avenues of investigations and raising a number of 
interrogations. For instance, it would be interesting to similarly investigate by 
targeted capture the remainder of the human karyotype in order to discover 
more noncoding transcripts of potential biological significance. Given the 
impressive prevalence of noncoding transcripts resolved in this experiment, it 
is easy to foresee a tipping point in publicly available annotations in the close 
future, where the catalogue of noncoding transcripts will surpass its coding 
counterpart. On the other hand, a hypothesis-driven approach could use the 
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probes design used in the present work to capture Hsa 21 from patients 
suffering from Down syndrome, to investigate differential expression and 
splicing of rare events caused by Hsa 21 aneuploidy. 
6.3 Application of CaptureSeq to functional genomics 
 
Within this thesis, I have used RNA CaptureSeq to resolve features of the 
transcriptome at high resolution. This targeted sequencing approach could be 
similarly applied to resolve alternative features of the genome that currently also 
exhibit a wide dynamic range. Functional genome sequencing assays that 
measure chromatin accessibility (Thurman et al., 2012), histone modifications 
(Bernstein et al., 2002) and protein occupancy (Lee et al., 2006) all exhibit a 
dynamic range which is similar to observations for RNAseq. Such a wide range 
presents a familiar problem for these functional assays that we propose can be 
solved using targeted sequencing. Combining CaptureSeq with these techniques 
would provide a profile of unprecedented detail and resolution for selected 
features at a genomic region of interest. 
 
DNaseI hypersensitivity sequencing is a well established tool to measures 
numerous epigenetic features, including loci of open-chromatin, supercoiled 
DNA, nucleosome positioning and transcription factor footprint (Neph et al., 2012; 
Thurman et al., 2012). Genomic sites of active regulation and transcription are 
marked by a remodeled, “open” chromatin that allows binding of functional 
proteins. Such regulatory regions are highly sensitivity to cleavage by DNaseI, 
producing small DNA fragments that can be subject to high-throughput 
sequencing (Hesselberth et al., 2009). CaptureSeq can be employed to enrich 
DNA fragments derived from genomic intervals of interest, providing a more 
detailed DNaseI-cleavage profile. 
 
Due to similarities between DNaseI and CaptureSeq protocols both including 
library preparation steps, CaptureSeq can easily be implemented by hybridizing 
SeqCap probes to DNaseI libraries for enrichment prior to sequencing. 
Acknowledging this, I have started to explore these possibilities. We have 
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generated a preliminary dataset where we capture Hsa 21 from DNaseI and 
MNaseI K562 libraries. While yet to be analysed in detail, this experiment is a 
proof-of-principle for the merging of CaptureSeq and DNaseI hypersensitivity 
sequencing, as we have been able to capture and enrich DNaseI hypersensitive 
sites across Hsa 21. 
 
Other assays, such as Chromatin Immunoprecipiation (ChIP), are often 
inefficient, and incapable of resolving all but the most abundant features. To 
combine and modify ChIP-Seq with targeted sequencing would extend the 
sensitivity, resolution and quantification of these technologies. Targeted 
epigenetic assays would allow the detailed and comprehensive targeted analysis 
of any regions of interest that cannot be sufficiently analysed with non-targeted 
global approaches. We expect the next generation of genomic research will be 
based on the enhanced sensitivity and accuracy provided by targeted methods 
for more informed, hypothesis driven research outcomes.  
 
6.4 Clinical application of CaptureSeq 
 
Large-scale structural variations, such as chromosomal translocations, deletions 
and amplifications are commonly observed in tumours, in particular in 
haematological malignancies. Chromosomal rearrangements often fuse genes 
that generate chimeric oncogenic proteins. For example, fusions between the 
BCR and ABL genes originate from a translocation between chromosomes 9 and 
22, and may yield 3 chimeric isoforms depending on the breakpoint site within 
the BCR gene (Melo, 1997). This translocation, known as the Philadelphia 
chromosome, is recurrent in CML and present within the immortalized CML cell 
line, K562 (Grosveld et al., 1986). The chimera BCR-ABL1 protein has enhanced 
tyrosine kinase activity, fuelling oncogenic transformation of hematopoietic stem 
cells in leukemias (Ren, 2005). Accordingly, the presence of fusion genes can 
serve as accurate prognostic indicators, with the BCR-ABL1 fusion gene 
correlating with poor clinical outcome in acute lymphoblastic leukemia (Gleißner 
et al., 2002).  
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Fusion genes also provide therapeutic opportunities. For example, the tyrosine 
kinase inhibitor imatinib mesylate (also known as STI571 or CGP 57148B) 
effectively induces selective apoptosis in BCR-ABL1 bearing cells (Kawaguchi et 
al., 2001; Le Coutre et al., 1999) and has promoted complete remission in 
patients without substantial associated toxicity (Druker et al., 2001). Similarly, in 
acute promyelocytic leukemia (APL), progenitor cancer cells harbouring RARA 
fusion transcripts (FTs) resume differentiation upon treatment with all trans 
retinoic acid (De Braekeleer et al., 2014). Nonetheless, clonal evolution may 
occur and erode treatment efficacy. For instance, mutations within the aberrant 
BCR-ABL1 fusion genes can confer resistance to imatinib mesylate and require 
alternative therapies (Shah et al., 2002; Sigl et al., 2013).  
 
The detection of gene fusions is therefore crucial in managing cancer treatment. 
Fusion gene detection confirms diagnosis, evaluates a prognosis, informs an 
appropriate treatment strategy, and can indicate potential clonal evolution and 
residual disease during treatment. Currently, diagnostic laboratories typically use 
monoplex qRT-PCR with primers specific to partner genes involved in the 
potential fusion as indicated by the clinician (MD Anderson Cancer Centre). While 
sensitive, this technique is only able to detect a fusion between two specified 
genes, and is unable to detect gene fusions between multiple or unknown 
partners. For example, monoplex qRT-PCR is ill-suited to detect fusions involving 
the gene RARA that can combine with up to 8 other genes partners in APL (De 
Braekeleer et al., 2014) and accordingly a large number of reactions are required. 
As another example, more than 121 gene fusions involving the mixed lineage 
leukaemia (MLL) gene have been documented to date in acute myeloid 
leukaemia (AML) (Meyer et al., 2013), promising overwhelming complexity for 
routine diagnosis with monoplex qRT-PCR. In addition, the clinical relevance of 
splice variants incorporated within gene fusions is becoming increasingly 
appreciated (Adamia et al., 2013; Ommen et al., 2010). These splice variations 
require additional primers to resolve chimeric splice junction and thereby add 
further to the work burden. 
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With the relevance of fusion genes being increasingly revealed in cancer, 
improved molecular diagnostic tools are required for facilitated identification. In 
the research setting, multiplex qRT-PCR kits enable multiple transcripts to be 
profiled simultaneously. For example, the Q-Fusion Leukemia Fusion Gene 
Screening Kit (QuandDX), can concurrently detect 30 fusion gene products, 
including BCR-ABL1 , and some common MLL and RARA fusions. However, 
while this approach constitutes an improvement over monoplex qRT-PCR 
assays, the number of fusion genes that can be detected in a single reaction 
remains limited due to the formation of unspecific products and primer 
dimerization. Therefore multiplex qRT-PCR is of modest utility in resolving 
numerous, complex or novel fusion events. Microarray-based detection of RT-
PCR products has been proposed, where cDNA is amplified either before 
(Giusiano et al., 2010; Maroc et al., 2004) or after (Nasedkina et al., 2003) 
hybridization to a chip bound to fusion- and splice variant-specific probes. 
Detection is based on colorimetric or fluorometric reactions, benefiting these tests 
with a straightforward visual read-out to indentify a tested FT and its probable 
breakpoint. While some microarrays are disease specific (Giusiano et al., 2010), 
designs may incorporate the major FTs occurring in multiple leukemias (Xiong et 
al., 2013). However, despite a facilitated read-out and the possibility to multiplex 
detection of > 50 fusion variants, these assays are limited to known fusion events, 
and designs would require continued development to remain up-to-date (Acunzo 
et al., 2014; Lilljebjörn et al., 2014). In addition, PCR-based assays cannot 
identify small mutations within fusion products that are associated with clonal 
evolution and therapy unresponsiveness (O'Hare et al., 2007; Sigl et al., 2013).  
 
Some cryptic FTs of significant clinical impact can only be identified through 
sequencing (Park et al., 2009; Welch et al., 2011). However, despite increased 
sensitivity provided by sequencing, rare, residual mutated fusion products may 
remain undetected in remission patients and contribute to therapy resistance in 
relapse events (Parker et al., 2013). Whole genome sequencing has the potential 
to identify these fusions events, however, unambiguous interpretation of complex 
chromosomal rearrangements remains difficult for genome assembly, particularly 
when tumour cells harbouring the genotype may only comprise a small fraction 
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of the sequenced samples. By contrast, RNAseq directly detects the generation 
of the chimeric RNA products that is translated into aberrant oncoproteins.  
 
The RNA CaptureSeq protocol (described in detail in Chapter 2 and applied to 
cancer samples in Chapter 5) is able to address many of the challenges above. 
Within a single experiment, RNA CaptureSeq was employed to interrogate 467 
cancer-related genes with a design I term here OncoSeq (Futreal et al., 2004b). 
Because the oligonucleotide probes capture exon boundaries rather than 
traversing exon-exon junctions, OncoSeq identifies and quantifies any isoform 
originating from targeted cancer gene, enabling the detection of rare or novel FTs 
involving any of the targeted cancer genes. Furthermore, mutations within FTs 
may be simultaneously detected, providing additional prognostic information. 
Given multiple samples can be individually indexed during library preparation, 
multiple samples can be simultaneously captured and sequenced to reduce time 
and cost. In Chapter 5, I provide proof-of-concept for the diagnostic significance 
of OncoSeq for the fusion transcript BCR-ABL1. The detailed and comprehensive 
datasets generated by OncoSeq performed on cancer samples will provide a 
valuable resource for research into the impact of chromosomal rearrangements 
and their contribution to cancer, possibly revealing additional gene fusions that 
constitute novel therapeutic targets in irresponsive or intolerant patients. 
 
CaptureSeq currently remains an involved and expensive technique. 
Nevertheless, with high-throughput sequencing increasing in popularity and 
decreasing in cost, a cost-benefit analysis may soon favour the routine use of 
CaptureSeq in the detection of fusion genes. While further work is required to 
standardise and simplify data analysis, which currently requires considerable 
bioinformatic skills, we propose that CaptureSeq will be an appropriate diagnostic 
technology in the near future. 
 
As we reach saturation of knowledge for canonical genes and molecular 
processes, the research interest is switching towards innovative technologies 
to investigate newly indentified populations of rare, regulatory transcripts. The 
limitations of current sequencing technologies being increasingly recognized, 
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many studies report various genomic partitioning protocols for enhanced 
resolution. This work participates towards enhancing the output of sequencing 
techniques, which will certainly stem the identification of novel transcripts and 
mechanisms occurring in the backdrop of the eukaryotic cell transcription. 
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Chapter / Use Name of primer Sequence 
Chapter 3 / F1 mouse genotyping PCR Mouse Jam2 Forward 5'-GCAGGGAGACTGAAGTCCTG-3' 
Chapter 3 / F1 mouse genotyping PCR Mouse Jam2 Reverse 5'-CATCTTTCTTGGGCTCTTCG-3' 
Chapter 3 / F1 mouse genotyping PCR Human Jam2 Forward 5'-CATCGCACAGCTCAAGTGAT-3' 
Chapter 3 / F1 mouse genotyping PCR Human Jam2 Reverse 5'-CCAGCCTACCTCTCTGTTGC-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070315_325 Forward 5'-GGCCAAAGAGCACATACTGG-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070315_325 Reverse 5'-CGTTCTTGGCTGAACTCACA-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00065574_22 Forward 5'-CAAGCCGACACAGAGAACAG-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00065574_22 Reverse 5'-TTGATTTTGCTTATCTTAGTGTGTCC-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070944_388 Forward 5'-CGTGTTAGCCAGGATGGTCT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070944_388 Reverse 5'-GAAAAACCACAGCTGCCACT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070977_200 Forward 5'-TCTTGAGTTCTCCCTGAAAGG-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070977_200 Reverse 5'-TGAGCAGCCTTAGGGATCAT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00069968_49 Forward 5'-AACTCGACTGCCTGCAAACT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00069968_49 Reverse 5'-TTCTGTGCTCCACATCGTTC-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00071209_31 Forward 5'-TGGTTCTCAAGCCTTTGGAT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00071209_31 Reverse 5'-TTTTCACTGTCCACCGCTTT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070525_155 Forward 5'-TGCCCCATAGTCTCATTGAA-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070525_155 Reverse 5'-GAGCACCAGACCAATCATCA-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070717_183 Forward 5'-CTGCCTGTTCAATACGGTCA-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00070717_183 Reverse 5'-ACCCCTCCCTCGACCTAGA-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00077232_22 Forward 5'-TTAAGTCTGCAACCCCCACT-3' 
Chapter 3 / RT-PCR validation of Ch21 novel transcripts PCR JUNC00077232_22 Reverse 5'-CCCCTGTGCCATGTTTCTAT-3' 
Chapter 4 / SF3B1 screening gDNA (CLL) PCR SF3B1 gDNA exon14 Forward 5'-CCAACTCATGACTGTCCTTTCTT-3' 
Chapter 4 / SF3B1 screening gDNA (CLL) PCR SF3B1 gDNA exon16 Reverse 5'-TGTTAGAACCATGAAACATATCC-3' 
Chapter 4 / SF3B1 screening cDNA (MDS) PCR SF3B1 cDNA  Forward 5'-TGAGAAAGGCTGCATTGCGTCA-3' 
Chapter 4 / SF3B1 screening cDNA (MDS) PCR SF3B1 cDNA  Reverse 5'-AGCCATCCTGTGCTGCCAGAAG-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Roche 237 Forward 5'-CGCATTCCTCATCCCAGTATG-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Roche 237 Reverse 5'-AAAGGACTTGGTGCAGAGTTCAG-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR ERCC 31 Forward 5'-CGGGATGCAACTAACACCAG-3' 
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Chapter / Use Name of primer Sequence 
Chapter 3&4 / Post Capture Enrichment validation qPCR Human DSCR3 Forward 5'-GCTCAGTGCCAAAAGTGTGG-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Human DSCR3 Reverse 5'-ATTTCCCCGGCTTCACCATT-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Human YBEY Forward 5'-CCAACCGATGTGCTTTCTTT-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Human YBEY Reverse 5'-TGAATCCCAGCAAGTGACAG-3' 
Chapter 3 / Post Capture Enrichment validation qPCR Mouse YBEY Forward 5'-CACTTCGCAGGAAGATGGAT-3' 
Chapter 3 / Post Capture Enrichment validation qPCR Mouse YBEY Reverse 5'-AGTGTGGCTGAGGAAATTCG-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Human ALAS1 Forward 5'-GGCAGCACAGATGAATCAGA-3' 
Chapter 3&4 / Post Capture Enrichment validation qPCR Human ALAS1 Reverse 5'-CCTCCATCGGTTTTCACACT-3' 
Chapter 3&4 / gDNA PCR YWHAZ Forward 5'-CAAAGACAGCACGCTAATAATGCAA-3' 
Chapter 3&4 / gDNA PCR YWHAZ Reverse 5'-CCCCTCCTTCTCCTGCTTCA-3' 
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Genome-wide discovery of human splicing
branchpoints
Tim R. Mercer,1,2,8 Michael B. Clark,1,3,8 Stacey B. Andersen,4 Marion E. Brunck,4
Wilfried Haerty,3 Joanna Crawford,5 Ryan J. Taft,5,6,7 Lars K. Nielsen,4 Marcel E. Dinger,1,2
and John S. Mattick1,2
1Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia; 2St Vincent’s Clinical School, Faculty of Medicine,
UNSW Australia, Sydney, New South Wales 2052, Australia; 3MRC Functional Genomics Unit, Department of Physiology, Anatomy,
and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom; 4Australian Institute for Bioengineering and Nanotechnology,
The University of Queensland, Brisbane, Queensland 4072, Australia; 5Institute forMolecular Bioscience, The University of Queensland,
Brisbane, Queensland 4072, Australia; 6Illumina, Inc., San Diego, California 92122, USA; 7School of Medicine and Health Services,
Department of Integrated Systems Biology and Department of Pediatrics, George Washington University, Washington DC 20037, USA
During the splicing reaction, the 59 intron end is joined to the branchpoint nucleotide, selecting the next exon to in-
corporate into the mature RNA and forming an intron lariat, which is excised. Despite a critical role in gene splicing, the
locations and features of human splicing branchpoints are largely unknown. We use exoribonuclease digestion and tar-
geted RNA-sequencing to enrich for sequences that traverse the lariat junction and, by split and inverted alignment, reveal
the branchpoint. We identify 59,359 high-confidence human branchpoints in >10,000 genes, providing a first map of
splicing branchpoints in the human genome. Branchpoints are predominantly adenosine, highly conserved, and closely
distributed to the 39 splice site. Analysis of human branchpoints reveals numerous novel features, including distinct
features of branchpoints for alternatively spliced exons and a family of conserved sequence motifs overlapping branch-
points we term B-boxes, which exhibit maximal nucleotide diversity while maintaining interactions with the keto-rich U2
snRNA. Different B-boxmotifs exhibit divergent usage in vertebrate lineages and associate with other splicing elements and
distinct intron–exon architectures, suggesting integration within a broader regulatory splicing code. Lastly, although
branchpoints are refractory to common mutational processes and genetic variation, mutations occurring at branchpoint
nucleotides are enriched for disease associations.
[Supplemental material is available for this article.]
Themajorityofhumangenes are spliced, aprocesswhereby introns are
removed from the nascent RNA and the remaining exonic sequence
joined together into a mature RNA transcript. In addition, alternative
splicing generates complex networks of isoforms from human gene
loci andplays amajor role in shaping thediversityof the transcriptome
(Kapranov et al. 2005; Gerstein et al. 2007; Djebali et al. 2012).
Splicing occurs in the spliceosome, a large ribonucleoprotein
complex that recognizes at least three genetic elements within
each intron: the 59 splice site (59SS), the 39 splice site (39SS), and the
branchpoint (Will and L€uhrmann 2011). RNU2-1, the U2 spliceo-
somal RNA (snRNA) base pairs to the sequence surrounding the
unpaired branchpoint nucleotide, which then undergoes trans-
esterification with the 59 end of the intron to form a closed lariat
structure. The spliceosome then scans for the downstream 39 splice
site, which undergoes a second trans-esterification reaction to join
together the two exon ends and excise the intron lariat (Fig. 1;
Smith et al. 1989; Will and L€uhrmann 2011).
Branchpoint selection by the spliceosome is an early step in
the splicing reaction and one that subsequently defines the 39
splice site and leads to inclusion of the downstream exon in the
mature RNA (Hornig et al. 1986; Reed and Maniatis 1988; Smith
et al. 1993). Mutations that abolish the branchpoint nucleotide can
result in exon skipping and aberrant splicing and cause human
disease (Padgett 2012; Singh and Cooper 2012). Despite such im-
portance, only a few hundred human branchpoints have been
identified, thereby preventing a detailed analysis of this basal splic-
ing element (Gao et al. 2008; Taggart et al. 2012; Bitton et al. 2014).
Human branchpoints are difficult to predict by sequence
alone due to the reported high degeneracy of the sequence around
the branchpoint (Gao et al. 2008). Further complicating de novo
branchpoint predictions are reports that some introns have mul-
tiple branchpoints, branchpoints distal from the 39 splice site, or
without the canonical adenine base at the branchpoint nucleotide
(Gao et al. 2008; Taggart et al. 2012; Bitton et al. 2014). However,
during the preparation of cDNA, reverse transcriptase can traverse
the 59SS/branchpoint junction, thereby generating a cDNA with
the 59 intronic sequence juxtaposed to the sequence immediately
upstream of the branchpoint (Vogel et al. 1997). The split and
inverted alignment of the resultant cDNA identifies not only the 59
donor splice site but also the branchpoint nucleotide (Fig. 1;
Taggart et al. 2012; Bitton et al. 2014), yet such events are en-
countered so rarely as to have hitherto prevented efficient and
comprehensive genome scale annotation.
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To enrich for such rare cDNAs that traverse the branchpoint
junction, we have used two complementary approaches: purification
of lariats by exoribonuclease digestion of linear RNAs; and capture
of the branchpoint junction with oligonucleotide probes for tar-
geted RNA sequencing. The sequencing and alignment of these
approaches enables the first genome-wide discovery and analysis
of human splicing branchpoints.
Results
Intron lariat sequencing and alignment
We recently developed RNA Capture Sequencing (CaptureSeq),
a technique that focuses sequencing on targeted RNA transcripts
(Mercer et al. 2012, 2014). This approach is ideal for achievinghigh
sequencing coverage of transient intronic species to resolve branch-
point sites. We designed oligonucleotide probes targeting human
intronic sequences immediately upstreamof the 39 splice site as well
as 59 intronic sequences that, following the 29 trans-esterification
reaction, lie immediately downstream from the branchpoint junc-
tion. By targeting lariat sequences both upstream of and down-
stream from putative branchpoint locations, we thereby enrich for
cDNA transcripts that traverse the lariat junction (Fig. 1A; Supple-
mental Fig. 1A,B; Supplemental Data 1). We interrogated 238,576
introns (90.2% of annotated total) in this manner. We performed
CaptureSeq similarly to previously describedmethods (Mercer et al.
2012) with total RNA harvested from three biological replicates of
humanK562 cells (seeMethods).We achieved greater than 100-fold
enrichment of targeted RNA as determined by qPCR and analysis of
RNA spike-in controls, corresponding to ;10.6-fold more reads
(;133million reads) that align to introns relative to matched RNA-
seq controls (Supplemental Fig. 1C,D).
Figure 1. Identification of splicing branchpoints. Splicing joins the 59 splice site to the branchpoint (BP) nucleotide near the 39 end of the intron to form
a lariat. Reverse transcriptase can traverse the branched 29 to 59 junction to generate informative sequencing reads (blue/red reads) that indicate the
branchpoint location when aligned to the genome. We pursued two alternative strategies to enrich for sequenced reads containing branchpoints. (A)
CaptureSeq (left orange pathway) uses labeled oligonucleotide probes to capture informative reads for targeted sequencing. (B) RNase R (right green
pathway) digests linear mRNAs and selectively purifies circular RNAs including intron lariats. (C ) Following sequencing, informative reads are split and
inverted for alignment to the reference genome (black lower pathway), with 39 termini of split alignment indicating the branchpoint nucleotide. (D)
Example of informative alignments used to identify branchpoints (blue arrows) within the EEF2 gene.
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As an alternative strategy, we also used RNase R digestion to
selectively enrich for intron lariats. RNase R is a 39 to 59 exoribonu-
clease that digests linear RNAs but not circular lariats (Fig. 1B; Suzuki
et al. 2006). We performed RNase R digestion in duplicate on two
human cell-types (K562 and HeLa) along with matched mock-
digested controls (seeMethods; Supplemental Fig. 2A).We confirmed
circular RNA protection using PCR targeting linear and circular iso-
formsofMAN1A2andFBXW4genes (Supplemental Fig. 2B,C; Salzman
et al. 2012). Digested libraries were sequenced and aligned to the
genome, indicating a global 9.6-fold global enrichment for introns
lariats and commensurate depletion of exons (Supplemental Fig. 2D).
Informative sequenced reads that traverse the 59SS/branchpoint
junction require nonconventional alignment to the genome.
From reads that do not otherwise align to the genome, we first fil-
tered for reads containing 59 intronic sequence before trimming the
59 intronic sequence from the read and aligning the remaining se-
quence to introns at the same loci, using the 39 termini of the read to
indicate the branchpoint nucleotide (see Methods; Supplemental
Fig. 3A). We applied this alignment strategy to both RNase R and
CaptureSeq libraries, as well as to 234 publicly available conven-
tional RNA sequencing libraries derived fromawide rangeofhuman
cell types (Djebali et al. 2012). Using this approach, we aligned
532,405 informative sequenced reads that identified 88,748
branchpoints. The relative proportion of sense/antisense alignment
estimated a 0.2% false alignment rate (see Methods). For compari-
son, we returned one informative read for each 7473 sequenced
reads using CaptureSeq, one per 41,725 reads from RNase R di-
gestion and sequencing, and one informative readper 146,617 reads
sequenced with standard RNA-seq (Supplemental Fig. 3B). We also
determined the contribution of each technique to the identification
of high-confidence branchpoints (Supplemental Fig. 3E). Despite
the large number of conventional RNA sequencing libraries we ex-
amined, the majority of unique branchpoints were discovered by
CaptureSeq and RNase R, confirming their value for branchpoint
identification. Lastly, we detected two biases within our branch-
point annotations. Given that sequence coverage of branch junc-
tions does not reach saturation, highly expressed genes are better
represented within branchpoint annotations; and although we
identify branchpoints in introns larger than 100 kb, we observe an
overall bias for branchpoints in short introns.
Validation of branchpoint annotations
Nucleotide misprocessing often occurs when reverse transcriptase
traverses the noncanonical 29 to 59 linkage between the 59 splice
site nucleotide and branchpoint at the lariat junction, resulting in
a mismatch error, microinsertion or deletion in the generated
cDNA (Fig. 2A; Vogel et al. 1997; Gao et al. 2008). Sequenced reads
with small insertions or deletions are present at 8673 branchpoints
but are unable to precisely locate the branchpoint nucleotide
(Supplemental Fig. 3C). However, single mismatch errors in the
cDNA are diagnostic of the exact branchpoint nucleotide (Gao
et al. 2008). We found 70.4% of sequenced reads (375,178 total)
aligning to branchpoints contained mismatches at the branch-
point nucleotide, comprising an 392.1-fold higher error rate over
background and confirming the location of 74.1% (59,359) of
branchpoint nucleotides (Fig. 2B,C). Branchpoint annotations for
each level of supporting evidence are provided (Fig. 2D; Supple-
mental Table 1; Supplemental Data 2).
The majority of branchpoints (75.2%) are supported by mul-
tiple reads, with coverage encompassing a 103-fold dynamic range
(Supplemental Fig. 3D). This quantitativeprofile is closely correlated
between biological replicates (Pearson’s r2 = 0.92) and provides a
quantitative measure of branchpoint selection preference.
Detailed analysis of RNase R-digested alignment profiles also
revealed the selective digestion of lariat regions downstream from
the branchpoint, which corresponds to the exposed linear tail,
whereas the regions upstreamof the branchpoint corresponding to
the closed circular lariat remain protected (Fig. 3A,D).We observed
a global 3.7-fold depletion (P = 0.029, paired t-test) of intron lariats
immediately downstream from branchpoints annotations (corre-
sponding to the lariat tail) in RNase R-treated samples (with 26,758
branchpoints exhibiting greater than twofold downstream de-
pletion) (Fig. 3B,C), lending further support to branchpoint lo-
cations identified by RNase R digestion. Intron-specific RT-PCR
amplification followed by Sanger sequencing was also performed
to independently confirm the location of 10 branchpoint nucle-
otides (Supplemental Fig. 3F).
Branchpoint features
This first large-scale experimental annotation of branchpoints
afforded an opportunity for the global analysis of branchpoint
features. We restricted our analysis to the 59,359 high-confidence
branchpoints confirmed by mismatch sequencing errors that cor-
respond to ;17.4% of introns occurring within 10,773 genes
(24.8% of total).
Branchpoints annotations exhibited several previouslydescribed
features (Gao et al. 2008; Corvelo et al. 2010; Taggart et al. 2012),
including a restricted distribution upstreamof the 39 splice site, with
90% of branchpoints occurring within 19 to 37 (median 25) nu-
cleotides upstream (Fig. 4B). The majority of branchpoint nucleo-
tides correspond to adenine (78.4%),with lower frequency selection
of cytosine (8.4%), uracil (8.4%), and guanine (4.7%) nucleotides
that have been shown to function, albeit with lower efficiency, as
branchpoints (Fig. 4A; Reed and Maniatis 1988). Three non-
canonical branchpoints were selected and confirmed by RT-PCR/
Sanger sequencing (Supplemental Fig. 3F). The region downstream
from the branchpoint exhibits a strong depletion of AG di-
nucleotides (4.0-fold depletion, with 77% of intervening regions
containing no AG dinucleotides with the exception of the 39 splice
site), consistent with the spliceosomal scanning model of 39 splice
site recognition (Fig. 4D; Supplemental Fig. 4A; Smith et al. 1989).
Genome-widemaps also showed new branchpoint features. A
large proportion of exons (32.4%) were associated with more than
one branchpoint, indicating flexibility or redundancy in branch-
point selection (Supplemental Data 3). These multiple branch-
points are generally clustered in close proximity to each other and
conform to a similarly tight distribution in relation to the 39 splice
site as for individual branchpoints (Fig. 4E), although exceptional
distal branchpoints were identified (Supplemental Fig. 4B). Mul-
tiple branchpoints were not equally used, with themajority of exons
(52.9%) having one or a small number of dominant branchpoints.
Multiple branchpoints exhibit lower conservation and a lower
preference for adenine (Supplemental Fig. 4C). Dense multiple
branchpoint clusters are notably enriched for cytosine branchpoints
that are conserved relative to surrounding sequence (Supplemental
Fig. 4D). Cytosine branchpoints have been shown to be resistant to
debranching (Hornig et al. 1986) andmay comprise a distinct subset
recently associated with stable lariat and long noncoding RNA for-
mation (Zhang et al. 2013).
Alternative splicing can also be detected at the branchpoint
level. Using our split/inverted read alignments to pair branchpoints
with their partner 39 and 59 splice sites, we identify alternative splic-
Branchpoint discovery
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ing events within 12.6% of alignments, whereby multiple intron 59
termini are joined to a common branchpoint, or a common 59 ter-
mini is joined to multiple branchpoints (Fig. 4F). Examples of dif-
ferential branchpoint selection and usage during alternative splicing
were also observed at the branchpoint level, with alternative 59 splice
sites exhibiting different preferences for multiple branchpoints that
precede a single common exon (Supplemental Fig. 4E).
The vast majority of identified branchpoints are within pro-
tein-coding genes; however, we also identify 551 branchpoints
from 255 long noncoding RNA (lncRNA) loci, including well-
known lncRNAs such as HOTAIR, XIST, and a number of snoRNA-
host lncRNAs.
Branchpoint identification can also lend support to the in-
clusion of associated exons and exon variants presently absent
fromcomprehensive gene catalogs such asGENCODE (Harrow et al.
2012). Strict filtering identified a group of 16 exons, including a
conserved 21-nt micro-exon in theMAST2 gene (Supplemental Fig.
4F; Supplemental Table 2).
Branchpoint motifs
The nucleotides flanking branchpoints bind U2 snRNA and are
highly conserved, suggesting the proximity of regulatory sequence
elements (Fig. 4C). Extreme examples of such proximal conserva-
tion include branchpoints found within ultraconserved elements
that govern the unproductive splicing of the SR gene family (Sup-
plemental Fig. 5A; Lareau et al. 2007).
To identify cis-elements, we performed de novo motif iden-
tification around the branchpoint (Neph et al. 2012). This resolved
a set of 5- to 6-nt sequence motifs that overlap ;53% of all branch-
point annotations and can undergo base-pairing interactions with
the U2 snRNA (Fig. 5A; Supplemental Fig. 5B). We term these B-box
Figure 2. Validation of branchpoint annotations. (A) Schematic indicating incorporation of mismatch nucleotide (gray X) within cDNA (blue/orange
bar) by reverse transcriptase when traversing the 29 to 59 branch junction. (B) UCSCGenome Browser view of branchpoints within EZH2 gene (lower panel)
showing capture of sequences at intron ends (histogram) and sequenced read alignments that indicate branchpoints (red/blue bar). RT-PCR using outward
facing primers (blue) generates an amplicon that validates branchpoint annotations (blue/orange upper panel). Zoom of chromatograph (top left) shows
sequence mismatch error (T) at the branchpoint nucleotide (boxed). (C ) Histogram indicates rate of mismatch errors at the branchpoint nucleotide in
sequenced reads that align across the lariat junction (center). (D) Summary of branchpoint annotations with varying levels of support: split/inverted
alignment, exact match across lariat junction, match with mismatch, or insertion/deletion errors at branchpoints. At each level of support, the number of
identified branchpoints, nucleotide composition of the branchpoint, and fraction of GENCODE introns with an annotated branchpoint are indicated.
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elements since they are enriched for B-nucleotides (C, G, and U)
(Cornish-Bowden 1985) and depleted of adenosine nucleotides
(with the exception of the branchpoint itself). B-box nucleotides
base pairwith the high density of keto-residues (G andU)within the
U2 snRNA, and the abundance and conservation of different B-box
families correlates with predicted U2 binding strength (Fig. 5B;
Supplemental Fig. 5C). Due to RNA wobble-base pairing, the U2
snRNA keto-residues can interact with two possible nucleotides at
the opposing position in the B-box element. This enables B-boxes to
have greater informational diversity while maintaining their ability
to bind U2 snRNAs (Fig. 5A,C). This diversity underpins the ob-
served range of sequence families that when collectively analyzed
have been previously considered degenerate (Gao et al. 2008). Sim-
ilar enriched interactions between B- and keto-nucleotides have
been observed for microRNA seed sequences (Nelson and Green
1989; Wang 2013).
B-box elements can be further classified into distinct subset
families according to divergent uracil or cytosine nucleotide con-
tent (particularly at the 3 upstream nucleotide) (Fig. 5D; Sup-
plemental Fig. 5B) and divergent conservation profiles (see below).
Notably, the distinction between cytosine (CUNAN) and uracil
(UUNAN) B-box elements is not limited to the branchpoint motif;
rather, each motif family is preferentially associated with distinct
types of intron–exon architecture (Fig. 5E,F; Supplemental Fig. 5D–
F). Cytosine B-box motifs are associated with cytosine-rich poly-
pyrimidine tracts (PPTs) and high GC% introns and downstream
exons. Conversely uracil B-boxes associate with uracil-rich PPTs
and low GC% introns and exons. Al-
though uracil B-boxes are characterized
by the lowest exonic and intronic GC
content, they exhibit the greatest differ-
ence inGC content between the exons and
their 59 flanking introns (P < 0.001 in all
comparisons after Bonferroni correction).
In contrast the opposite results are found
for the cytosine motif (P < 0.001 in all
comparisons after Bonferroni correction)
(Fig. 5F; Supplemental Fig. 5E,F). These al-
ternate intron–exon architectures share
characteristics with those proposed by
Amit et al. (2012) to segregate exons
according to splicing by either intron- or
exon-definition mechanisms.
Competitionbetween splice elements
helps decide exon inclusion, with strong
splice sites associated with constitutive
splicing; whereas competition between
weaker splice sites results in alternative
splicing (Mullen et al. 1991). Using pre-
dictedU2 snRNAbase-pairing as ameasure
of branchpoint strength, we investigated
the relationship between branchpoint
strength and the splicing status of its as-
sociated downstream exon. We confirm
that B-box elements exhibiting strongest
U2 binding affinity are enriched at con-
stitutively spliced exons (1.26-fold, un-
paired t-test,P-value 1.323 109),whereas
weaker motifs are associated with alterna-
tively spliced exons (1.67-fold, unpaired
t-test, P-value 3 3 104). Focusing on spe-
cific types of alternative splicing events, we
find a global shift toward weaker B-box elements for skipped exons
(P < 0.001), but not within retained introns (one-way ANOVA-
Kruskal-Wallis test with Dunn’s post-test). B-boxes associated with
alternatively spliced exons are also more conserved (1.90-fold, P =
3.13 105, unpaired t-test) than counterparts at constitutive exons,
a trend similarly observed for other splicing elements (Sorek 2007).
A model in which B-box strength influences splicing outcome
further predicts that when multiple branchpoints can be utilized to
splice an exon, branchpoints with stronger U2 binding affinity
should out-compete thosewithweaker B-boxes. Consistentwith this
hypothesis, we find a positive correlation between B-box strength
and branchpoint selection frequency at exons with multiple
branchpoints (Spearman r = 0.1709, P < 0.0001). Closer examina-
tion further suggests that splicing outcome is only impacted once
B-box strength crosses a threshold of potential U2 hydrogen
bonds, and nonadenosine branchpoints are outcompeted by
adenosine branchpoints (one-way ANOVA with Tukey correction
for multiple testing) (Fig. 5G).
In addition, we also identified 102 branchpoint sites that
conform to the branchpoint sequence UCCUURAYand splice sites
of RNU12-dependent introns that are spliced by the minor spli-
ceosome (Supplemental Fig. 6A; Turunen et al. 2013).
Conservation of branchpoints and surrounding elements
To investigate branchpoint conservation, we analyzed syntenic
nucleotides across 100 vertebrate species (Blanchette et al. 2004).
Figure 3. RNase R digestion of intron lariats. (A) Schematic showing digestion of the lariat tail (green)
downstream from the branchpoint by RNase R, while the closed lariat protects sequences upstream of
the branchpoint (blue). (B) Heatmap indicates the relative enrichment of sequences upstream of in-
dividual branchpoints within RNase R digested libraries (x-axis) compared to untreated control (y-axis)
libraries. The majority of branchpoints show enrichment of upstream sequences after digestion (in-
dicated by positive horizontal spread), whereas the clustering at zero on the y-axis indicates that se-
quences around individual branchpoints show no enrichment inmock-digested libraries. (C ) Histogram
indicates significant depletion of intronic sequences downstream from branchpoints (to the 39SS) rel-
ative to the upstream region following RNase R digestion. Two human cell types, each with two bi-
ological replicates with matched untreated controls (paired t-test, n = 4, error bars SEM). (D) Genome
Browser view showing enrichment of DDX3X intron lariats following RNase R digestion. Close detail in-
dicates selective digestion of intronic sequence downstream from the identified branchpoint. In contrast,
equivalent pre-mRNA is observed both up- and downstream from branchpoints in untreated libraries.
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We found that 57.7% of branchpoints were conserved between
human and fish lineages, 66.1% within mammal lineages and
95.2% were conserved within primate lineages. B-box elements
also exhibit a distinct evolutionary signature, with enrichment for
nucleotide substitutions acrossmammalian lineages thatmaintain
the ability of the B-box to base pair with the U2 snRNA (Fig. 5C).
Among most B-box families, the 2 U nucleotide is the most
conserved followed by the branchpoint adenosine (Supplemental
Fig. 6B). These nucleotides were especially highly conserved in B-
box motifs matching the canonical yeast (S. cerevisiae) motif
(CUAAC). In contrast, B-boxes without a branchpoint adenosine
displayed little or no increase in conservation above the local
background. Comparison of the common CUNAN (cytosine) and
UUNAN (uracil) motifs revealed similar levels of conservation at
the2 uracil and the branchpoint, but the predominance of uracil
nucleotides surrounding the UUNAN B-boxes was also associated
with the higher conservation of these nucleotides (Fig. 5E).
We also investigated the relationship between branchpoints
and the conservation of associated exons. Similar to the results for
exonic GC content, we find a significant difference in exonic
nucleotide conservation depending upon the nucleotide composi-
tion of the B-box. Exons flanked by CUNANmotifs are significantly
less conserved than exons flanked by a UUNAN motif (Mann-
WhitneyU-test,P < 2.23 1016) (Fig. 5E; Supplemental Fig. 6C). The
opposite phenomenon is observed for the 39 splice site strength,
where exons flankedbyCUNAN showa significantly stronger signal
(P = 8.34 3 1011), suggesting a compensatory mechanism and the
interplay between different splicing elements for the accurate
splicing of exons (Supplemental Fig. 6D; Dewey et al. 2006).
Human genetic variation at branchpoints
Mutations that abolish branchpoints can result in exon skipping
and aberrant splicing with disease consequences (Li et al. 1998;
Khan et al. 2004; Padgett 2012). Although branchpoints are re-
fractory (;3.1-fold) to common single nucleotide polymorphisms
(SNPs) relative to surrounding sequences (Fig. 6A), we estimate an
average ;53 branchpoints are mutated within an individual’s ge-
nome (The 1000 Genomes Project Consortium 2010).
In contrast to the depletion of common SNPs at branchpoints,
we observe a strong enrichment (16.5-fold) for SNPs associated with
disease (Fig. 6B; Supplemental Fig. 7A; Forbes et al. 2011; Stenson
et al. 2012). In most cases, these disease-associated mutations result
in the abolition of conserved adenosine branchpoint nucleotides
(Supplemental Table 3). Mutation of the branchpoint can result in
exon skipping. For example, we identified a branchpoint nucleotide
within the RB1 gene that when mutated, results in the skipping of
the downstream exon in patients with retinoblastoma (Fig. 6C;
Houdayer et al. 2008; Zhang et al. 2008). Similarly, we identified
a branchpoint within the MET oncogene that when deleted, results
in skippingof exons encoding the juxtamembranedomain, resulting
in MET activation in lung adenocarcinoma (Onozato et al. 2009).
Common human genetic variation also exhibits selective
constraint in B-box elements, with enrichment for SNPs that
maintain base-pairing with the U2 snRNA (Fig. 6D). Notably, the
wobble-base pairing ability to pair with two possible nucleotides
also protects B-box elements from transition mutations (C-T and
A-G). Transitionmutations, which are the most commonmutation-
al process (65.6% of mutations) in the human genome, do not
Figure 4. Sequence context and usage of branchpoints. (A) Distinct nucleotide composition (upper panel) of branchpoints and downstream PPT. Fold
enrichment of nucleotide composition relative to local genome background (lower panel). (B) Frequency distribution of branchpoints relative to the 39
splice site (dashed lines indicate 10th, 50th, and 90th percentiles). (C ) Vertebrate conservation profile (100 species) across 100-nt window shows con-
servation peak around the branchpoint (boxed). Downstream elevated conservation is due to exon sequence. Detailed inset shows relative conservation of
the branchpoint and flanking 2 upstream nucleotide (red). (D) AG dinucleotide counts upstream of branchpoints (blue) and in the downstream in-
tervening region (red) show that the majority of AG dinucleotides in intervening regions correspond to the 39 splice site. (E) Frequency distribution of
singleton (black) and multiple (blue) branchpoints relative to the 39 splice site. (F) Alternative splicing of a cassette exon (green) in the MECR gene is
revealed by lariat reads which have a common 59 intron termini but utilize branchpoints associated with different 39SS (red and blue arrows). Blue lariat
reads include the cassette exon into the mRNA, while the red lariat reads exclude the cassette exon.
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compromise the ability of B-box elements to base pair with the
U2 snRNA (Fig. 5A; Zhao and Boerwinkle 2002).
In addition, there is a depletion of adenine and guanine
polymorphisms (1.2-fold) between the branchpoint and 39 splice
site. This is likely due to the selection against polymorphisms that
can form cryptic splice sites that compete with bona fide 39 splice
sites and cause aberrant splicing (Smith et al. 1993). In contrast,
40% (an ;10.4-fold enrichment over expected) of disease associ-
Figure 5. Branchpoint motifs and conservation. (A) Schematic illustrating base-pairing of consensus branchpoint flanking sequence to U2 snRNA IBP-
box. (B) Bubble plot indicating the overrepresentation and conservation of pentamer sequences overlapping branchpoints. Color indicates predicted U2
binding strength and circle radius is proportional to total motif count. Overrepresented motifs, such as CUGAC, exhibit both high conservation and
predicted U2 binding strength. (C ) Enrichment for substitutions that maintain U2:B-box binding. The upper schematic shows the predominance of G and
U bases within the U2 snRNA IBP box that can bind via complementary or wobble base-pairing to two different possible opposing nucleotides in the B-box.
The lower histogram indicates the fold enrichment for nucleotide substitutions at syntenic bases within the B-box between themouse and human genome.
Fold enrichment is normalized for background rates of nucleotide substitutions between mouse and human genomes. We observe enrichment for
nucleotide substitutions thatmaintain complementary or wobble base-pairing between the B-box and U2 snRNA. (D) Examplemotifs identified de novo in
sequences flanking the branchpoint (branchpoint at +4 nt). (E) Average nucleotide conservation score (phyloP 100 vertebrates) for 100 nucleotides
flanking the branchpoints. U motifs indicated in red; C-motif indicated in blue. Canonical CUAAC motif is not included in order to examine only derived
motifs. Shaded areas represent the 95% confidence intervals. (Inset) Twenty nucleotides around the branchpoint, error bars are 95% confidence intervals.
(F) Box-whisker plot (5%–95% range) of GC% differential between branchpoint introns and associated downstream exons for various families of B-box
elements: (Yeast) CUAAC; (others) motifs without a branchpoint adenosine. (G) Box-whisker plot (2.5–97.5% range) of relationship between U2 binding
energy and branchpoint selection frequency (per exon). (Non A) Nonadenosine branchpoints. Summary of significant differences shown. (****) P <
0.0001; one-way ANOVA with Tukey correction for multiple testing.
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ated SNPs occurring downstream from branchpoints result in the
formation of a new AG dinucleotide that can potentially act as
a cryptic 39 splice acceptor site (Supplemental Fig. 7B).
Branchpoint prediction and the evolution of branchpoint usage
The identificationof explicit B-boxmotifs allows for theprediction of
additional branchpoints in instances in which overrepresented mo-
tifs occur in intronic sequences (seeMethods).We identified a further
202,646 B-boxes that when combined with our experimentally de-
termined annotations, expands the branchpoint annotations to ac-
count for 52.3% of human exons. Predicted B-boxes exhibit sense
strand asymmetry and a similarly constrained 39 proximal peaked
distribution as observed for known branchpoints (Fig. 7A). Further-
more, predicted B-boxes exhibit a higher evolutionary conservation
(2.1-fold) than surrounding sequence, with only moderately less
conservation (;24% lower) than experimentally determinedmotifs
(Fig. 7A; Supplemental Fig. 7D). Similar to known branchpoints,
these predicted sites are also refractory to common SNPs and
enriched for disease-associated SNPs (Supplemental Fig. 7A,C;
Supplemental Table 3). This predictive approach may be necessary
to identify branchpoints for lowly expressed exons that are diffi-
cult to identify even after sequence capture (Supplemental Fig. 7D)
and provide a mechanistic hypothesis for ;1.6% of total disease-
associated intronic noncoding DNA variants (Stenson et al. 2012).
The predictive power of B-boxes also extends to other ge-
nomes, permitting us to consider usage and innovation of branch-
point motifs in multiple metazoan lineages. Instances of B-boxes
were identified in the introns of ninemodel organisms and assessed
according to sense-strand asymmetry and 39 splice site proximal
distribution to enable delineationof lineage-specific trends (Fig. 7B).
For example, the most common predicted human CUGAC B-box
exhibits an enriched peaked distribution and strand asymmetry
within vertebrate lineages, but it is poorly represented within other
lineages analyzed. In contrast, the B-box motif, CUAAU is enriched
in older human genes that are shared across the vertebrate lineage
(1.2-fold, P = 6 3 107) (Zhang et al. 2010). This ancient motif ex-
hibits a conserved distribution in all eukaryote lineages analyzed;
but while thismotif is associated with 26% ofD. melanogastor exons
for which motifs were predicted, its prevalence progressively de-
creases in the vertebrate lineage, being associated with only 9.1% of
human exons (Fig. 7C; Lim and Burge 2001).
The changing usage of branchpoints in different metazoan
lineages led us to investigate branchpoint usage in primate specific
exons, specifically those associatedwithAlu repeats. In the inverted
orientation, the A-rich region between the left and right arms
of an Alu element and its 39 polyA tail create cryptic polyT PPTs
(Supplemental Fig. 8A). Previous studies have demonstrated the
exonization of Alu elements requires minimal additional muta-
tions (Lev-Maor et al. 2003; Sorek et al. 2004).
Figure 6. Common and disease-associated genetic variation at branchpoints. (A) Frequency distribution of common SNPs across a 200-nt window
shows that branchpoints are refractory to common genetic variation (note that downstream exon enrichment is confounded by SNP ascertainment bias).
(B) Frequency distribution of disease-associated SNPs (with inset showing detail) indicates enrichment at branchpoint. (C ) UCSC Genome Browser view of
nucleotide identified as a branchpoint (A; green) in the Retinoblastoma gene (RB1). Mutations at this nucleotide have been associated with exon 24
skipping (dashed arrow) in retinoblastoma patients (Houdayer et al. 2008; Zhang et al. 2008). High conservation (Vertebrate 46way) of branchpoint
indicated by lower blue histogram. (D) Histogram indicates fold enrichment for nucleotide substitutions (SNPs) between individual human genomes. Fold
enrichment indicates the observed rate of SNPs relative to the expected genome background rate of nucleotide substitution. This demonstrates en-
richment for SNPs that maintain complementary or wobble binding between the B-box and U2 snRNA. U2 snRNA and B-box base-pairing nucleotide
possibilities are indicated in the lower schematic.
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Utilizing our experimentally determined branchpoints, we
identified 154 (90% of which were adenosine) associated with
exonized inverted Alus. Exonized right and left Alu arms utilized
different sets of B-boxes; 48% of left arm motifs were CUAAU
(Supplemental Fig. 8B,C) compared to 1% of right armB-boxes (P <
0.001, 1000 permutations). The CUAAUB-box is present in theAlu
inverted consensus sequence just 59 of the internal polyT tract.
CUAAU is an ancient B-box motif with very high U2 binding ca-
pability; its presence beside a PPT supports the hypothesis that Alu
elements are ‘‘pre-exons’’ well placed for inclusion intomature RNA
transcripts (Sorek et al. 2004). In contrast, no single position dom-
inatesAlu right arm exonization, themost common B-box UUUAU
(12% of motifs) reflecting instead the T-rich nature of the se-
quence, with branchpoints present both within the inverted Alu
polyA tail or close by (Supplemental Fig. 8C,D).
Left arm B-boxes show significantly stronger U2 binding
strength (P < 0.0001 unpaired t-test) (Supplemental Fig. 8E) in
contrast to other splicing elements, which have stronger right
arm signals (Gal-Mark et al. 2008). Given the impact of B-box
strength on splicing outcome (see above), the B-box may com-
pensate for the other left-arm splicing elements and allow
exonization.
Discussion
The 59 and 39 splice sites of more than;300,000 exons have been
identified within the human genome to date (Harrow et al. 2012).
In contrast, only a few hundred corresponding branchpoints have
been collectively described in literature (Taggart et al. 2012; Bitton
et al. 2014), and the identification and analysis of branchpoints
has been absent from ambitions for a full catalog of functional
genetic elements.
The extreme rarity of branchpoint-containing intron lariats
has made them almost intractable to genomic analysis. Previous
attempts to experimentally determine branchpoints has relied on
laborious, low-throughput RT-PCR or 2D-gel purification of lariats
(Gao et al. 2008; Awan et al. 2013) or identified several hundred
branchpoints from large-scale RNA-sequencing atlases (Taggart
et al. 2012; Bitton et al. 2014). In contrast, RNA CaptureSeq and
RNase R digestion significantly enrich for intron lariats, allowing
genome-wide branchpoint detection in wild-type cells without
blocking intron debranching (Bitton et al. 2014). Another advan-
tage of our approach, including the requirement for a diagnostic
mismatch at the branchpoint, is the identification of branchpoint
nucleotides with both greater accuracy and confidence, allowing
us to identify nonstandard branchpoints, including those without
an adenosine or distal from their 39 exon.
This genome-wide annotation provides a unique opportunity
to analyze branchpoint features, conservation, and distribution.
Although the branchpoint nucleotide itself is strictly constrained
in distance from the 39 splice site and exhibits a strong selection
preference for adenosine, the B-box sequences flanking the
branchpoint exhibit the full sequence diversity afforded the ex-
panded base-pairing possibilities provided by the keto-nucleotide
dense U2 snRNA. These distinct features of B-box elements were
previously observed for microRNA seed sequences and may reflect
common strategies for sequence specific RNA base pair interactions
(Nelson and Green 1989; Wang 2013).
Similar to microRNA selection, the observed heterogeneity of
B-box elements may enable the sequence-specific selection of al-
ternate branchpoints by the spliceosome, resulting in splicing reg-
ulation and exon inclusion. Although the U2 snRNA branchpoint
interacting sequence is strictly conserved throughout eukaryotic
lineages (Marz et al. 2008), the density of nucleotide modifications
within this branchpoint interacting sequence could further modu-
late base pair binding possibilities (Yu et al. 1998). Furthermore, it
was recently shown that different U2 snRNAs genes exhibit cell-
specific expressionwithmutations to a singleU2 snRNA resulting in
the disruption of a subset of alternative splicing events, including
small introns, in a tissue-specific manner (Jia et al. 2012).
Our results provide some insight into the importance of
branchpoint signals and how they are integrated into the wider
Figure 7. Branchpoint prediction and usage in different species. (A) Vertebrate conservation profile (100 species) of known (blue, left panel) and
predicted (red,middle panel) branchpoint sequence (BPS) motifs. Frequency distribution (right panel) of known (blue) and predicted (red) motifs relative
to the 39 splice site, with matched scrambled control (gray) indicated. (B) Frequency distribution of common branchpoint motifs across a 75-nt window
upstream of the 39 splice site from the range of model organism genomes reveals differential usage of branch motifs across different lineages. (C ) Bubble
plot/histogram indicates the proportion of exons from model organism genomes that are associated with selected motifs. Circle radius is proportional to
motif overrepresentation against the expected background in each organism.
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mechanisms that determine productive splicing. Branchpoints
with strong U2 binding (strong B-boxes) outcompete those with
weak B-boxes and thosewithout a branchpoint adenosine, to specify
exon inclusion (Fig. 5G). In addition, U2 binding strength positively
correlates with both B-box occurrence and conservation (Fig. 5B;
Supplemental Fig. 5C), supporting the importance of the B-box to
efficient splicing.Despite this, splicing is resistant to the impact of B-
box mutations. The flexible nature of U2 binding allows transition
mutations without a significant impact on B-box strength, whereas
our results demonstratemanyweaker B-boxmotifs can participate in
branchpoint selection, albeit with decreased efficiency. Furthermore,
many genes have multiple branchpoints that can be utilized, pro-
viding some redundancy to branchpoint selection.
Our results support previous suggestions that the common
2 U and branchpoint A (UnA) are central to the branchpoint
motif (Gao et al. 2008), with these nucleotides showing thehighest
levels of conservation andmotif occurrences as well as depletion of
SNPs and overrepresentation in disease. One of the earliest steps in
spliceosomal assembly is the binding of SF1 to the branchpoint, a
process for which mammalian SF1 requires only the UnA motif,
providing amechanistic explanation for the importance of the2U
nucleotide (Berglund et al. 1997).
B-box families preferentially associate with distinct classes of
intron–exon architecture that can be distinguished by PPT nucle-
otide content, GC content, and conservation (Fig. 5D–F; Supple-
mental Figs. 5d–f, 6b–d). It has been proposed these alternative
architectures correspond to intron- and exon-defined splicing
mechanisms (Amit et al. 2012). Therefore, B-boxmotifs contribute a
further distinction between these two alternative architectures. This
integration of multiple splicing features suggests the coevolution of
B-box motifs with the surrounding sequence and their integration
into the competitive and compensatory mechanisms that regulate
splicing.
Uracil-rich PPTs are ancestral with a shift to cytosine enrich-
ment appearing in birds and increasingly in mammals in associa-
tion with high GC content introns (Amit et al. 2012). U2AF, which
binds PPTs cooperatively with the branchpoint binding SF1, has
highest affinity for uracil-rich sequences (Coolidge et al. 1997),
suggesting that cytosine-rich PPTs, and hence cytosine B-boxes and
associated exons, may require additional splicing enhancer se-
quences to mediate efficient splicing.
Aberrant splicing is responsible for an estimated 15% of hu-
man diseases (Singh and Cooper 2012), with exon skipping result-
ing from the failure of a splicing element, such as mutation to a
branchpoint, being the most common cause. We observe disease-
associated genetic variation is enriched at both experimentally de-
termined and predicted branchpoints, where it may interfere with
splicing. However, branchpoint selection may also have a much
broader contribution toward cancer. A range of cancers, in particular
hematological malignancies, has been found to harbor mutations
to genes encoding the U2 spliceosome responsible for selecting
branchpoints (Yoshida et al. 2011). We expect this resource will
inform themechanistic interpretation of disease-associated intronic
noncoding variation and aid investigation into how deregulated
branchpoint selection constitutes a novel oncogenic pathway.
Methods
Capture array design
Oligonucleotide probeswere designed in conjunctionwithDr. Ryan
Bannen at Roche/NimbleGen using proprietary bioinformatics to
optimize array probe sequence and omit repetitive regions. All hu-
man genome (hg19) regions from the 100-nt 59 and 39 termini of
publicly annotated introns (GENCODE v12 comprehensive as-
sembly) were targeted (Harrow et al. 2012). Regions overlapping an
annotated exon or a region of high transcription (as determined
frompublicly available humanK562 RNA-seq alignments) (Djebali
et al. 2012) were excluded. This final design covered 36.8 Mb and
targets both 39 and 59 100-nt termini for 76.4% (206,747) publicly
annotated introns or a single terminus for 90.2% (244,125) in-
trons. Additional control probes, including probes targeting all
ERCC controls (Baker et al. 2005), were included within the design
to assess CaptureSeq performance. The final design was manufac-
tured on a Custom Sequence 2.1M Array (Roche/NimbleGen; Cat
#05329841001). Human genome coordinates (hg19) are provided
in Supplemental Data 1.
Capture experiment
Capture sequencing was performed similar to previously described
(Mercer et al. 2012, 2014) by combining and modifying the
NimbleGen SeqCap EZ Library SR User’s Guide V3.0 and the
NimbleGen Arrays User’s Guide: Sequence Capture Array Delivery
v3.2. RNA sequencing libraries of ribodepleted total RNA from
three K562 biological replicates were created using the TruSeq
StrandedmRNA Sample Preparation Kit (Illumina). Precapture and
post-capture LMPCRwere performed for an average of nine and 17
cycles, respectively. Precapture and post-capture samples (pools of
3 K562 biological replicates) were each sequenced on a single lane
of an Illumina HiSeq. See Supplemental Methods for full details.
RNase R treatment
RNase R (Epicentre) digestion was conducted on batches of 100-ng
ribodepleted RNA. The standard digestion procedure was 30 units
enzyme: 1 mg RNA for 30 min at 37°C. Mock digestion controls
lacking RNase Rwere also performed. See SupplementalMethods for
full details.
Validation of RNase R digestion
Digestion of linear RNAs in preference to circular RNAs was con-
firmed by RT-PCR on untreated Ribo-Zero RNA, RNase R-treated
RNA, and RNase R negative mock-treated RNA samples. PCR and
Sanger sequencing was used to validate the maintenance of cir-
cular multiexonic RNAs within FBXW4 and MAN1A2 identified
previously (Salzman et al. 2012), while linear RNAs from these same
genes were degraded. The fold depletion of linear RNAs was also
measured by quantitative real-time PCR (qPCR). Primer sequences
are listed in Supplemental Table 4. See Supplemental Methods for
full details.
RNase R RNA-seq library preparation
RNA sequencing libraries were made with the TruSeq RNA Sample
Preparation v2 Kit (Illumina). Samples were sequenced on an
Illumina HiSeq. See Supplemental Methods for full details.
Alignment to identify branchpoint nucleotides
The alignment approach to identify branchpoints is based on the
Bowtie 2 read aligner (Langmead and Salzberg 2012) and TopHat2
splice junctionmapper (Kim et al. 2013). This pipeline proceeds as
follows (illustrated in Supplemental Fig. 3):
Sequenced reads (.fastq file) was firstly aligned to the human
genome using TopHat2:
Mercer et al.
10 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on May 31, 2015 - Published by genome.cshlp.orgDownloaded from 
1468
$tophat2–xhg19.index–gGENCODEv12.comprehensive.
gtf \
-1 sequences.1.fastq -2 sequences.2.fastq
Reads aligning to the reference genome are omitted from
further analysis.
An index corresponding to unaligned reads is then assembled
(unaligned_reads.index). The 59 (23 nt) sequence of each
unique intron (23nt_59introns.fa, using GENCODE v12 com-
prehensive assembly) is then aligned to unaligned read index:
$ bowtie2 -x unaligned_reads.index -U 23nt_59intron.
fa
Unaligned reads with no match to an intron 59 sequence are
omitted. For reads towhicha 59 intron sequence aligns, the sequence
downstream to the region aligning to the 59 intron sequence is
trimmed (trimmed_reads.fa). The sequence that remains fol-
lowing trimming is required to be longer than 20 nt and is then
aligned to the reference human genome:
$ bowtie2 -x introns.index -U trimmed_reads.fq
The .sam output is then analyzed for intronic alignments.
Read alignments are required to occur <250nt of the 39 splice site of
an intron, whose 59 termini is required to match the original 59
sequence that was trimmed from the read (i.e., both the splice 59
intron sequence and trimmed read alignment are required derive
from single intron). The 39 nucleotide of the final alignment in-
dicates the predicted branchpoint nucleotide.
As a secondary filter for spurious alignments, we then gen-
erated a lariat junction index centered on predicted branchpoints
(lariat.index). This lariat junction index comprises the 100 nt
upstream of the branchpoint nucleotide followed by the 100-nt
sequence from the matched intron 59 termini, together constitut-
ing the expected sequence that traverses the intron lariat junction
for each branchpoint. Lariat sequenceswere required to have <80%
homology with human genome. We then realigned all reads that
do not align to genome:
$ bowtie2 -x lariat.index -U unaligned_reads.fq
The .sam output was filtered for reads requiring a full-length
and uniquematch, with a requisite 20-nt minimumoverlap across
branch junction. This provides the final annotation of branchpoints
across which lariat reads align.
Identification of sequence errors at branchpoint nucleotides
Reverse transcription across the 29 to 59 linkage between the
branchpoint and 59 intron nucleotide is associatedwithmismatch,
insertion, and deletion errors (Vogel et al. 1997).
Mismatch errors were identified within sequenced reads
using samtools calmd (v1.18) and to determine the MD/NM
tags that indicate sequence mismatch (Li et al. 2009). Sequence
errors were required to correspond to the central branchpoint
nucleotide.
Insertion and deletions were identified using:
$ bowtie2 -x lariat.index -U unaligned_reads.fq
with standard output producing insertion and deletion coordi-
nate (insertion.bed, deletions.bed) files. Insertions or de-
letions were required to occur exact at the branchpoint nucleotide
or, when stranded sequencingwas used, be no longer than 3nt and
initiate coincident with the 29 to 59 linkage.
Alternative splicing events
Sequenced reads may encompass alternative splicing events. In-
tron lariats that fully overlapped annotated exons indicate alter-
native splicing events.
Sequenced reads providing direct evidence for alternative
splicing events could be identified as follows: First, reads con-
taining a single unique 59 intron sequence, joined to multiple
unique alignments within 250 nt of 39 splice site of the same gene
model (using GENCODE v12 transcript ID). Second, reads con-
taining a single match to a branchpoint joined to multiple unique
59 intron sequences.
Lists of human skipped exons and exons containing retained
intronswere obtained fromhttp://miso.readthedocs.org/en/fastmiso/
annotation.html (Katz et al. 2010). See Supplemental Methods for
full details.
Quantification of branchpoint selection
Unique read alignments to the lariat junction index (see ‘‘Align-
ment to identify branchpoint nucleotide’’ above) provide a raw
count of sequence coverage across branchpoint junctions. Align-
ments were normalized according to combined library size. Anal-
ysis was focused on K562 and HeLa.
Branchpoint selection frequency was the read counts for a
branchpoint divided by the total number of counts for all branch-
points associated with that same exon. Exons were defined as hav-
ing dominant branchpoint(s) if the maximum minus the median
percentage counts was $30%. See Supplemental Methods for full
details.
Branchpoint validation by RT-PCR
Nested primer sets (Sigma-Aldrich) were designed to amplify the
branchpoint for each chosen candidate after reverse transcription.
Purified, amplified DNA was ligated into pGem-T Easy (Promega)
and transformed into E. coli (Bioline). Sanger sequencing con-
firmed branchpoints. See Supplemental Methods for full details.
Motif identification
We used the MEME SUITE (Bailey et al. 2009) for de novo motif
identification using the following parameters:
meme 20nt_sequence_flanking_BPs.fa –dna –minw
5 –o BP_motif
To identify genome-wide instances of identified motifs, we
used FIMO (Grant et al. 2011) with the default parameters:
fimo BP_motif.txt hg19.fa
We also identified the fold enrichment of core pentamer se-
quences flanking branchpoints compared to background (fre-
quency of matched pentamer sequence in a 20-nt window 10 nt
directly upstream of the branchpoint). See Supplemental Methods
for full details.
Motif strand asymmetry
Strand asymmetry was determined by the frequency of motifs on
the sense strand and within 100 nt of the 39 splice site, relative to
motif frequency on combined sense and antisense strand and
within 100 nt of the 39 splice site (i.e., 1 indicates 100% occurrence
on sense strand).
Motif intron distribution
To provide a measure of 39 biased intronic distribution for pre-
dicted motifs, the mean frequency of sense motifs within 20 to
50 nt relative to the 39 splice site was compared to themean sense
motif frequency across the entire intron length.
Nucleotide substitution rate
The nucleotide substitution rate across vertebrate lineages and
human genetic variation was determined for sequences flanking
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branchpoints. The rate of change for each nucleotide flanking
branchpoints against reference human sequence was determined
using 100-species Vertebrate MULTIZ Alignment (.maf ) from
UCSC (Karolchik et al. 2014). Background nucleotide substitution
rate was determined from the sequence upstream (;25 nt) to each
branchpoint. Nucleotide substitution rate for human genetic var-
iation relative to reference was determined using dbSNP (build 37,
http://www.ncbi.nlm.nih.gov/SNP/), with total nucleotide sub-
stitution rate providing background.
Conservation of motifs and surrounding sequence
Human nucleotide conservation score for all branchpoints and
associated sequences was retrieved from UCSC Genome Browser
(PhyloP Basewise Conservation with 46- or 100-species Vertebrate
MULTIZ Alignment) (Blanchette et al. 2004; Pollard et al. 2010).
We computed the average nucleotide conservation for 100 nucle-
otides flanking the branchpoint. Additionally, for each exonwith a
characterized branchpoint, we computed the average phastCons
score across vertebrates (Siepel et al. 2005). Likewise we used
MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_
scoreseq_acc.html) (Yeo and Burge 2004) to compare the strength of
39 splice sites, depending upon B-box composition.
If multiple branch points were identified for an exon, we se-
lected the site with the strongest support.
The phastCons scores of exons as well as the 39 splice site
MaxEntScan scores classified according to the nucleotide compo-
sition of their associated B-box motif were compared using a
Mann-Whitney U test (with Bonferroni correction). See Supple-
mental Methods for full details.
Motif mapping
Instances of branchpoint pentamer motifs can be identified from
genome sequence and gene assemblies. We determined genome
coordinates corresponding to instances of motif sequences within
the human introns. Motifs coordinates were identified using
the findMotif from the Kent source utilities UCSC Tool kit
(Karolchik et al. 2014) (http://genomewiki.ucsc.edu/index.php/
Kent_source_utilities) that finds exact matches to motif sequence.
Identified motifs that overlapped known introns (GENCODE v12
comprehensive assembly) were retained for further analysis. Ge-
nome coordinates for motif sequence were also identified in
a range of model organism genomes as above. Genome sequences
and gene models were downloaded from the UCSC Genome
Browser (http://hgdownload.soe.ucsc.edu/downloads.html) as fol-
lows: C. elegans (ce10; WormBase), D. melanogastor (dm3; FlyBase),
D. rerio (danRer7; RefSeq), G. gallus (galGal4, RefSeq), and
M. musculus (mm10; RefSeq).
U2 binding energy
U2 binding energy measures the number of hydrogen bonds
modeled between the motif sequences to the canonical branch-
point binding sequence in theU2 snRNA.Weused theViennaRNA
(v2.07) package (Lorenz et al. 2011), RNA duplex script to de-
termine the optimal hybridization structure between U2 snRNA
sequence (GUGUAGUA) and the motif (with branchpoint nucle-
otide removed). Predicted binding energy is determined from the
sum of hydrogen bonds forming between complementary motif
and U2 snRNA nucleotides.
Gene evolutionary age
The evolutionary age of genes was retrieved from Zhang et al.
(2010). Gene names were paired to GENCODE attributes for
analysis. Fisher’s exact test with multiple hypothesis correction
was performed to ascribe significance to enrichments for genes at
each lineage.
Branchpoints for exonized Alu elements
We downloaded all RepeatMasker Alu elements from UCSC (June
17, 2014) and identified all GENCODE exons with an inverted Alu
element overlapping the 59 of the exon. We utilized our set of
branchpoint-closest 39 exon associations to identify Alu exons with
identified branchpoints. See Supplemental Methods for full details.
Branchpoint overlapping disease SNPs
We used the following data sets to determine the overlap between
branchpoints and human variation. Common SNPs (dbSNP 137)
that are found in >1% of the humans (Sherry et al. 2001), were
downloaded fromNCBI. Cancer associated SNPs were downloaded
from COSMIC (http://cancer.sanger.ac.uk/cancergenome/projects/
cosmic/) (Forbes et al. 2011). Mutations and SNPs associated with
disease were downloaded from HGMD (Stenson et al. 2012).
Bioinformatics
A number of bioinformatics tool suites were used during analysis.
These include BEDTools (Quinlan and Hall 2010), Kent Source
Tools, and internal perl/python scripts. Data was downloaded
through the UCSC Genome Browser (Karolchik et al. 2014). Sta-
tistical analysis and graphing was performed with GraphPad Prism
(http://www.graphpad.com/) and R (R Core Team 2013) (http://
www.r-project.org/).
Data access
Sequenced RNA-seq libraries have been submitted to the NCBI
Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE53328. Capture probe regions
and a list of experimentally determined branchpoints are available
as Supplemental Data.
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Absolute Counting of Neutrophils in Whole
Blood Using Flow Cytometry
Marion E. G. Brunck,1 Stacey B. Andersen,1 Nicholas E. Timmins,1 Geoffrey W. Osborne,1,2*
Lars K. Nielsen1
 Abstract
Absolute neutrophil count (ANC) is used clinically to monitor physiological dysfunc-
tions such as myelosuppression or infection. In the research laboratory, ANC is a valua-
ble measure to monitor the evolution of a wide range of disease states in disease
models. Flow cytometry (FCM) is a fast, widely used approach to confidently identify
thousands of cells within minutes. FCM can be optimised for absolute counting using
spiked-in beads or by measuring the sample volume analysed. Here we combine the
1A8 antibody, specific for the mouse granulocyte protein Ly6G, with flow cytometric
counting in straightforward FCM assays for mouse ANC, easily implementable in the
research laboratory. Volumetric and Trucount
TM
bead assays were optimized for mouse
neutrophils, and ANC values obtained with these protocols were compared to ANC
measured by a dual-platform assay using the Orphee Mythic 18 veterinary haematology
analyser. The single platform assays were more precise with decreased intra-assay vari-
ability compared with ANC obtained using the dual protocol. Defining ANC based on
Ly6G expression produces a 15% higher estimate than the dual protocol. Allowing for
this difference in ANC definition, the flow cytometry counting assays using Ly6G can
be used reliably in the research laboratory to quantify mouse ANC from a small volume
of blood. We demonstrate the utility of the volumetric protocol in a time-course study
of chemotherapy induced neutropenia using four drug regimens. VC 2014 International
Society for Advancement of Cytometry
 Key terms
absolute count; neutrophils; ANC; flow cytometry; volumetry; single-platform; double-
platform
THE concentration of blood circulating neutrophils is considerably altered by a wide
range of physical and chemical stimuli such as microbial infections, gamma irradia-
tion, and chemotherapy. Fluctuations outside of the normal range of absolute neu-
trophil count (ANC) correlate with increased morbidity and mortality (1). ANC is a
relevant clinical parameter (2) and is routinely obtained from automated haematol-
ogy instruments. However, more than 25% of samples require additional manual
review of peripheral blood smears, usually because measurements fall outside the
acceptable range of the instrument (3). Manual smear inspection increases workload
and cost while reducing ANC accuracy. Hence, standardized flow cytometry (FCM)
absolute count protocols are being pursued for implementation in the clinic (4).
Even in research laboratories where flow cytometers are prevalent, ANC is obtained
with veterinary haematology analysers (5) and often outsourced (6). At the time of
writing, there is no published protocol to measure mouse ANC using a single,
straightforward, flow cytometric assay.
FCM protocols are available for absolute counting of other white blood cell
(WBC) subpopulations in animal experimental models and in humans (7). Volumet-
ric FCM involves the systematic measurement of all volumes throughout the proce-
dure, including the volume acquired on the flow cytometer. Therefore, with a simple
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post-hoc calculation, volumetric FCM permits absolute count
calculation of the fluorescently labelled population of interest
(Fig. 1). The BD TrucountTM tube is an alternative for abso-
lute counting that can be used on flow cytometers that do not
offer sampled volume measurement. The Trucount assay uses
tubes containing a lyophilized pellet of a known number of
brightly fluorescent polystyrene beads that disperse during
sample processing in a measured volume of cell sample. Abso-
lute counts are calculated based on the known count of the
reference bead population and the ratio of the number of
Figure 1. Schematic representation of mouse blood sample processing using the two flow cytometric assays developed in this article.
Pre-acquisition processing is similar between the two techniques, except for the tubes used. For the volumetric assay, users must record
the sample volume acquired on the FCM instrument in addition to the number of Ly6G1 events. A: Histogram of unstained (black), isotype
rat IgG2a K-FITC (green), and 1A8 Ly6G-FITC (orange) events displayed as FITC-relative fluorescence intensity without any gating strategy
on the acquired events. For the TrucountTM assay, the manufacturer’s instructions are followed apart from the lysis buffer step. Users
need the number of acquired Trucount beads and the number of acquired Ly6G1 events to determine ANC. B: Forward versus side scatter
plot of Ly6G-FITC stained, lysed blood, acquired in Trucount tubes on the AC6 flow cytometer. This plot is representative of the event
acquisition strategy employed in this protocol to count acquired Ly6G1, namely an acquisition threshold of 300,000 on FSC without any
further gating, see complete acquisition criteria on the MIFlowCyt checklist in Supporting Information). C: FITC-relative fluorescence inten-
sity versus red relative fluorescence intensity scatter plot of Ly6G-FITC stained, lysed blood, acquired in Trucount tubes. Ly6G1, FITC-
labeled events fluoresce in the FL-1 channel only while Trucount beads fluoresce in all four acquisition channels. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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acquired beads to the cell population of interest in the
sampled volume (Fig. 1).
The use of fluorescent, cell-specific antibodies facilitates
unbiased cell identification of the cell populations of interest.
The BD Trucount tube protocol was initially developed to
count human CD41 T lymphocytes for HIV diagnosis (8).
Since then, antibody panels and gating strategies have been
designed to count 14 human blood cell subsets at once (9) but
the Trucount platform has also been optimized exclusively for
rare WBC populations not included in that panel, such as reg-
ulatory T cells (10), which suggests its applicability to neutro-
penic samples. For mouse ANC, the 1A8 antibody is a
promising candidate, since it is specific to an Ly6G epitope on
the surface of mouse neutrophils and injections of the 1A8
antibody selectively depletes neutrophils in mice (11,12).
There is a current need for a rapid and reliable method to
determine mouse ANC in the research laboratory, and FCM
provides a platform of choice. This article describes the devel-
opment and validation of volumetric and TrucountTM tube
protocols for ANC using the 1A8 Ly6G-specific antibody. We
compared these methods to the widespread dual assay, and
demonstrate direct application of the volumetric ANC assay
by measuring the depth of neutropenia and the kinetics of
ANC recovery in blood following four regimens of cyclophos-
phamide administration.
MATERIALS AND METHODS
Sample Collection
All animal procedures were approved by the University of
Queensland Research Ethical Committee. BALB/c female mice
(6- to 10-week-old) were bled through the retro-orbital lobe
and an average of 200 lL peripheral blood collected using cap-
illary tubes (Hirshmann Laborgerate) into K3EDTA mini-
collect tubes (Greiner). Blood samples were gently inverted to
ensure proper mixing with anticoagulant, and stored at room
temperature before processing and data acquisition. All sam-
ples were prepared within one hour of collection. For the
comparative study, blood samples from three mice were col-
lected on three separate occasions (n5 9).
FCM Assays: TrucountTM and Volumetric
All dispensing was performed using reverse pipetting.
The volume of sampled blood was recorded. For the volumet-
ric assay, 50 lL of peripheral whole blood (WB) were added
to 1.5 mL tubes. For the Trucount method, 50 lL of mouse
WB were added into Trucount tubes (BD Biosciences) and
processed as per the manufacturer’s protocol except for the
lysis buffer used. Briefly, samples were stained within 1 h of
collection with saturating concentrations of anti-mouse Ly6G-
FITC (clone 1A8, BD Pharmingen) for 15 mins at room tem-
perature in the dark. Isotype control was rat IgG2a, K-FITC
(BD Biosciences). Following incubation, 450 lL of NH4Cl
lysis solution were added to the tubes and samples were incu-
bated for 20–40 min with gentle inversions before data acqui-
sition on the Accuri C6 flow cytometer (AC6, BD Biosciences,
see complete acquisition criteria on the MIFlowCyt checklist
in Supporting Information). The stock NH4Cl lysis solution
consisted of 1 mM EDTA (Invitrogen), 11.3 mM KHCO3
(INC Biochemicals), and 150 mM NH4Cl (Biochemicals) in
sterile water (Gibco), filtered through a 0.2 lm mesh (Milli-
pore) and the working solution was made fresh by diluting the
stock 1 in 10 in sterile water (Gibco). For sample acquisition
on the AC6, the event detection threshold was set at 330,000
on FSC-H, which delivered the best signal to noise ratio for
both assays. A volume trigger of 50 lL was used to stop event
acquisition. For the volumetric assay, ANC in original WB
was calculated as shown in Eq. (1), where all volumes (V) are
expressed in lL (Fig. 1).
ANC ðcells=lL Þ5 Number of Ly6G
1events
Vacquired on cytometer3Vtotal in acquisition tube
3Vprocessed blood
(1)
For the TrucountTM assay, the formula provided by the
manufacturer [Fig. 1, Eq. (2)] was used to calculate ANC.
ANC ðcells=lL Þ5 Events in cells containing region
Events in absolute count bead region
3
Number of beads per test
Test volume
(2)
In naive BALB/c blood, the fluorescence intensity of the
Trucount beads overlaps with the fluorescence intensity of the
main Ly6G1 population (data not shown). The Trucount
beads fluoresce in the four main channels. Therefore counting
Ly6G1 events from Trucount samples was performed from
double-positive events on scatter plots (Fig. 1C).
For instrument validation and Trucount beads resuspen-
sion experiments, 10 lm spike-in beads (Flow-check, Beck-
man Coulter) or Trucount beads (BD) were resuspended in
ultrapure water or lysis buffer and counted on a Coulter
Counter Multisizer 4 (Beckman Coulter). When the volumet-
ric platform was used to count beads, an average of 4,000
beads (from 50 lL acquisition trigger) was acquired.
Dual-Platform
Whole blood was analyzed within 2 h of collection on a
veterinary haematology analyzer (Mythic 18 Vet, Orphee) to
obtain absolute leukocyte count (total leukocyte /L WB). A
blood smear was performed for each sample and the fre-
quency of neutrophils was determined from microscopic
examination and manual classification of 100 leukocytes per
sample. Dual-platform ANCs were then determined by apply-
ing the percentage of neutrophil within the total leukocyte
population, determined from smear classification, to the con-
centration of leukocytes obtained using the haematology
analyzer.
Cyclophosphamide-Induced Neutropenia
Four groups of female BALB/c mice were injected intra-
peritoneally with 20 mg/mL cyclophosphamide solution
(Baxter) according to four different regimens and blood sam-
ples (100 lL) obtained from the retro-orbital lobe, as per
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the schedule in Table 1. Each mouse was sampled only once,
in order to comply with ethics requirements for repeated sam-
pling schedule, and to prevent interference of repeated sam-
pling on obtained ANC. Sampled blood was processed using
the volumetric assay to determine ANC. For baseline ANC,
5 littermate BALB/c females were bled and ANC determined
on Day 1.
Statistical Analysis
ANC assays were compared against each other using
paired t-tests. Correlations between the different ANC assays
were determined using Spearman’s rank correlation, q. To
compare the number of Trucount beads per tube, counted
using flow cytometry, versus the theoretical number of beads
present in the tube, a one-sample t-test was used. All statistical
tests were performed using the R software and graphs were
generated using GraphPad Prism version 6 software.
RESULTS AND DISCUSSION
Development of Mouse ANC Assays Using Single FCM
Platforms
Unlike veterinary haematology analyzers, flow cytometers
are versatile instruments widely available in the research com-
munity. A good correlation was demonstrated between flow
cytometry-based and manual classification of rat neutrophils,
which suggests that flow cytometry could replace manual clas-
sification as part of a dual-platform protocol to enumerate rat
neutrophils (13). However, there is a current need for a sim-
ple, single-platform FCM-based method to obtain ANC from
mouse blood in the research laboratory. The Trucount tube
system has been adapted to enumerate mouse erythrocytes
(14), dendritic cells and lymphocytes (15) but to the best of
our knowledge no assay combining counting and classification
has been designed for mouse ANC. Volumetric FCM is popu-
lar in resource poor settings, as a tool to diagnose HIV infec-
tions in human (16,17). No extension of the protocol was
developed for mouse WBC absolute counting.
Measuring ANC in neutropenic blood was a major moti-
vation for the development of these assays. In mouse periph-
eral blood, Ly6G is expressed exclusively on granulocytes
(11,18), and the density of Ly6G on circulating neutrophils is
increased compared to Ly6G density on bone marrow segre-
gated neutrophils (18). Ly6G is absent from basophils, while
low to intermediate Ly6G density has been reported on eosin-
ophils (18). During the course of neutropenia, the bone mar-
row releases its reserves of Ly6GInt neutrophils into the blood,
therefore we cannot exclude Ly6GInt from the total count. The
number of eosinophils, however, is low with a 30 : 1 ratio of
neutrophils-to-eosinophils reported in naive female BALB/c
peripheral blood (19). Hence, the Ly6G1 count is a valid
absolute neutrophil count except under certain experimental
treatments that provoke eosinophilia (20).
Ly6G density was high and homogenous for 98% of
blood circulating granulocytes in naive BALB/c female mice,
with 2% Ly6GInt events with light scattering properties simi-
lar to granulocytes (Fig. 1A). Although non-specific staining
with the mouse 1A8 isotype control is low, there is a concern
of omitting real events when measuring ANC in neutropenic
blood. Hence, both proposed protocols adopt the common
approach of deliberately omitting isotype control when analy-
sing rare events (21). The unstained sample is used instead of
an isotype-incubated sample to define autofluorescence and
background interference in order to optimize Ly6G1 events
recovery.
Erythrocyte lysis is required before acquisition on the
flow cytometer for both Volumetric and BD Trucount proto-
cols. The fragility of neutrophils and their propensity for acti-
vation and apoptosis call for particular care, and protocols
need to minimise sample processing and exposure to the lysis
buffer. We adopted a lyse-no-wash approach, which has been
shown to greatly reduce counting inaccuracy compared to a
lyse-then-wash approach when enumerating CD341 cells
(22). The choice of lysis buffer can significantly impact final
counts (23) and—after unsuccessfully trialling the BD FACS
Lyse buffer (data not shown)—we settled on an ammonium
chloride hypotonic solution. The final step was to evaluate the
effect of exposure time on the concentration of Ly6G1 cells
over time. Six biological replicates were processed as per volu-
metric protocol and incubated for up to 90 min in the NH4Cl
lysis solution with acquisition on the AC6 flow cytometer
approximately every 12 min. All samples showed stable Ly6G1
event concentrations for up to 90 min post-addition of lysis
buffer (Fig. 2). Sustained Ly6G concentrations in lysis buffer
over lengthy time period are advantageous in large experi-
ments where several samples must be processed concurrently.
An alternative to erythrocyte lysis has been proposed where
Table 1. Schedule of injection and blood sampling for the comparison of four neutropenia-inducing cyclophosphamide regimens
REGIMEN 1 (250 MG/KG) REGIMEN 2 (100 MG/KG) REGIMEN 3 (150 MG/KG) REGIMEN 4 (100 MG/KG)
Day 1 Injection 23 mice Injection 1,12 mice Injection 1,9 mice Injection 1,8 mice
Day 2 ANC 135 mice Injection 2,12 mice Injection 2, 8 mice
Day 3 ANC 233 mice Injection 3,12 mice Injection 3, 8 mice
Day 4 ANC 333 mice ANC 132 mice Injection 2, 9 mice Injection 4, 8 mice
Day 5 ANC 433 mice ANC 232 mice ANC 133 mice ANC 132 mice
Day 6 ANC 533 mice ANC 332 mice ANC 232 mice
Day 7 ANC 633 mice ANC 432 mice ANC 233 mice
Day 8 ANC 733 mice ANC 532 mice ANC 332 mice
Day 9 ANC 833 mice ANC 632 mice ANC 333 mice ANC 432 mice
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acquisition is triggered from fluorescence in diluted WB sam-
ples (24). The reduced number of processing steps proposed
by this alternative is attractive, but it remains to be tested
whether this lysis-free technique can be adapted for absolute
counting.
ANC Using the Volumetric Assay with the Accuri C6
Flow Cytometer
Accurate and precise volume measurements are critical for
a reliable volumetric assay, and depend on the flow cytometer
used. The fluidic system of the AC6 is based on a peristaltic
pump which may cause a surge effect. Therefore potential var-
iations in counts over acquisition time were investigated. Ultra-
pure water aliquots were spiked with 10 lm-sized latex beads,
similar in size to blood circulating neutrophils. Twenty five, 50,
or 100 lL of spiked water were acquired on the AC6. Five repli-
cate measurements were obtained for each volume stop trigger
(Fig. 3A). These volumes were chosen based on preliminary
experiments, where processing an average of 50 lL original
blood on the AC6 was necessary to acquire at least 10,000
events in the leukocytes region for an 8-week-old, naive BALB/
c female mouse (data not shown). Triggering the end of acqui-
sition based on the volume processed rather than a number of
events is motivated by anticipated limitations in initial blood
volume, and by low cell concentrations occurring in the case of
neutropenic mice. A regression analysis of the number of beads
acquired as a function of the volume stop trigger shows
R25 0.9997 (Fig. 3A); therefore, it was concluded that for vol-
umes between 25 lL and 100 lL, the calculated concentrations
are unbiased by acquired volume. Moreover, the AC6 volumet-
ric measurements were precise, especially for volume 50 lL
where CV< 2%. Concentrations obtained with the 50 lL stop
trigger were not significantly different from concentrations
determined using the Coulter Counter, a reference instrument
for absolute counting (Fig. 3B). Concentrations calculated
based on processing 10 lL sample were significantly lower
(P5 0.0005; t-test) than concentrations determined from
processing 50 lL of sample (Fig. 3B). These results suggest the
AC6 has a threshold of acquisition volume below which deter-
mined concentrations are biased possibly by the peristaltic
pump surge effect, and an acquisition volume of 50 lL is above
this threshold and delivers good reproducibility. The volumet-
ric protocol can in principle be used on any FCM platform,
since the flow rate is a constant parameter. The documented
flow rate and its stability should be validated using standard
QC protocols and calibration beads.
Comparison of Dual Protocol, Volumetric, and
TrucountTM ANC
We compared the two mouse ANC FCM methods against
each other and the commonly used dual protocol which
Figure 2. Concentration of Ly6G1 events over incubation time in
NH4Cl lysis buffer. Six female BALB/c mice were bled and 50 lL
blood per mouse were stained using saturating concentrations of
the 1A8 Ly6G antibody. After antibody incubation, lysis buffer
was added to six biological replicate bloods. Each sample was
acquired on average every 12 min on the AC6 for up to 90 min
post-NH4Cl lysis buffer addition.
Figure 3. Validation of robust volumetric measurements on the Accuri C6 flow cytometer: 10 lm latex beads (Flow check, Beckman
Coulter) were spiked (1 in 10) in NH4Cl lysis buffer and distributed in equal size aliquots. Five technical replicates were acquired for each
volume; raw data were artificially jittered to facilitate the visualization of the replicates clustering on the figure. A: Linear regression of the
number of beads acquired depending on the volume processed on the Accuri C6 cytometer. CV was 3.41%, 1.59%, and 1.61% for the 25,
50, and 100 lL volume stop trigger, respectively. B: Calculated bead concentrations using the 50 lL acquisition volume were significantly
different from concentrations obtained with 10 lL acquired on the Accuri, but not from Coulter Counter concentrations.
Technical Note
Cytometry Part A  00A: 0000, 2014 5
159
combines haematology analyzer absolute counts and neutro-
phils proportions determined by smear inspection. Blood
samples from nine BALB/c female mice were processed using
the three assays (Fig. 4A). The highest mean ANC was
obtained using the Trucount assay (1,090 neutrophils/lL vs.
1,007 for volumetric and 846 for dual assay). The dual assay
yielded significantly lower values than the Trucount and volu-
metric assays (P5 0.0007 and 0.0040, respectively; paired t-
test with unequal variance). The difference between the dual
and volumetric assays was 1606 93 neutrophils/lL or 15%.
The Trucount assay was correlated with the volumetric
assay (Spearman rho, P5 0.008), while the dual platform was
not correlated to either FCM platform (P5 0.23 and 0.05,
respectively). The dual assay also delivered results with the
highest SD (193.7 vs. 141.5 for the Trucount assay and 151.3
for the volumetric assay), and the lowest intra-assay reprodu-
cibility (mean CV% 7.1 vs. 3.5 for Trucount and 6.1 for volu-
metric). Processing samples with lysis buffer may result in
sample loss, estimated up to 35% for leukocytes (25). In this
context the dual method, which does not involve a lysis step,
would be expected to deliver the highest concentrations of
neutrophils compared with FCM assays, but such conclusions
were not reached in this study.
The Trucount assay yielded higher values than the volumet-
ric assay in eight out of nine samples (P5 0.0010; paired t-test).
This discrepancy may be attributed to the previously reported
“vanishing counting bead phenomenon” leading to an overesti-
mation of neutrophil count in the Trucount assay (26). The
“vanishing counting bead phenomenon” has been attributed to
vortex induced electrostatic charging of the tube in low protein-
containing solvent (26). We confirmed that in the protein-free
lysis buffer, the absolute bead count in Trucount tubes deter-
mined using either a Coulter Counter or volumetric FCM is sig-
nificantly below the theoretical number (one-sample t-test,
P5 4.4 3 1027 and 0.0035, respectively) (Fig. 5B). Adding
1.25 mg/mL bovine serum albumin was sufficient to prevent this
phenomenon in published work with human samples (26). In
this case, mouse blood is diluted 1 in 10 in lysis buffer only, and
by extrapolating protein content from previous work, the electro-
static effect should be minimal. Experimentally however, Tru-
count bead counts in mouse blood are even lower (34,2296 518)
than in lysis buffer alone (43,2266 1257) (Fig. 4C). It is possible
that hemoglobin or another blood protein causes clumping. The
propensity of neutrophils for activation and resulting phagocyto-
sis suggests an alternative explanation with ANC obtained using
Trucount beads being biased by neutrophil-mediated bead
Figure 4. A: Comparison of the volumetric, TrucountTM, and dual assays for ANC. Blood samples from nine mice were collected on three
separate occasions and anticoagulated peripheral blood volumes shared in three aliquots for processing using the three ANC methods in
parallel. B: Absolute numbers of Trucount beads per tube were determined following resuspension in NH4Cl lysis buffer and acquisition
on the Coulter Counter or the AC6. Each symbol represents a replicate measurement. C: Absolute number of Trucount beads per tube
were determined following acquisition of 50 lL sample on the AC6 in either processed blood or NH4Cl lysis buffer. Experiments B and C
were performed on different days, using different batches of Trucount tubes.
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ingestion. The 4.5 lm Trucount beads are similar in size to com-
mon microbes and others have shown polystyrene beads to be
readily ingested by neutrophils even in the absence of additional
stimulus (27). However, preliminary experiments in our labora-
tory failed to demonstrate colocalization of neutrophils and
beads in activated samples (data not shown).
Although, we recommend caution for users of the Tru-
countTM bead tubes with mouse whole blood when quantitative
results are crucial, it is accepted that subtle protocol variations
such as blood sampling site, have a significant impact on the
ANC values reported (19). Therefore, to follow disease progres-
sion, standardization of techniques, and protocols for results
precision in the research laboratory, can be achieved more eas-
ily than accuracy. Using Ly6G as a neutrophil marker for FCM
rather than cell volume on a haematology analyzer, coupled to
analyzing a 100-fold larger sample of the WBC population
using FCM analysis vs. manual classification increases the speci-
ficity of ANC compared to dual protocols. We propose the
developed FCM techniques can be used reliably in the research
laboratory especially when semiquantitative, paired results are
needed, such as during kinetic studies.
Use of the Volumetric Assay for ANC to Follow the
Kinetics of Chemotherapy-Induced Neutropenia
To assess the utility of the assay in routine mouse research,
we monitored the effect of four different cyclophosphamide
regimens on neutrophil repopulation kinetics. The volumetric
assay was chosen as a tool to measure mouse ANC for its low
cost and simplicity of execution and analysis. BALB/c female
mice were infused with four different regimens of cyclophos-
phamide intra-peritoneally and ANC measured regularly until
resolution of neutropenia. The results define a pharmaco-
dynamic profile of the effect of different cyclophosphamide reg-
imens on mouse blood ANC (Fig. 5). Each mouse was bled
only once to avoid interference of sampling and blood loss on
measured ANC. The assay allowed to count down to 16 neutro-
phils/lL sample (Regimen 4, Day 6). A comparison of ANC
obtained with the four different regimes suggest that a low dose
regime of cyclophosphamide (100 mg/kg/day) administered
daily for 4 days (Regimen 4) leads to a longer period of deep
neutropenia (<150 neutrophils/lL in mice) compared with the
three other regimens tested (4 days vs. 1 day for Regimens 1
and 3, and 3 days for Regimen 2). This timeframe allows for
contaminating microorganisms to establish pathogenesis.
Therefore Regimen 4 should be used preferentially, to study
neutropenic diseases. Regimens 1 and 3 are commonly found
in the literature in neutropenic infection studies (28).
Here we have reported the development of two FCM
counting assays for mouse ANC in the research laboratory.
Both techniques were more precise than the existing dual-
platform method. Reduced error from FCM measurements is
critical to accurately interpret ANC data, which has implica-
tions for further management in the clinic. For instance,
recent data demonstrate differential timing of initiation of
therapy in HIV-infected patients, depending on which plat-
form was used to obtain determining data (29).
Using the Ly6G antibody 1A8, the FCM methods can be
performed on a single instrument, and requires a minimal
amount of blood, convenient for animal studies. The volumet-
ric assay is rapid (about 1 h from sample collection to data
analysis), and minimal processing decreases the impact of
technical bias and enhances data objectivity. The omission of
counting beads, coupled to the use of a single mouse
neutrophil-specific antibody makes the volumetric assay a less
expensive option for ANC. Such a straightforward assay can
be implemented as a routine part of any in vivo neutrophil-
depletion, or neutropenic infection experimental set-up, to
support the quality and interpretation of obtained results.
Finally, the simplicity of the current FCM ANC assays facili-
tates future multiplexing by adding phenotyping antibodies,
in order to obtain ANC and neutrophil phenotype from a sin-
gle experiment, optimizing time, and cost.
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Concise Review: Next-Generation Cell Therapies to
Prevent Infections in Neutropenic Patients
MARION E. G. BRUNCK, LARS K. NIELSEN
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ABSTRACT
High-dose chemotherapy is accompanied by an obligate period of neutropenia. Resulting bacterial
and fungal infections are the leading cause ofmorbidity andmortality in neutropenic patients despite
prophylactic antimicrobials and hematopoietic growth factor supplements. Replacing neutrophils in
the patient through transfusion of donor cells is a logical solution to prevent fulminant infections. In
the past, this strategy has been hampered by poor yield, inability to store collected cells, and possible
donor morbidity caused by granulocyte colony-stimulating factor injections and apheresis. Today,
neutrophil-like cells can be manufactured in the laboratory at the clinical scale from hematopoietic
stem and progenitor cells enriched from umbilical cord blood. This article reviews the rationale for
focusing researchefforts towardexvivoneutrophil productionandexplores clinical settings for future
trials. STEM CELLS TRANSLATIONALMEDICINE 2014;3:541–548
PREVENTING INFECTIONS IS VITAL FOR
NEUTROPENIC PATIENTS
Neutropenia is a disorder characterized by an ab-
normally low number of circulating blood neutro-
phils. Patients are considered neutropenic when
their absolute neutrophil count (ANC) falls below
1,500 cells permicroliter ofperipheral blood. Sub-
classifications are reported based on the depth of
neutropenia,which range frommild (1,000–1,500
cells per microliter) to moderate (500–1,000 per
microliter) to severe (,500 cells per microliter)
[1]. In their landmark study, Bodey et al. observed
that the rate of infections increases with the
depth of neutropenia, and the severity of infec-
tions correlates with duration of neutropenia
[2]. About one third of severely neutropenic
patients develop life-threatening infections within
a week. Intensive chemotherapy schedules cause
obligatory neutropenic periods and are associ-
ated with a higher risk of infections [3]. Therefore,
patients treated for leukemias andmyeloprolifer-
ative disorders are particularly at risk. Moreover,
neutropenia frequently dictates dose reduction
or treatment interruptions, thereby worsening
outcomes, especially in pediatric and elderly
patients [4–6].
Established infections threaten the lives of
neutropenic patients and considerably burden
the health care system. Early diagnosis of infec-
tion is vital but difficult because these patients
cannot mount potent and specific inflammatory
responses [7, 8]. Improvement of diagnostic tools
has ameliorated patient prognosis, but 10% of
admitted febrile neutropenic patients still die
of infections [9]. Therefore, robust prophylactic
strategies are crucial to prevent the onset of
infections and related complications. Antibacte-
rials such as fluoroquinolones were initially suc-
cessful at preventing gram-negative bacterial
infections. However, their systematic use pro-
gressively led to the emergence of resistant
strains and frequent shifts between gram-
negative and gram-positive pathogens [10]. In
addition, the use of antibacterial agents eliminates
niche competition for yeast andmolds, whichmay
enhance the risk for fungal infections [11]. Prophy-
lactic antifungals reduce infection-related mor-
tality, but the associated toxicity, emergence of
resistant strains, and possible drug reactions ren-
der this option a solution for small patient cohorts
only. Autopsy studies in multiple institutions re-
veal that the rate of fungal infections is increasing
among patients treated for leukemias, with up to
78% positive cases. Within this group, a dramatic
30% of deaths can be attributed to fungal infec-
tions in spite of antifungal prophylactic use [12,
13]. Moreover, Viscoli et al. suggested a correla-
tion between patients receiving antifungal pro-
phylaxis and a higher risk of bacteremia [14].
The available literature demonstrates that the
success of antibiotics in prophylactic, empiric,
or pre-emptive strategies depends on an edu-
cated guess of the most probable pathogen for
a particular neutropenic patient. This practice
can cause toxicity and resistance, with associated
negative impact for the patient and the broader
community.
Although antibiotics reducemorbidity by pre-
venting the spread of infecting pathogens, the
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prevailing determinant for the onset of infection remains blood
ANC. Neutrophils being short-lived cells, the maintenance
of a healthy blood ANC relies on constant neutrophil produc-
tion from hematopoietic stem and progenitor cells (HSPCs).
Chemotherapy-induced niche exhaustion is the underlying cause
for neutropenia. A strategy to dampen the myelosuppressive ef-
fect of chemotherapy is to maintain HSPCs in a quiescent state
transiently during the anticancer treatment. The crucial role of
HSPC binding to E-selectins on the epithelium is exemplified by
a significant decrease in proliferation and self-renewal of HSPCs
in E-selectin knockout mice [15]. Injections of the E-selectin an-
tagonist GMO-1017 during chemotherapy or irradiation protect
the HSPC pool from exhaustion, which significantly accelerates
the recovery of ANC in wild-type mice [15]. Similarly, Lucas
et al. demonstrated that protecting adrenergic nerves during
chemotherapy by administration of 4-methylcatechol or glial-
derived neurotrophic factormaintained the HSPC niche, which
significantly improved hematopoietic recovery [16]. Although
these results are promising, the current procedure is to facilitate
neutrophil recovery from the remaining HSPC pool to restore pa-
tient immunity. Granulocyte colony-stimulating factor (G-CSF)
promotes neutrophil production and release from the bonemar-
row. In patients in whom myeloablation is incomplete, support
with G-CSF achieves significant reduction in neutropenic days
and related complications [17, 18]. In contrast, for patients receiv-
ing high-dose chemotherapy that damages the HSPC niche, such
as for treating acute myeloid leukemia (AML), restoring protec-
tive blood ANC takes too long to significantly affect infection-
related morbidity and mortality despite G-CSF support [19, 20].
Furthermore, although G-CSF may shorten the neutropenic win-
dow, complete abrogation cannot be achieved as neutrophil pro-
duction takes several days. A constant pursuit for alternatives or
complementing factors toG-CSF has beenmotivated by these pit-
falls. Among these agents, recent efforts have proposed prosta-
glandin E2 (PGE2). Administration of PGE2 agonists, such as
dimethyl PGE2, increases the stem cell pool in zebrafish andmice
[21]. A recent study showed that injections of dimethyl PGE2 to
irradiated mice enhanced hematopoietic recovery and survival
[22]. These results propose that, similar to G-CSF, administration
of PGE2 agonists to neutropenic patients may boost healthy ANC
recovery. However, the effect of PGE2 is biphasic as continued ex-
posure eventually inhibits expansion of the progenitor pool [23].
Therefore, clinical trials are expected in the future to confirm the
role of early PGE2 injections in neutropenic patients and to con-
trast with results currently obtained with G-CSF. Meanwhile, de-
spite some benefits provided by combinations of G-CSF and
antimicrobial prophylactics, neutropenic infections remain the
leading cause of chemotherapy-associated death.
In contrast toG-CSF support,neutrophil transfusions canpoten-
tially restore protective ANC immediately. Similar to red blood cell
and platelet transfusions used to treat anemia and thrombocytope-
nia, respectively, neutrophils can be collected from healthy donors
for transfusion intoneutropenicpatients.Neutrophils areharvested
usingdensity sedimentationduringapheresis.Althoughneutrophils
usually make up.70% of collected cells, the product also contains
the other granulocytes, eosinophils and basophils. Hence, neutro-
phil transfusions have been commonly named granulocyte transfu-
sions (GTx) [24]. The first GTx trials were conducted in the early
1960s, but the low cell yields possible at the time barely impacted
host ANC upon transfusion. Transfusions of granulocytes harvested
from chronic myelogenous leukemia patients did provide proof of
concept as recipients showing blood ANC increment demonstrated
rapid clinical improvement post-transfusion [25]. G-CSF administra-
tiontohealthydonorshasenabledcollectionofclinicallymeaningful
neutrophil numbers and several small trials have suggested some
degree of efficacy. Additional large-scale trials of therapeutic GTx
have been proposed in light of the current knowledge of neutrophil
biology and transfusion [26].
Even if efficacy is demonstrated in large-scale trials, signifi-
cant logistic and donor safety issues remain. Neutrophils have
a short half-life; therefore, GTx is usually performed daily or every
second day during the neutropenic period. Neutrophils do not
store well and must be infused within 24 hours of collection. Fi-
nally, whereas G-CSF is usually well tolerated in healthy donors, it
can cause bone pain, flu-like symptoms, and spleen enlargement
that in rare cases leads to spleen rupture [27, 28]. There are also
long-term safety concerns for G-CSF-mobilized donors [29].
Finally, steroids such as prednisone and dexamethasone, fre-
quently used in combination with G-CSF to mobilize donor neu-
trophils, may increase the risk of developing subcapsular
cataracts later in life [30, 31]. Accordingly, there is a clear need
for alternative cell products.
STEM CELL-DERIVED THERAPIES TO TREAT NEUTROPENIA:
RATIONALE AND OPTIONS
In order to mitigate neutropenia, possible strategies are to regener-
ate the hematopoietic niche or to immediately replace functional
cells in the blood (Fig. 1). Autologous transplantation of mobilized
peripheral blood (mPB) HSPCs coupled with cytokine support pro-
motes engraftment andblood cell recovery [32]. Clinically significant
delays to protective blood ANC recovery are common and have
prompted efforts to expand HSPCs ex vivo prior to transfusion
[33]. The development of the Amgen-defined serum-free medium
containing a key cocktail of the three cytokines stem cell factor
(SCF), thrombopoietin (TPO), andG-CSF eased large-scale ex vivo ex-
pansion of HSPCs, with bias toward differentiation into a neutrophil
phenotype [34]. Transfusion of ex vivo-expanded HSPCs (eHSPCs) to
chemotherapy-treated patients caused significantly fewer neutro-
penic days, febrile episodes, and shorter hospital stays [35, 36].
Furthermore, the reduction in time to engraftment corresponded
to the transfuseddose, reinforcing theneed forbetter ex vivoexpan-
sion protocols [36, 37]. Subsequent studies have assessed a wide
range of parameters for increasing eHSPC yields, including different
culture vessels, seeding densities, feeding schedules, oxygen ten-
sions, addition of small molecules to culture medium, and genetic
manipulations of developmental factors, all of which have been ex-
tensively discussed in recent reviews of the literature [38–40].
A fundamentally distinct approach promotes HSPC expansion
by preventing intercellular communication and ensuing repressive
feedback. Csaszar et al. [41] and Kirouac et al. [42] have modeled
and validated the hypothesis that secreted factor-mediated inter-
cellular communication regulates the fate of HSPCs. Preventing au-
tologous feedback through a dilution strategy caused an 11-fold
expansion of umbilical cord blood (UCB)-enriched HSPCs without
impacting self-renewalordifferentiationpotential [41].A remaining
concern is the concomitantmobilizationof tumor cells during autol-
ogousHSPCcollection thathas causedrelapse in transfusedpatients
[43, 44]. Therefore, this strategy may be restricted to nonhemato-
poietic cancer treatments only, although some studies suggest that
purging the graft from malignant cells using chemotherapy is
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possible [45]. When autologous transplantations are not advised,
patients may turn to allogeneic options.
AllogeneicmPBHSPC transfusions are an alternative if human
leukocyte antigen (HLA)-matched donors are available. Success-
ful neutrophil engraftment relies on further expansion of eHSPCs
in vivo; therefore, the product cannot be irradiated before trans-
fusion (Fig. 1). Hence, a significant concern with allogeneic trans-
fusions is the risk of developing acute and chronic graft-versus-
host-disease (GVHD) due to engrafting lymphoid cells. Cellerant
Therapeutics, Inc. (San Carlos, CA, www.cellerant.com) has dem-
onstrated that the protocol for producing the off-the-shelf cell
therapy CLT-008 overcomes this problem [46]. mPB HSPC are ex-
panded in a myeloid-driving, defined medium consisting of X-
VIVO 15 (Lonza, Basel, Switzerland, www.lonza.com) supple-
mented with SCF, Fms-related tyrosine kinase 3 ligand,
interleukin-3, and TPO. Elimination of lymphoid cells is achieved
passively, alongside expansion of myeloid progenitors (Fig. 1).
Over 8 days of culture, this process averages a 40-fold expansion.
TheCLT-008 product is cryopreserved and it is suggested thatHLA
matching is not required, facilitating access to patients. At the
time of writing, Cellerant Therapeutics, Inc. is recruiting patients
to investigate the safety and efficacy of CLT-008 to abrogate neu-
tropenia in chemotherapy-treated patients [47]. Despite clear
improvements over the current therapies, a major issue with
the CLT-008 strategy remains the source of stem cells. Cellerant
Therapeutics, Inc. uses mobilized healthy donors to source a suf-
ficient number of HSPCs. Furthermore, the average fold expan-
sion of the myeloid compartment is similar to that obtained by
Paquette et al. a decade ago [36, 37]; therefore, severalmobilized
blood donations may be required per patient. UCB has been used
as a source of HSPCs for transplantations for the past 25 years and
is a promising alternative to using mPB [48]. Historically, UCB
HSPCs have been transfused in patients for whom autologous
transplants are not advised andmatched donors are unavailable.
Advantages of UCB as a source of HSPCs include the ease of
procurement and decreased incidence of GVHD; however, delays
in engraftment remain an issue. Ex vivo expansion protocols have
been developed to transfuse a larger number of cells, and down-
stream transplantations in vivo havebeenperformed successfully
[49, 50]. In specific settings, UCB eHSPCs have yielded better ex-
pansion than mPB eHSPCs [51].
The delay to engraftment of transfused eHSPCs can be clini-
cally significant. A natural extension to the eHSPC protocol con-
sists of expanding and differentiating a fully mature neutrophil
product from HSPCs. Our group has developed a protocol to dif-
ferentiate UCB HSPCs toward a neutrophil-like phenotype [52].
Over 15 days of culture, an average 5,800-fold expansion of
UCBHSPCs is reached. Accounting for themean CD34+ HSPC yield
from a single donation of cord blood (2–53 106 CD34+ cells), this
expansion is estimated sufficient for a single prophylactic dose
(1010 cells per day) [53]. However, during the culture process,
the entire HSPC pool inevitably enters differentiation, so that
the ex vivo-manufactured neutrophils (eNeut) yield is currently
finite. These eNeut can be produced under good manufacturing
practice conditions at the clinical scale. The mature product is
composed in its majority of postmitotic neutrophils that exhibit
bactericidal functions in vitro. eNeut are poorly immunogenic
as assessed by the granulocyte immunofluorescence test (GIFT)
and the granulocyte agglutination test (GAT), endorsing the
product for allogeneic use. eNeut transfusions should cause im-
mediate increments in ANC, as observed post-GTx with donor
neutrophils (Fig. 2) [54]. Interestingly, the culture process used
in this work merges a dilution feeding strategy to the key culture
medium protocol to enable the highest yield of eNeut to date
from expanded UCB-enriched HSPCs. Again, a major challenge
is toproduce largequantitiesof cells. Current studiesareattempt-
ing clever combinations of culture protocols to further enhance
eNeut yields [55].
Approval of eNeut by regulatory bodies will be crucial for
implementation in the clinic. The U.S. Food and Drug
Figure 1. Simplified representation of granulopoiesis. (A): Location of cell types in the human adult. (B): The known successive maturation
phenotypes and the corresponding composition of existing cell products proposed tomitigate neutropenia. Abbreviations: CMP, commonmy-
eloid progenitors; eHSPC, ex vivo-expanded hematopoietic stem and progenitor cell; HSPC, hematopoietic stem and progenitor cell; eNeut, ex
vivo-manufactured neutrophils.
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Administration (FDA) is evolving its regulatory processes on re-
generative medicine products, with a handful of ex vivo-
generated cellular therapies recently approved for the market.
These therapies include autologous cultured cells like chondro-
cytes (Carticel) and allogeneic solutions like Gintuit, a product con-
taining keratinocytes and fibroblasts cultured in bovine collagen.
FDA approval for biologic licensing has doubled in the last 2 years,
which suggests the imminent infiltration of cellular therapies in
the clinic [56].Nonetheless, emerging therapiesmustbe fully sup-
ported by clinical data before licensure, especially in the booming
field of ex vivo-cultured hematopoietic cells. Although the clinical
potential of eNeut is promising, controlled randomized trials re-
main to be implemented (Fig. 2).
A major determinant holding preliminary human trials is the
high cost of manufacture for cell therapies (Fig. 2). For instance,
aunit of platelet pool,which is considered abloodproduct by the
FDA, costs ∼450 Euros to the receiving hospital [57]. By compari-
son, Provenge (sipuleucel-T), an autologous dendritic cell therapy
for prostate cancer, is sold by itsmanufacturer for U.S. $93,000 per
patient [58]. The preparation of a platelet unit involves donor
apheresis, leukocyte depletion, resuspension in a platelet additive
solution, storage, and irradiation prior to infusion. This process
evokes the culture protocol for eNeut, although the differentiation
part of the protocol may suggest that eNeut be considered under
the “cell therapy” scheme.Although the regulatory format framing
eNeut production will dramatically impact product cost, other fac-
torsmay contribute to loweringmanufacture expenses, such as au-
tomationand implementationof closed systems,discussed indetail
elsewhere [38]. A direct comparison of the cost of eNeut treatment
to themeanpatient cost of neutropenia-associatedhospitalization,
estimated at U.S. $19,100 per episode of febrile neutropenia [9],
may not be sufficient as cost-benefit analysis should also consider
patients’ reduced morbidity and increased survival.
LESSONS LEARNED FROMGTX AND THEIR RELEVANCE FOR ENEUT
PRODUCTION AND CLINICAL USE
Lesson 1: Keeping the Transfusion Recipient Safe
In transfusion medicine, part of the “non-self” nature of the
transfused product is dealt with through lymphoreduction
and irradiation to prevent GVHD. A remaining source of concern
is alloimmunization, which occurs when antibodies in the trans-
fusion recipient target their cognate antigen present on the re-
cipient cells. Consequently, the infused product survives poorly
in the recipient who becomes refractory to future transfusions
[59, 60]. Alloimmunization against human leukocyte antigens
usually causes transplant rejection, and if the involved antibod-
ies target human neutrophil antigens (HNAs), the transfused
neutrophils may become activated, pool in the lungs, and ex-
hibit limited chemotaxis to infection sites [61, 62]. In addition
to limiting transfusion efficacy, alloimmunization can initiate
a cascade of events leading to life-threatening complications
such as transfusion-related acute lung injury (TRALI) [62]. Lastly,
transfusion of incompatible neutrophils causes delayed HSPC
engraftment [63]. These issues prompt HLA and HNA typing
prior to granulocyte collections, further burdening the health
care system and restricting potential donor availability [64].
On the other hand, mature eNeut cultures have been tested
by GIFT and GAT techniques using a positive serum pool. Mild
or complete absence of reaction confirmed that eNeut are
not immunogenic and therefore may present a lower risk of
transfusion-associated complications compared with donor
neutrophils [52]. Also, eNeut are generated in a chemically de-
fined medium, devoid of animal products, potential pathogens,
or blood contaminants responsible for adverse reactions. These
precautions further suggest that eNeut may be a safe donor
granulocyte alternative for transfusions (Fig. 2), which may
Figure 2. Venn diagrams of the currentmain advantages and disadvantages of existing cell products proposed tomitigate neutropenia. Abbre-
viations: ANC, absolute neutrophil count; CMP, common myeloid progenitors; eHSPC, ex vivo-expanded hematopoietic stem and progenitor
cell; eNeut, ex vivo-manufactured neutrophils; HLA, human leukocyte antigen; HNA, human neutrophil antigen; mPB, mobilized peripheral
blood; UCB, umbilical cord blood.
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not require frequent, time-consuming, and expensive immuno-
typing and serotyping.
Despite these measures, eNeut remain allogeneic in nature.
g irradiationof bloodproducts is anobligatorypractice toprevent
engraftment andGVHD.g-Irradiatedmyeloid progenitor cells dis-
play dose-dependent viability over 6 days, which suggests arrest
of expansion of mitotic cells [65]. Although further studies are
necessary to assess the effects of the 25-Gy irradiation dose re-
quired for blood product transfusions, these data demonstrate
that irradiation does not prevent final maturation of progenitor
cells. This feature is attractive if one considers that current neu-
trophil differentiation protocols do not use synchronized cells. It
will be interesting to see whether irradiated eNeut transfusions
confer longer lasting protection than donor GTx through post-
transfusion late-phase maturation in vivo. In addition, if non-
synchronized HSPCs are used to initiate eNeut cultures, the
mature cells will appear in waves. As a result, the product pheno-
type can be characterized as soon as the first mature eNeut are
available. This feature is important to avoid delays in patient
transfusions given that typing assays can be time consuming [66].
Lesson 2: Timing of GTx Is Key to Benefit Recipients
To date, no randomized controlled trial has clearly demonstrated
the benefit of GTx. However, most clinical studies set to assess
GTx have been performed in the context of febrile or septic neu-
tropenic patients for whom the pathogen replication has not
been contained by innate immunity. Arguably, choosing the set-
ting of an established infection, it is inappropriate to expect im-
provement using GTx as there is a large discrepancy between
the dose of neutrophils needed to abrogate the infection and
the dose of neutrophils actually transfused. In a healthy individ-
ual, 1011 neutrophils are released every day from the bone mar-
row tomaintainhomeostasis in tissuesand steadybloodANC, and
the bone marrow reserve contains approximately 6 times more
neutrophils [67]. Following amicrobial insult, neutrophils aremo-
bilized from the bone marrow reserve, which creates a dramatic
increment in blood ANC [68]. Apheresis of G-CSF-mobilized neu-
trophils typically yields only 4–8 3 1010 neutrophils, leaving
donors in a state of transient neutropenia [54, 69]. It is unreason-
able to expect that a lower-than-homeostatic neutrophil dose
should be able to treat an established infection. Therefore, the
apparent lack of benefit of GTx may be attributable to trials in in-
adequate settings rather than fundamental misconceptions of
GTx antimicrobial potential.
A more favorable situation is prophylactic GTx in at-risk pop-
ulations, such as AMLpatientswho receive aggressivemyeloabla-
tive chemotherapy. The proposed objective of prophylactic GTx
would be to maintain peripheral immunological surveyance. This
suggestion is supported by successful prevention of infection re-
lapse in patients receiving GTx as secondary prophylaxis [70]. In
addition, a landmark meta-analysis of GTx prophylaxis trials indi-
cates that a transfusion dose of as few as 1010 neutrophils is suf-
ficient to improve prognosis [53].
Lesson 3: Patient Outcome Depends on the Phenotype
of Transfused Granulocytes
The immunological phenotype of donor neutrophils is likely to
change during harvest and ex vivo procedures, which may have
a dramatic impact on transfusion efficacy. Cell purification pro-
cesses can inadvertently damage or activate neutrophils. For
instance, neutrophil enrichment using filtration leukapheresis
leads to neutrophil phenotype modification including activation.
Furthermore, enriched concentrates may contain apoptotic neu-
trophils and other damage-associated molecular patterns, which
cause activation of neutrophils. Activated neutrophils exhibit an
altered phenotype of apoptosis, decreased deformity potential,
and spontaneousdegranulation, all ofwhichpromote tissuedam-
age in the transfused host and may participate in the initiation of
TRALI [43]. Determining factors for activation are diverse and in-
clude the type of anticoagulant used, temperature and length of
storage period, and contamination by other blood products. Mo-
bilization agents also have an impact on the phenotype of col-
lected neutrophils: collection using G-CSF plus dexamethasone
increased CD11b and CD18 surface receptors, which suggests cell
activation. [71]. G-CSF-mobilized neutrophils are larger than ho-
meostatic blood neutrophils, have a different surface molecule
phenotype, and some reports suggest reduced efficacy in vivo.
Similar to G-CSF-elicited neutrophils, eNeut display a larger
surface area compared with unstimulated donor neutrophils.
However, eNeut are maintained under consistent conditions
throughout their production, which may limit prospects for acti-
vation. Furthermore, mature eNeut can be harvested quickly and
directly prior to transfusion, while the lengthy apheresis process
and associated temperature variations may contribute to donor
neutrophil activation. Current expansion strategies used for
eNeut production grant the equivalent of at least one protective
dose from a single UCB donation, eliminating the need for inva-
sive procedures on donors. Defined durations of cultures to ama-
ture product promise definite availability of protective neutrophil
doses at a particular time without relying on donors. Because
standard protocols lead to a uniform eNeut phenotype, transfus-
ing patients using eNeut standardizes the transfused product
by eliminating the naturally occurring variability within donor
neutrophil phenotype and subpopulations. Therefore, from a re-
search perspective, transfusing eNeut instead of donor neutro-
phils may emphasize correlations between patient conditions
and GTx success without being confounded by inconsistencies
in donor neutrophil characteristics and numbers. Furthermore, us-
ing a single homogenous product devoid of contaminants, such as
antibodies and serum proteins, reduces donor exposure and possi-
bly the rate of complications (Fig. 2).
CONCLUSION
Despite obvious advantages of eNeut over donor neutrophils,
critical milestones must be met before clinical implementation
can be suggested. Quality control guidelines, automation of bio-
reactors, and costs consideration are examples of current optimi-
zation concerns, discussed recently elsewhere [38]. The ultimate
optimization strategy for eNeut production would be conditional
immortalization of UCB HSPCs. In addition to solving the yield
issue, this outcomewould standardize themanufactured product
into a well-characterized, off-the-shelf solution for neutropenic
patients. Although neutrophil-like cell lines are currently avail-
able, they originally derive from human leukemic samples, which
may hamper safe clinical use. Lin et al. have shown that HL-60-
differentiated neutrophil-like cells, named ATAK, improve overall
outcome in a chemotherapy-treated neutropenic mouse model
challenged with Candida albicans and Aspergillus fumigatus
[72]. Their effort to engineer a “suicide trap” within these cells
points toward the significant safety concern of transplanting
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immortalized cells into patients. Conditional immortalization of
primary cells through targeted genetic manipulation may there-
fore be preferred. Wang et al. have demonstrated unlimited pro-
duction of neutrophils through conditional regulation of Hoxb8 in
HSPCs from mouse bone marrow [73]. Further studies are war-
ranted inhumancells, however, as similarmanipulationsofHSPCs
may lead to different outcomes in different species [74]. Regard-
less of theused strategy, the risk of tumorigenesis post-transplant
must be carefully examined before implementing a human trial.
We feel that assessments of phenotypic stability and long-term
survival of transplanted cells must also be performed for non-
immortalized but in vitro-manipulated eHSPCs.
It is relevant to consider the extreme condition of common
candidates for GTx. Chemotherapies damage the gut mucosa
dramatically, facilitating dissemination of microbes. Therefore,
transfused neutrophils must be highlymobile, respond to the fin-
est chemotactic signals, and must be able to kill microbes effi-
ciently. Hence, it may be appropriate to investigate prospects
of producing more competent eNeut by culture manipulation.
Li et al. showed that SF1670 enhances neutrophil function and
GTx efficacy in vivo [75]. Similarly, addition of the retinoid agonist
Am80 to eNeut cultures gives rise to neutrophils with enhanced
bactericidal abilities compared with G-CSF-derived neutrophils
[76]. We recommend extreme caution in the exploration of this
field, however, as there is a fine balance between functional su-
periority and promotion of inflammation that might culminate in
patient tissue damage.
Successful studies of GTx highlight specific patient subpopu-
lations and treatment context. Exploration of this niche is critical
in the emerging era of personalized medicine to confirm and re-
veal new degrees of responses. Using eNeut instead of donor-
mobilized neutrophils to facilitate futureGTx studies ismotivated
by their practical and physiological advantages including rela-
tively weak immunogenicity. Using a more generic and readily
available eNeut productmay eliminate issues associatedwith do-
nor safety and accessible dose of neutrophils. Finally, research in
the field of eNeut production and transfusion should attractmax-
imal allocation of resources as the rate of cancers and associated
neutropenic disorders is increasing dramatically with general
population aging. Therefore, we foresee an increase in the neu-
tropenic population requiring neutrophil support.
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